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GENERAL AIMS
To study the endogenous biosynthesis of thromboxane in 
man and evaluate the biochemical and functional 
consequences of selective inhibition of thromboxane 
formation in an appropriate clinical model.
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SUMMARY
The principal product of arachidonic acid in the 
platelet is thromboxane A This compound is 
the most potent endogenous platelet agonist and 
vasoconstrictor known in man. Thromboxane A
2
has been implicated in diverse human diseases in 
which platelet activation and vasospasm are known 
to occur. There has therefore been considerable 
interest in the development of therapeutic regimens 
designed to inhibit thromboxane biosynthesis. The 
studies described in this thesis investigated 
endogenous formation of thromboxane in human 
syndromes of platelet activation and examined the 
biochemical and functional effects of different 
approaches to inhibition of thromboxane production 
in health and disease.
Thromboxane biosynthesis was found to be 
enhanced in patients with evidence of platelet 
activation in vivo. There was a concomitant 
increase in endogenous prostacyclin biosynthesis in
31
such patients. Prostacyclin, the major product of 
arachidonic acid metabolism in vascular
endothelium, is a potent vasodilator and inhibits 
platelet aggregation in response to all platelet 
agonists. Evidence from these and other studies 
supports the hypothesis that this increase in 
prostacyclin synthesis reflects enhanced
platelet-vessel wall interactions in patients with 
platelet activation in vivo. The importance of 
prostacyclin as a local regulator of
platelet-vascular interactions in this setting 
provides the rationale for therapeutic regimens 
which are able to enhance, or at least maintain, 
prostacyclin formation in these conditions.
Specific inhibitors of the enzyme thromboxane 
synthase were shown to increase endogenous 
prostacyclin synthesis coincident with their
inhibitory activity on platelet thromboxane 
generation. In contrast, aspirin, although a potent 
inhibitor of thromboxane production and platelet 
function, significantly depressed prostacyclin
production even when administered in low doses. In 
patients with platelet activation in vivo and
enhanced biosynthesis of thromboxane, thromboxane 
production was markedly reduced both by a
thromboxane synthase inhibitor and by dietary 
supplementation with fish-oil rich in
eicosapentaenoic acid. However, complete,
cumulative inhibition of thromboxane formation was 
not achieved and platelet activation persisted.
The results suggested that accumulated
endoperoxides substitute in vivo for the
proaggregatory effects of thromboxane A when
2
further metabolism of arachidonic acid is blocked 
by inhibitors of thromboxane synthase. Also, in 
order to suppress platelet activation in these 
conditions, inhibition of the platelet capacity to 
generate thromboxane must be virtually complete and 
maintained throughout the dosing interval. These 
studies indicate that to achieve that objective 
research should be directed towards the development 
of new, long-acting thromboxane synthase 
inhibitors, to be used in combination with 
endoperoxide/thromboxane A^ receptor
antagonists, and also towards further evaluation of 
long-term administration of pharmacological doses 
of fish-oil.
33
Abbreviations
AA: arachidonic acid 
ADP: adenosine diphosphate 
ASA: aspirin 
B-TG: B-thromboglobulin
CGS 13080: imidazo(1,5-2)pyridine-5-hexanoic acid 
CPA ratio: circulating platelet aggregate ratio 
DCHA: docosahexanoic acid 
EET: epoxy-eicosatrienoic acids 
EPA: eicosapentaenoic acid
GC/MS: gas chromatography/mass spectrometry 
HETE: hydroxyeicosatetraenoic acid
HPETE/HPAA: hydroperoxyeicosatetraenoic acid
5HT: 5-hydroxytryptamine
LT: leukotriene
LT - lag time to achieving 50% of maximal 
50
aggregation
MO HCl: methoxyamine hydrochloride
MO-PFB-TMS: methoxime-pentafluorobenzyl-trimethylsilyl 
m/z: mass/charge
NA: no aggregation or not available, as stated
34
ND: not detected
NSAID: non-steroidal anti-inflammatory drugs 
PA: primary wave of platelet aggregation 
PAF: platelet activating factor 
PDGF: platelet-derived growth factor 
PF4: platelet factor 4
PGD2 : prostaglandin
PGE^ /E^: prostaglandin /E
PGFi^ prostaglandin F /FlCk 2cC IgL 2cC
PGG * prostaglandin G 
^ z
P^H2: Prosta9^ -an^:*-n H2 
Prostacyclin
pGl^: prostaglandin 1^
PGI-M or PGI^-M: 2,3-dinor-6-keto-prostaglandin 
F
ICC
PGI2~M: 2,3-dinor-6-keto-17-ene-prostaglandin 
F
loC
PRP: platelet-rich plasma
SA: secondary wave of platelet aggregation 
SEM: standard error of the mean
TmaXgj height of the platelet aggregation trace 6 
minutes after addition of the agonist
Tx®2 /A2: t^rom^oxane ®2 /A 2
Tx-M or TxB -M: 2,3-dinor-thromboxane B 
2 2
35
Tx B^-m : 2,3-dinor-17-ene-thromboxane 
UK 38,485:
3-(lH-imidazol-l-yl-methyl)-2-methyl-lH-indole-l- 
propanoic acid
36
Chapter 1
INTRODUCTION
37
General Introduction
HISTORICAL BACKGROUND
PATHWAYS OF ARACHIDONIC ACID METABOLISM:
Cyclooxygenase Pathway 
Lipoxygenase Pathways- 
12-lipoxygenase 
15-lipoxygenase 
5-lipoxygenase 
Epoxygenase Pathway
Interactions Between the Pathways of Arachidonic 
Acid Metabolism
CYCLOOXYGENASE PRODUCTS OF ARACHIDONIC ACID: 
Their Metabolism and Biological Properties
Prostaglandin Endoperoxides:
Metabolism
Biological Properties- 
Cyclic endoperoxides
PGD PGE and PGF 
2 2 2oC
38
Thromboxane A :
2
Metabolism
Biological Properties- 
Effects on platelets 
Effects on smooth muscle
Prostacyclin:
Metabolism
Biological Properties-
Effect on platelets
Effect on vascular smooth muscle
PLATELET-VESSEL WALL INTERACTIONS: Role of 
Arachidonic Acid Metabolites
Platelet Adhesion 
Platelet Aggregation 
Platelet Secretion
Prostacyclin-Thromboxane "Balance" in 
Haemostasis and Thrombosis 
Importance of Prostacyclin
THE ROLE OF THROMBOXANE IN HUMAN DISEASE
39
Syndromes Putatively Associated with Enhanced 
Thromboxane Synthesis
Assessing Thromboxane Synthesis and Platelet 
Activation: methodological problems
APPROACHES TO INHIBITION OF THROMBOXANE 
FORMATION IN MAN
1.Inhibition of Enzymes in the Arachidonic Acid 
Cascade:
Cyclooxygenase- 
Irreversible Inhibition 
Reversible Inhibition
Thromboxane Synthase
2.Alternative Fatty Acid Substrates
SUMMARY AND SPECIFIC OBJECTIVES
40
General Introduction
Thromboxane A^ is the major metabolite of 
arachidonic acid formed in the platelet. It is the most 
potent endogenous platelet agonist and vasoconstrictor 
known in man and has therefore been implicated in the 
pathogenesis of acute thrombotic events and in the 
evolution of diffuse vasoocclusive disease. The biological 
properties of thromboxane A^ provide a rationale for 
the development of regimens to prevent or reduce
thromboxane formation in such conditions. These studies
aim to investigate the pharmacology of selective
inhibitors of thromboxane synthesis in man. Furthermore, 
in order to identify potential therapeutic targets and the 
likely impact of such an approach in a clinical setting, 
human models of platelet activation were sought in which 
thromboxane biosynthesis was increased.
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HISTORICAL BACKGROUND
The important role of platelets in normal haemostasis 
and the development of thrombosis was first recognized by 
Juilius Bizzozero in a monograph published in 1882 (1). He 
showed that platelets rapidly accumulated at sites of 
vascular injury to form a haemostatic plug and made the 
important observation that, in contrast to damaged 
vessels, normal undamaged endothelium appeared to present 
a non-thrombogenic surface (2). Although considerable 
progress has been made since that time in elucidating the 
biochemical basis for the interaction between platelets 
and vascular endothelium, the mechanisms underlying this 
complex process remain poorly understood and the role of 
arachidonic acid metabolites has only been appreciated in 
the last two decades.
Arachidonic acid is the principal precursor of a group 
of compounds with a wide variety of potent biological 
effects, the prostaglandins. Von Euler first proposed the 
name "prostaglandin" in 1935 to describe an endogenous
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substance in human semen with vasodepressor and smooth 
muscle stimulating activity (3). Thirty years later Kloeze 
showed that one of the prostaglandins, prostaglandin E, 
inhibited ADP-induced platelet aggregation (4). This was 
followed by Vane's observation in 1971 that non-steroidal 
anti-inflammatory agents caused a dose-dependent reduction 
in prostaglandin synthesis in guinea pig lung homogenates, 
leading him to propose inhibition of prostaglandin 
formation as the biochemical mechanism of action for 
aspirin-liJce drugs (5), which had long been known to 
profoundly inhibit platelet aggregation. At the same time 
Smith and Willis confirmed that aspirin inhibited 
prostaglandin production in human platelets (6).
A series of important papers was subsequently published 
by Samuelsson's group at the Karolinska Institutet in 
Stockholm and by Vane and his colleagues at the Wellcome 
Research Laboratories in Kent describing the metabolism 
of arachidonic acid to the potent eicosanoids, thromboxane 
A^ and prostacyclin (PGIg), in platelets and 
vascular tissue respectively (7-12). Samuelsson's group 
identified thromboxane A^ (8) as a highly unstable 
intermediate formed from prostaglandin endoperoxides which 
caused irreversible platelet aggregation and which 
constituted the major component of rabbit aorta 
contracting substance (RCS), described some years
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previously by Piper and Vane (13). Thromboxane A^ 
has recently been chemically synthesized and the bicyclic 
oxetane strucure originally suggested by Hamberg et al 
confirmed by workers at Columbia University and the Upjohn 
Company (14). Moncada et al found that prostaglandin 
endoperoxides could also be transformed by an enzyme 
isolated from rabbit or pig aortae to an unstable 
substance which inhibited platelet aggregation and relaxed 
isolated blood vessels (10). Initially known as PGX (11), 
its chemical structure was subsequently elucidated and it 
was renamed prostacyclin (12).
The biological properties of thromboxane as a 
potent platelet agonist and vasoconstrictor, and of 
prostacyclin, the most active endogenous inhibitor of 
platelet aggregation known and a vasodilator, have 
focussed interest on their role in the regulation of 
platelet-vessel wall interactions in man, both under 
physiological conditions and in the setting of 
vaso-occlusive disease (15)(16)(17). Consequently, since 
the first description of these potent eicosanoids almost 
ten years ago, research has been directed towards methods 
of inhibiting thromboxane synthesis and/or enhancing 
prostacyclin formation in disease states in which platelet 
activation and vasoconstriction are thought to be 
important mediators.
PATHWAYS OF ARACHIDONIC ACID METABOLISM
Arachidonic acid, or eicosatetraenoic acid, is the 
major precursor of prostaglandins in man. It is a 
20-carbon polyunsaturated fatty acid and is found within 
the phospholipids of the cell membrane of all mammalian 
tissues. After being released from membrane phospholipids, 
arachidonic acid is rapidly metabolized into oxygenated 
products via three distinct pathways (Figure 1.1):
, <i) the cyclooxygenase pathway, to produce prostanoids 
and thromboxanes;
(ii) via a series of lipoxygenases, to produce mono- 
and di- hydroxyeicosatetraenoic acids (HETES) and the 
leukotrienes; and
(iii) via cytochrome p-450 to form epoxy-eicosatrienoic 
acids (EETs)(18).
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Thromboxane A^, the prostaglandins, leukotrienes 
and the epoxygenase products are collectively known as 
icosanoids, reflecting their common origin from 
eicosatetraenoic (arachidonic) acid. In platelets and 
endothelial cells arachidonic acid metabolism is mainly 
directed towards the cyclooxygenase pathway although, as 
outlined below, the potential importance of lipoxygenase 
products is being increasingly recognized. As recent 
evidence suggests that leucocytes also play a significant 
role in platelet-vascular interactions, the following 
section includes discussion of arachidonic acid metabolism 
in these cells, in which, by contrast with platelets and 
endothelial cells, the lipoxygenase pathway predominates. 
A third pathway of arachidonic acid metabolism, the 
epoxygenase pathway, has recently been identified in 
isolated cell suspensions from rabbit renal tissue 
(19)(20). Whether these compounds are synthesized in man 
and their possible role remains to be established. In 
addition, there are now many examples of biochemical 
interactions between the different cell types as a result 
of sharing of various precursors and intermediates of 
arachidonate metabolism.
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Cyclooxygenase Pathway;
Arachidonic acid is converted into the cyclic
endoperoxides, prostaglandin G (PGG ) and
2 2
prostaglandin H (PGH ) via the action of the
2 2
cyclooxygenase enzyme. Cyclooxygenase is present in most 
tissues, with relatively high concentrations in platelets 
and endothelial cells (7)(21)(22), as well as in the 
kidney, spleen and lung (23) ( 24) ( 25). The enzyme is 
membrane-associated and has been localized by
immunocytochemical studies to the endoplasmic reticulum 
and nuclear membrane (26).
Cycloxygenase has now been solubilized and purified to 
homogeneity (27)(28). It is composed of two subunits with 
a molecular weight of 72,000 daltons (29). The enzyme 
catalyses two reactions: the cyclooxygenase reaction in
which two molecules of oxygen are incorporated into 
arachidonate to produce P G G ^  and the
hydroperoxidase reaction in which the 15-hydroperoxide of 
PGG^ is converted to a hydroxyl group to produce 
PGH^ (Figure 1.2). The cycloxygenase and peroxidase 
activities have been shown to reside in a single 
membrane-associated protein (28). Several investigators
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have demonstrated self-deactivation of cycloxygenase in
intact cells suggesting that such a mechanism may be
important in regulating prostaglandin synthesis in vivo
(30)(31).
The cyclic endoperoxides formed by cyclooxygenase are
unstable and are therefore rapidly metabolized to a number 
of different biologically active products depending on 
cell type (Figure 1.2). In platelets and macrophages, for
example, the principal metabolite is thromboxane
(9) (32)(33), whereas in vascular endothelium it is
prostacyclin (11) and in the kidney PGE2
predominates (34).
FIGURE 1.2 CYCLOOXYGENASE PATHWAY OF ARACHIDONIC ACID METABOLISM.
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Lipoxygenase Pathway;
A series of lipoxygenases has been described in various 
mammalian tissues which peroxidize arachidonic acid at 
different carbon atoms. These include:
(i) the 12-lipoxygenase enzyme in platelets (7) and the 
kidney (35)f which converts arachidonate into
12-hydroperoxyeicosatetraenoic acid (12-HPETE), which in 
turn is rapidly reduced to the corresponding hydroxy acid 
12-hydroxyeicosatetraenoic acid (12-HETE);
(ii) the 15-lipoxygenase enzyme in endothelial and 
vascular smooth muscle cells (36), renal glomeruli (35), 
leucocytes and reticulocytes (37), which reacts with 
arachidonate to produce 15-hydroperoxyeicosatetraenoic 
acid (15-HPETE) and 15-HETE; and
(iii) the 5-lipoxygenase enzyme in leucocytes including
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neutrophils (38), eosinophils (38) and monocytes (39),
which catalyses the conversion of arachidonate to
5-hydroperoxyeicosatetraenoic acid (5-HPETE). This in turn 
may be reduced to the hydroxy acid 5-HETE or further
metabolized to generate the leukotrienes (Figure 1.3).
FIGURE 1.3 LIPOXYGENASE PATHWAYS OF ARACHIDONIC ACID METABOLISM.
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12-lipoxygenase:
The precise biological role of the 12-lipoxygenase 
products formed by platelets is unclear. Recent reports 
have shown that in vitro 12-HETE induces migration of 
aortic smooth muscle cells at very low concentrations 
(40)(41), leading to the suggestion that this may be of 
some importance in the pathogenesis of atherosclerosis. 
12-HETE is also the major product formed from endogenous 
arachidonic acid in isolated rat pancreatic islet cells 
and may be involved in glucose-induced insulin secretion 
by these cells (42). 12-lipoxygenase products have been 
implicated in the regulation of cell to cell interactions. 
Platelet-derived 12-HETE can be utilized by neutrophils to 
form another icosanoid, 12,20-diHETE, the function of 
which is unknown (43). It has also been suggested that 
12-HPETE inactivates prostacyclin synthase or may play a 
role in endothelial cell-dependent relaxation of vascular 
smooth muscle, although the evidence in support of these 
hypotheses is inconclusive (44).
15-lipoxygenase:
The physiological significance of the 15-lipoxygenase 
products is also unclear. They have been shown to inhibit 
prostacyclin synthase (45), platelet aggregation (46) and
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leukotriene formation in vitro (47). In atherosclerotic 
rabbit aortae, synthesis of 15-HETE was found to occur in
the absence of any 15-HETE production by normal control 
aortae, leading to the suggestion that this may be 
important in explaining why atherosclerotic vessels are 
prone to thrombosis (48). However, cultured human 
umbilical vein endothelial cells have been shown to 
synthesize significant amounts of 15-HETE (36). This 
observation and the presence of 11-,12- and 
15-lipoxygenase products in vascular smooth muscle cells 
suggest that the products may be involved in
platelet-endothelial and neutrophil-endothelial
interactions (49)(50). Recent studies in which 15-HPETE 
was added to stimulated leucocytes have led to the
identification of a new series of biologically active 
compounds, the lipoxins (51). One of these, lipoxin A has 
been shown to be a potent stimulator of neutrophil 
superoxide generation and lysosomal elastase release (52).
5-lipoxygenase:
Metabolism of arachidonic acid via the 5-lipoxygenase 
pathway in leucocytes results in leukotriene formation. 
The individual leukotrienes possess distinct biological
properties and although previously thought to be mainly
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active in acute inf lamination (53), their possible role in
platelet vessel wall interactions is now being recognized.
Leukotriene is a potent stimulator of neutrophil
chemotaxis, chemokinesis, aggregation and adhesion to
endothelial cells (54)(55). Of considerable interest is
the recent evidence demonstrating that in vitro
neutrophils are also able to utilize both platelet-derived
arachidonic acid (56) and erythrocyte-derived leukotriene
A for leukotriene B synthesis (57).
4 4
Leukotriene A^ may be further converted to its
glutathione conjugate, leukotriene C , which is then
4
metabolized to leukotrienes D and E4. Leukotrienes
4
C
4 and D , which have been identified as the 
4
active constituents of SRS-A (slow-reacting substance of
anaphylaxis), contract vascular and bronchial smooth
muscle, increase vascular permeability and stimulate mucus
secretion (53). Some of the effects of leukotriene
G on bronchial smooth muscle are blocked by 
4
cyclooxygenase inhibitors, suggesting that thromboxane
A^ or other bronchoconstrictor prostaglandins may
contribute to the biological activity of these
leukotrienes (58). Leukotriene C has also recently
4 1
been shown to stimulate prostacyclin synthesis in human 
endothelial cells (59)(60).
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Epoxygenase Pathway:
Cytochrome p-450 enzymes in microsomal preparations 
from rabbit renal cortex and liver convert arachidonic 
acid into a series of epoxides (Figure 1.4), some of which 
have been shown to have interesting biological properties 
(19X20). Two of these compounds, 8,9-EET and 14,15-EET, 
inhibit human platelet cyclooxygenase (61). In addition, 
all the EET isomers so far investigated inhibit platelet 
aggregation, although in some cases this appears to occur 
by a non-specific mechanism independent of inhibition of 
thromboxane formation (61).
FIGURE 1.4 EPOXYGENASE PATHWAYS OF ARACHIDONIC ACID METABOLISM
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Interactions between the Pathways of Arachidonic Acid
Metabolism
Experiments in vitro have provided many examples of
biochemical interactions between platelets, leucocytes and
endothelial cells in which arachidonic acid precursors or
intermediates synthesized by one cell type may be utilized
by another. Thus, platelet-derived arachidonate may be
metabolized by neutrophils to leukotriene B (56)
4
and 12-HETE from platelets can be utilized by neutrophils
to form 12,20-diHETE (43). Other examples are the
synthesis by neutrophils of leukotriene B from
4
erythrocyte-derived leukotriene A (57) and of the
4
lipoxins from 15-HPETE (51). In addition, synthesis of 
prostacyclin by endothelial cells from platelet-derived 
endoperoxides has been demonstrated by several workers in 
vitro (62)(63). The observation from human studies that 
prostacyclin biosynthesis is increased after
administration of a thromboxane synthase inhibitor
provides evidence that such interactions may also be
relevant in vivo (64)(65).
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CYCLOOXYGENASE PRODUCTS OF ARACHIDONIC ACID; 
Their Metabolism and Biological Properties
Prostaglandin Endoperoxides
Metabolism;
The cyclic endoperoxides, PGG and PGH ,
2 2
are unstable prostanoids with a half-life of around 5 
minutes (66). They are further metabolized along a number 
of different pathways depending upon the type of tissue or 
species studied (Figure 1.2). In human platelets the major 
product formed from prostaglandin endoperoxides is 
thromboxane A^ by the action of the enzyme
thromboxane synthase (9). Prostaglandin E
2
(PGE^), prostaglandin (PGD^) and
small amounts of prostaglandin F (PGF ) can
2o( 2ot
also be synthesized by platelets either non-enzymatically 
or via the action of isomerases (32)(67). The metabolite 
malondialdehyde (MDA) is produced in approximately 
equimolar amounts with thromboxane A (15).
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In cultured endothelial cells from large blood vessels 
endoperoxides are predominantly converted into 
prostacyclin (68 ) (69 ). In the microvasculature, however,
recent evidence has shown that significant PGH-PGE 
isomerase activity is present and that, in this setting, 
PGE^ may be the major product generated from 
arachidonic acid (70) (71).
Thromboxane synthesis has also been demonstrated in
macrophages (33) (72), vascular tissue (73), and the lung
(25), kidney (34) and spleen (26). Although human
macrophages mainly metabolize arachidonic acid via the
5-lipoxygenase enzyme, they also synthesize significant
amounts of thromboxane and P G E 2 (53)(74). In the
kidney the spectrum of arachidonic acid metabolites
produced varies in the different parts of the nephron
(34) (75). The arteries and arterioles mainly synthesize
prostacyclin and PGE^ (76). Renal glomeruli produce
predominantly prostacyclin, but less PGE ,
2
thromboxane B and PGF (77 ) (78 ). In the
2 2<*
renal medulla the major metabolite synthesized by the 
collecting tubules and interstitial cells is PGE
2
(79 ) (80).
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Biological Properties:
Cyclic Endoperoxides:
Prostaglandin endoperoxides contract vascular,
bronchial and gastrointestinal smooth muscle in vitro
(9)(81)(82)(83 ). Although shown- to -be considerably more
potent than P G E 2 inducing contraction of rabbit.
aorta (66), the endoperoxides are approximately 50-fold
less potent in this respect than thromboxane A^ (9).
The effect of PGG and PGH on platelets is
2 2
proaggregatory, P G G 2 three times more active
than PGH (66).
2
Prostaglandins D ,E and F :
2 2 20t
PGD and its 9„jllfe-PGF metabolite inhibit2 * r 2ot
platelet aggregation (84)(85) by stimulating adenylate
cyclase and increasing the intraplatelet concentration of
cyclic AMP (86). The potency of PGD^ is about 10-20
fold less than prostacyclin (87). The 9otllfi PGF
r 2ot
metabolite also contracts human bronchial smooth muscle
(88) and coronary artery rings (89). PGE^ is very
weakly anti-aggregatory but in low concentrations has been
shown to enhance the secondary wave of ADP-induced
aggregation (90). PGE is also a vasodilator and may
2
play a role in the maintenance of renal blood flow and the
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glomerular filtration rate under conditions of
increased vasoconstrictor activity in the kidney (79).
Thromboxane A   2
Metabolism:
Thromboxane A^ is a highly unstable intermediate
formed from PGH by the action of thromboxane
2
synthase. It has a half-life of approximately 30 seconds
(8) and is rapidly hydrolysed non-enzymatically to its
stable derivative, thromboxane B . The metabolism of
2
thromboxane B in man (Figure 1.5) has been studied 
2
by infusing a supraphysiological dose (6.4
micrograms/minute) intravenously in a human volunteer and
identifying the urinary metabolites by gas
chromatography/mass spectrometry (91). Using this
technique, the major urinary metabolites were shown to be
2,3-dinor-thromboxane B and 11-dehydro-thromboxane
2
B^, accounting for 23% and 8% respectively of the 
total infused dose (91). Although subsequent infusion 
studies employing more "physiological" doses of 
thromboxane B^ (0.1-5 ng/kg/minute) found that only
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5.3% of the infused thromboxane B was excreted as
2
the dinor metabolite, this, and 11-dehydro-thromboxane
B remain the principal metabolites under normal
2
conditions (92). The discrepancy between these two studies
is likely to be due to saturation at the much higher
infusion rate of the pathway converting thromboxane
B into 11-dehydro-thromboxane B metabolites 
2 2
(93).
FIGURE 1 . 5  MAJOR METABOLIC PATHWAYS FOR THROMBOXANE B2
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Biological Properties;
Thromboxane A^ has two principal biological 
actions. It is the most potent endogenous inducer of 
platelet aggregation yet discovered in man (8) (14) and it 
contracts vascular and bronchial smooth muscle
(9)(14)(94)(95).
Effects on platelets:
The exact mechanism by which thromboxane activates 
platelets has not been elucidated. Although there are some 
reports suggesting that the effects of thromboxane are 
mediated, only indirectly via released ADP (96) (97), some 
of these were confounded by methodological problems (98) 
and there is now good evidence that its effects are 
mediated through thromboxane A^/endoperoxide 
receptor occupancy (99). It is thought that after binding 
to the receptor, thromboxane raises the intracellular 
concentration of unbound calcium leading to platelet shape 
change, primary aggregation and release (100). Experiments 
involving analogues of thromboxane and the prostaglandin 
endoperoxides are consistent with a single shared 
thromboxane A^/endoperoxide receptor on the platelet 
membrane (101)(102)(103). Thromboxane also causes the 
secondary wave of platelet aggregation initiated by other
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agonists such as ADP and adrenaline (104), perhaps by 
potentiating the exposure of fibrinogen binding sites by
these agonists (105). However, ADP does not appear to be
essential for the maintenance of thromboxane-induced
platelet aggregation (99 ) (105)(106).
Effects on smooth muscle:
Thromboxane A^ is a potent constrictor of 
vascular and respiratory smooth muscle (9)(14)(94 ) (95 ). 
Studies in which thromboxane A^ was generated by 
incubating P G H 2 Platelet microsomes showed that
as little as 30 picomoles of thromboxane A^ caused 
marked contraction of rabbit aorta ex vivo (107). There is 
now good evidence from studies with a variety of 
thromboxane A^ and endoperoxide analogues for the
existence of different thromboxane A^/endoperoxide 
receptors in platelets from those found in vascular smooth 
muscle (103)(108).
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Prostacyclin
Metabolism;
The conversion of ^nto prostacyclin is
catalysed by the enzyme prostacyclin synthase, which is 
found in the vascular tissues of all mammalian species 
(15). Prostacyclin synthase has been purified by 
immunoaffinity chromatography and found to have a 
molecular weight of 50,000 daltons (109). Early studies 
showed that in large vessels the endothelium was the major 
source of prostacyclin synthesis and that vascular smooth 
muscle had minimal prostacyclin synthase activity (110). 
Since that time, however, several investigators have 
demonstrated the capacity of arterial smooth muscle cells 
to synthesize prostacyclin in vitro (73)(111)(112 ). Recent 
experiments using improved immunocytochemical methods 
indicate that the concentration of prostacyclin synthase 
is actually the same in different layers of the 
vasculature, but that considerably lower concentrations of 
cyclooxygenase are‘ found in arterial smooth muscle 
compared to endothelial cells (22). It is not clear 
whether this observation is of functional importance in 
vivo, although it is possible that reduced cyclooxygenase
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activity in vascular smooth muscle may lead to reduced 
prostacyclin generation at sites of vascular injury.
Prostacyclin synthesis is known to be stimulated in 
vitro by endogenous platelet agonists such as thrombin 
(113)f ADP (114) and adrenaline (115). Platelet granule 
consituents, including platelet-derived growth factor 
(116), platelet activating factor (117) and
5-hydroxytryptamine (118) which are released by activated 
platelets are also potent stimuli for prostacyclin 
formation in vitro, as are leukotrienes C
4 and
and a-interferon ( 59 ) ( 60 )( 119 ). Although early in 
vitro studies suggested that vasoactive mediators, whether 
endogenous such as adenosine and endothelial cell-derived 
growth factor (120)(121), or exogenous such as organic 
nitrates (122), acted via prostacyclin release, more
recent work has not confirmed these findings 
(123)(124)(125)(126). Prostacyclin formation has been 
shown to be inhibited by 15-lipoxygenase products (45). In 
addition, prostacyclin synthesis by rabbit aortae ex vivo 
and by cultured endothelial cells causes deactivation of 
cyclooxygenase (30) (31). This phenomenon results in a
markedly reduced endothelial capacity for continued
prostacyclin generation for 24-48 hours (31) and may be 
important in the regulation of prostacyclin biosynthesis 
in vivo.
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Prostacyclin is unstable, with a half-life of 2-3 
minutes in whole blood (127). It is rapidly hydrolysed 
non-enzymatically to its stable metabolite, 6-keto-PGF
let
which can be measured in blood or urine
(128)(129)(130). The major urinary metabolites, however,
are 2,3-dinor-6-keto-PGF
lot
and
6,15-diketo-13,14-dihydro-2,3-dinor-6-keto-PGF
(129)(131) (Figure 1.6).
lot
FIGURE 1.6 METABOLISM OF PROSTACYCLIN IN MAN
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Measurement of these prostacyclin metabolites in urine 
provides a useful non-invasive index of endogenous 
prostacyclin production in man (131X132). Employing this 
approach, the estimated rate of secretion of prostacyclin 
into the circulation in normal individuals under basal 
conditions has been shown to be very low- in the order of 
0.08-0.10ng/kg/minute (132)- suggesting that, contrary to 
previous hypotheses (133), it is not a circulating hormone 
in man.
An alternative pathway of metabolism has also been
described in which prostacyclin or 6-keto-PGF are
101
converted into 6-keto-PGE^ via the enzyme 
9-hydroxyprostaglandin dehydrogenase (134). The enzyme has 
been demonstrated in a perfused rabbit liver preparation 
(135), in human platelets (134) and in human kidney (136). 
More recently, Pieroni et al clearly showed that the 
isolated perfused rabbit kidney generates material 
indistinguishable from 6-keto-PGE^ by immunoreactive 
and biological criteria and verified its structure (137). 
It has been suggested that such a pathway may be important 
in vivo as 6-keto-PGE^ has similar biological 
properties to prostacyclin (137)(138). This remains 
speculative, however, particularly as studies of the 
metabolic disposition of prostacyclin in man found no
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evidence of this metabolite in urine under physiological 
conditions (131) or after prostacyclin infusion (129). It 
therefore seems likely that endogenous 6-keto-PGE^ 
production is minimal under normal conditions in humans.
Biological Properties:
The two principal biological properties of prostacyclin 
are inhibition of platelet aggregation and relaxation of 
vascular smooth muscle. Prostacyclin also appears to exert 
a "cytoprotective" effect distinct from its anti-platelet 
and vasodilator activity, for example in preventing 
endotoxin-induced injury in animal models of shock and 
reducing myocardial infarct size (139). In addition, 
studies of cholesteryl ester hydrolytic activity in 
cultured aortic smooth muscle cells suggest that 
prostacylin may be an important regulator of cholesteryl 
ester metabolism in human arteries (140).
Effects on Platelets;
Prostacyclin is the most potent endogenous inhibitor of 
platelet aggregation yet discovered. It inhibits the 
aggregation of platelets by all recognized agonists and 
disaggregates previously aggregated platelets (15). It
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exerts these effects by increasing the intra-platelet 
concentration of cyclic AMP (141). It binds to a common 
prostacyclin/PGE^ receptor on the platelet membrane 
(142), thereby activating adenylate cyclase which in turn 
leads to accumulation of cyclic AMP (141). The ability of 
cyclic AMP to prevent platelet aggregation is thought to 
be mediated by inhibition of the mobilization of
fibrinogen and von Willebrand factor binding sites on the 
platelet membrane (143 ) ( 144) and/or a reduction in the
intraplatelet concentration of calcium (145) (146). The
effects of prostacyclin on platelet adhesion are unclear. 
Some reports suggest that it possesses inhibitory activity 
(147 )(148 ) ( 149 ), while others have failed to confirm these 
findings (150).
Effects on Vascular Smooth Muscle:
Prostacyclin relaxes vascular strips in vitro in all
species examined including man, with the exception of
porcine coronary artery and some preparations of human
saphenous vein and rat venous tissue (10)(151)(152)(153 ).
It is 4-8 times more potent than PGE^ and at least
100 times more active than its stable metabolite
6-keto-PGF (154). Prostacyclin has also been shown 
lot
to produce vasodilatation and lower diastolic blood
pressure when infused into animals (154) and man (155).
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PLATELET-VESSEL WALL INTERACTIONS; 
ROLE OF ARACHIDONIC ACID METABOLITES
Platelet Adhesion;
Under physiological conditions platelets do not adhere
to normal intact endothelium. However, when a blood vessel 
is injured, the exposed subendothelium rapidly becomes
covered by a layer of adhering platelets. The mechanisms 
underlying platelet deposition on the acutely damaged
vessel wall remain poorly understood and appear to be
extremely complex. A simplified scheme of the vascular and 
intravascular events following platelet adherence is shown
in Figure 1.7. Adhesiveness is markedly increased by 
thrombin. The formation of thrombin is initiated at sites 
of vascular injury by assembly of the prothrombinase
complex on the surface of platelets and involves the
binding of Factors V and Xa to specific receptors on the
platelet membrane (156). Substances present or synthesized 
in the vessel wall also induce platelet adhesion,
particularly ADP, von Willebrand Factor, collagen and
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fibronectin (157-161).
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The role of prostaglandins is far from clear. Most
investigators have examined the effects in vitro of
inhibition of prostaglandin synthesis by aspirin or
indomethacin and it is difficult to distinguish the
contribution of the different prostanoids and other
factors in these experiments (147 )(148 )(149 )(150 )(162 ).
The effects of a thromboxane receptor antagonist in an
animal model suggest that platelet adhesion is dependent,
at least in part, on thromboxane A (163). While
2
some studies have shown inhibition of platelet adhesion by 
prostacyclin, the concentrations employed appeared to be 
much greater than those inhibiting platelet aggregation 
(147) and subsequent work has not confirmed these findings 
(150).
Platelet Aggregation:
Following adhesion to "damaged" endothelium, platelets 
may then aggregate and release the contents of their 
granules. Platelet aggregation appears to occur by at 
least two, possibly three, distinct pathways (164):
(i) an ADP-induced pathway thought to involve the
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interaction of fibrinogen with its platelet receptor 
(165);
(ii) a prostaglandin dependent pathway mediated by 
thromboxane or cyclic endoperoxides binding to
the thromboxane A^/endoperoxide receptor
(99 ) (101)(102)( 103); and
(iii) a third pathway induced by calcium ionophore and 
thrombin which appears not to be blocked by inhibitors of 
arachidonic acid metabolism or ADP and which may be 
mediated by platelet activating factor (166).
ADP and also adrenaline cause a biphasic aggregation 
response. The second phase or wave of aggregation is 
associated with liberation of arachidonic acid, which is 
then metabolized to prostaglandins and thromboxane, and 
with release of platelet granule contents (104). The 
prostaglandin pathway may also be initiated directly by 
metabolism of exogenous arachidonic acid or by a number of 
other agonists including collagen and thrombin. In low 
concentrations collagen and thrombin are dependent upon 
the prostaglandin pathway for their effect. In higher 
concentrations, however, they appear to be able to 
stimulate platelet aggregation via several other pathways 
(164). Responses to all these platelet agonists are
ultimately mediated by changes in intracellular calcium 
and cyclic AMP. Thus, an increase in the intraplatelet 
concentration of calcium causes platelet shape change 
followed by aggregation, whereas an elevation in the level 
of platelet cyclic AMP, which blocks the mobilization of 
calcium and lowers the intracellular concentration of 
calcium, inhibits platelet aggregation (145)(146). This 
explains the potent platelet inhibitory effects of 
prostacyclin which causes very marked increases in 
platelet cyclic AMP levels and blocks the response to all 
platelet agonists (141).
Platelet Secretion;
Platelets contain three classes of secretory granules: 
ol-granules, dense granules and lysosomes. The ol-granules 
contain the platelet-specific proteins
beta-thromboglobulin, platelet factor 4 and
platelet-derived growth factor, as well as thrombospondin 
which is also synthesized by endothelial cells (167). In 
addition, homologues of various plasma proteins are 
present in the ol-granules, including von Willebrand 
factor, fibrinogen, factor V, fibronectin, plasminogen, 
high-molecular weight kininogen, albumin and some 
components of the alternative complement pathway (167).
The dense granules are storage organelles containing 
calcium, pyrophosphate, 5-hydroxytryptamine and adenine 
nucleotides. The lysosomes store several acid hydrolases 
which may be released by high concentrations of thrombin 
or collagen (168).
The contents of the ^-granules and the dense granules 
are released in response to platelet activation. Potent 
agonists such as thrombin and high doses of collagen are 
able to stimulate platelet secretion by a 
prostaglandin-independent mechanism (104). However, when 
weaker agonists, such as adrenaline, ADP and low-dose 
collagen, are employed, platelet secretion is mediated by 
the proaggregatory prostaglandins (104). Nevertheless, 
thromboxane and prostaglandin endoperoxides can also 
induce platelet aggregation in the absence of secretion 
(169).
Prostacyclin-Thromboxane "Balance1 in Haemostasis 
and Thrombosis:
The discovery of two products of arachidonic acid 
metabolism, thromboxane A^ from platelets and
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prostacyclin from vascular endothelium, which had potent 
but opposite effects on platelet function and vascular 
smooth muscle, led to the hypothesis that the balance 
between them may be of importance in haemostasis and 
thrombosis (15)(170). Early work suggested that 
significant reductions in the "thromboxane
A^tprostacyclin ratio" were apparent in various
animal models of thrombosis (171) (172) and also in human
thrombotic disease (173)(174). Furthermore, congenital 
deficiencies of cyclooxygenase and thromboxane synthase 
were identified which were associated with haemostatic 
defects (96)(175)(176). Since that time, however, two 
principal avenues of research have yielded information 
which has led to a reevaluation of the concept of a true 
"balance" between thromboxane and prostacyclin in 
vivo.
Firstly, the development of more accurate methods for 
measuring the biosynthesis of these evanescent compounds 
has shown that their rate of secretion into the 
circulation in normal man is exremely low ( 92)(93)(130 ). 
These observations demonstrated that the capacity of 
tissues to generate icosanoids in response to chemical and 
physical stimuli greatly exceeds their actual rates of 
biosynthesis in vivo and suggested that the levels of
thromboxane and prostacyclin reported in many of these
early reports are very likely to have been erroneously 
high (130). Secondly, not only have a number of new
biologically active icosanoids been discovered (18), but
there has also been increasing recognition of the
biochemical and functional interactions between the
different cell types participating in the development of 
vascular occlusion (177). Thus, while prostacyclin and 
thromboxane have been confirmed as endogenous compounds 
with potent biological effects in man, they represent only 
two of many factors which are important in modifying the 
development of thrombosis and atherosclerosis (Figure
1.8).
Importance of Prostacyclin;
There has been considerable interest in the importance 
of prostacyclin as a naturally occurring inhibitor of 
platelet activation both under physiological conditions 
and in response to diverse physical and chemical stimuli. 
Its precise role in maintaining vascular endothelium as a 
non-thrombogenic surface in health and disease states in 
man is at present unclear. Studies in vitro have shown 
that atherosclerotic blood vessels have a reduced capacity 
to synthesize prostacyclin (178 ) ( 179 ). However, subsequent 
work, has demonstrated that prostacyclin synthesis in vivo
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is actually enhanced in patients with severe 
atherosclerosis who have evidence of platelet activation 
(180). The authors of this study suggested that such an 
observation reflected an increased frequency and/or 
intensity of interactions between activated platelets and 
the vessel wall. Therefore, although prostacyclin 
biosynthesis under basal conditions in healthy individuals 
is apparently insufficient to achieve systemically active 
concentrations, the enhanced production in severe 
atherosclerosis may represent an important compensatory 
response by stimulated endothelium.
Additional evidence in support of the functional 
importance of prostacyclin in vivo derives from the 
effects of inhibition of prostacyclin synthesis by aspirin 
on platelet adherence to vascular endothelium. In a rabbit 
model of venous thrombosis high doses of aspirin 
(200mg/kg) increased thrombus formation (182). Similarly, 
platelet deposition on canine carotid artery vein grafts, 
pre-treated with aspirin to reduce prostacyclin formation, 
is enhanced compared with non-aspirin treated grafts
(183). Thus, prostacyclin may function mainly as a local 
modulator of platelet-vessel wall interactions and 
contribute, along with other endothelial cell-derived 
products, leucocytes and their products, the physical 
properties of endothelial cells, haemodynamic elements and
coagulation factors, to the prevention of
platelet-dependent thrombus formation at sites of vascular 
injury.
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THE ROLE OF THROMBOXANE IN HUMAN DISEASE
The potent biological properties of thromboxane have 
focussed attention on its potential role in the mediation 
of vaso-occlusive disease. It has been suggested that it 
may be important in conditions where vascular spasm is 
known or thought to occur, such as Raynaud's phenomenon
(184)(185) and unstable angina (186)(187 )(188 ). In 
addition, the effect of thromboxane on platelets has led 
many investigators to implicate thromboxane-dependent 
platelet activation in the pathogenesis of diverse disease 
processes in which platelets are thought to play an 
important role, including atherosclerosis (189-194), the 
thrombotic complications of myeloproliferative disorders 
(195)(196), lupus nephritis (197) and the microvascular 
problems of diabetes mellitus (171)(198-201). A summary of 
syndromes putatively associated with thromboxane is shown 
in Table 1.1.
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TABLE 1.1 SYNDROMES PUTATIVELY ASSOCIATED WITH ENHANCED THROMBOXANE 
SYNTHESIS:
Results from Animal Models and Preliminary Studies in Man
Ischaemic Heart Disease:
Coronary thrombosis (203-206)
Unstable and Prinzmetal's angina (186-8) (207-209) 
Chronic stable angina (209-210)
Arrhythmias and sudden death (211-216)
Essential hypertension (217-220)
Pregnancy-induced hypertension (221-223)
Cerebrovascular Disease:
Stroke (226-227)
Transient ischaemic episodes (228-232)
Peripheral Vascular Disease (233-234)
Renal Disease:
Immune complex glomerulonephritis (197) (235-237)
Chronic glomerulonephritis (238-239)
Hepatorenal syndrome (240)
Cyclosporin- and adriamycin-induced nephropathy (241-242) 
Renal vein thrombosis (243)
Allograft rejection (244-245)
Hypertension following sub-total renal ablation (246-247) 
Hydronephrosis in response to ureteric obstruction (248-249)
Diabetes Mellitus (171) (198-200)
"Collagen-Vascular” Disease:
Raynaud's phenomenon (184-185)
Systemic lupus erythematosus (197) (235)
Myeloproliferative Disorders (195-196)
Respiratory Disease:
ARDS and endotoxic shock (250-256) 
Asthma (257-259)
Assessing Thromboxane Synthesis and Platelet Activation:
Methodological Problems
Evaluation of the role played by thromboxane and other
arachidonic acid metabolites in the pathogenesis of
vaso-occlusive and vasospastic diseases has been
confounded by difficulties in measuring the synthesis of
these evanescent compounds in vivo (130). The short
half-lives, for example, of thromboxane and prostacyclin,
necessitated the development of methods to measure their
major metabolites rather than the parent compounds (259).
Using this approach plasma levels of thromboxane
and the prostacyclin metabolite 6-keto-PGF were
lot
initially reported to be in the order of 100-200 pg/ml 
(173)(233)(260)(261)(262). Subsequent work established 
that the true plasma concentration of 6-keto-PGF
lot
was less than 2-3 pg/ml (181) and that of thromboxane 
is likely also to be greatly over-estimated (92).
The reasons for such a large discrepancy are thought to 
derive partly from the phasic nature of arachidonate 
metabolite production (occurring in response to a stimulus 
rather than continuous biosynthesis) and also from the 
influence of ex vivo artifact due to invasive sampling 
techniques. Such a phenomenon is well known to occur with
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the introduction of catheters for cardiac catheterization 
(263)(264). In addition, if care is not taken to minimize 
ex vivo platelet activation, the conventional methods used 
to detect platelet activation in vivo yield markedly 
elevated plasma concentrations of platelet proteins in the 
absence of true platelet granule release in vivo (265).
An alternative method of assessing thromboxane 
formation in vivo, which removes the confounding influence 
of ex vivo platelet activation, is to measure the urinary 
metabolites of thromboxane. Sensitive and specific assays 
for the urinary metabolites of prostacyclin have already 
been developed which have been shown to accurately reflect 
prostacyclin synthesis in vivo (131)(132). Preliminary 
evidence suggests that such an approach may be useful for 
the evaluation of thromboxane formation in vivo 
(92)(93)(266). The development of accurate methods to 
measure endogenous biosynthesis of thromboxane is clearly 
essential for the critical appraisal of pharmacological 
approaches to the inhibition of thromboxane production in 
man and for the identification of appropriate clinical 
targets towards which to direct such therapeutic 
strategies.
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APPROACHES TO INHIBITION OF THROMBOXANE FORMATION IN MAN
Thromboxane formation can be inhibited by 
pharmacological agents which block the enzymes in the 
arachidonic acid cascade directly involved in thromboxane 
synthesis. The best known of these agents is the 
cyclo-oxygenase inhibitor, aspirin, which has been used in 
many large scale clinical trials for the prevention of 
vascular occlusive syndromes ( 229 )( 230-232)( 267-273 ). The 
major theoretical disadvantage of aspirin in this setting 
is the reduction in prostacyclin formation which results 
from concomitant inhibition of the cyclo-oxygenase enzyme 
in vascular endothelium (Figure 1.9). An alternative 
approach is to selectively inhibit thromboxane synthase by 
a specific thromboxane synthase inhibitor (274)(275) 
(Figure 1.10). There are now several different groups of 
compounds available which have been shown in vitro to 
selectively inhibit thromboxane synthesis without 
depressing prostacyclin production (276)(277). A third and 
novel approach to inhibition of thromboxane formation was 
suggested by observations in Greenland Eskimos who were 
found to have a lower incidence of death from ischaemic
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heart disease than Danes (278X279). This has been 
attributed to a diet rich in marine oils containing long 
chain polyunsaturated fatty acids. The principal active 
constituent appeared to be eicosapentaenoic acid (EPA) 
which, when given as a dietary supplement, partially 
replaces arachidonic acid in plasma and platelet lipids 
(280 X  281).
1.Inhibition of Enzymes in the Arachidonic Acid Cascade
CYCLOOXYGENASE
Irreversible Inhibition:
In 1971 three papers were published simultaneously 
which reported that non-steroidal anti-inflammatory drugs 
inhibited prostaglandin synthesis in guinea pig lung, 
human platelets and spleen (5) (6) (282). Roth et al showed 
that aspirin exerted its platelet-inhibitory effect by 
binding irreversibly to the cyclooxygenase enzyme 
(283 ) (284 )and acetylating a serine residue at its active 
site (285). Thus, as the anuclear platelet is incapable of 
de novo protein synthesis, aspirin causes irreversible 
inhibition of prostaglandin endoperoxide and thromboxane
A- formation for the duration of its lifespan, 
normally 8-9 days (286).
Aspirin is not only highly active against platelet 
cyclooxygenase, but also acetylates the enzyme in other 
tissues, including gastric mucosa, the kidney and vascular 
endothelium. Thus, coincident with the inhibition of
thromboxane A^ biosynthesis, aspirin has been shown 
to significantly reduce prostacyclin generation in
cultured endothelial cells (287), in isolated vascular 
segments (288)(289)(290) and in vivo (291). Inhibition of 
gastric cycloxygenase causes a marked reduction in
PGE^ and prostacyclin (292) and may play a role in 
the gastric mucosal damage induced by aspirin. Aspirin
also inhibits renal prostaglandin synthesis and may cause 
significant impairment of renal function under certain 
conditions (293).
In contrast to the prolonged inhibitory effects' on 
platelets, there is a much more rapid rate of recovery of 
endothelial cyclooxygenase after exposure to aspirin, 
perhaps as a result of resynthesis of the enzyme
(287 ) ( 294 ). In addition, vascular cyclooxygenase has been 
shown in some studies to be less sensitive to aspirin in 
comparison with the cyclooxygenase of platelets 
(295) ( 296 ), although others have failed to confirm this
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finding (287). These observations have led to the 
suggestion that aspirin exhibits dose-related selectivity 
with respect to its inhibitory effects on prostacyclin and 
thromboxane formation. Thus, while higher doses depress 
synthesis of both prostacyclin and thromboxane, it should 
theoretically be possible to determine a dose of aspirin 
at which significant inhibition of thromboxane will be 
achieved in the absence of a fall in prostacyclin 
production.
Reversible Inhibition:
Other non-steroidal anti-inflammatory drugs, for 
example indomethacin, ibuprofen, naproxen, sulindac and 
diflunisal (6)( 238 ) ( 297) inhibit cyclooxygenase in a 
reversible manner. In addition, sulphinpyrazone is a weak 
inhibitor of cyclooxygenase, the effect persisting only 
while the drug or its active metabolites remain in the 
systemic circulation (298)(299). Sulphinpyrazone,
indomethacin and diflunisal have also been shown to 
prevent the inhibitory action of aspirin on cyclooxygenase 
(300). This, and other evidence from the described 
interaction between aspirin and salicylate, suggests that 
there are two binding sites on platelet cyclooxygenase: an 
active or catalytic site and a supplementary site which
regulates, but is not directly involved with, the active 
site (301).
THROMBOXANE SYNTHASE
Thromboxane synthase has been partially purified by 
Ullrich and Haurand using affinity chromatography (302).
Their work also suggests that the enzyme, like
prostacyclin synthase, is a cytochrome P-450-type 
haemoprotein. Several classes of compounds have now been
developed which are able to selectively inhibit the
thromboxane synthase enzyme (274-277). These drugs were 
designed both as pharmacological tools to investigate the 
pathophysiological role of thromboxane A^ and as a 
potentially useful approach in the treatment of those 
vaso-occlusive disorders in which thromboxane was thought 
to be an important factor.
Three classes of thromboxane synthase inhibitors have 
been described (303)-:
(i) endoperoxide/thromboxane A structural
2
analogues, eg. 9,11-azaprostadienoic acid;
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(ii) imidazole and its analogues, eg. dazoxiben (UK 
37,248); and
(iii) pyridine derivatives, eg. OKY^1581.
In animal studies and in tissue preparations 
thromboxane synthase inhibitors have been shown to 
selectively and reversibly inhibit thromboxane formation 
(254 ) (277)(304)( 305)( 306). They exert no significant 
inhibitory effects on vascular endothelial cyclooxygenase 
or on prostacyclin synthase and therefore do not inhibit 
prostacyclin production. Indeed, a major theoretical 
advantage of these compounds derives from their potential 
to enhance prostacyclin biosynthesis as a result of 
rediversion of platelet-derived cyclic endoperoxides to a 
source of prostacyclin synthase, such as vascular 
endothelium (62).
Preliminary studies in man show that several of these . 
drugs inhibit the capacity of platelets to generate 
thromboxane ex vivo in healthy individuals
(64)(65)(307-310). There is also evidence that synthesis 
of prostacyclin may be increased by thromboxane synthase 
inhibitors in vivo (64 ) ( 65 ). Their effects on platelet 
function, however, have been variable and may be
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relatively minor in normal individuals (307)(309). The
ability of these drugs to inhibit thromboxane formation in 
vivo is investigated for the first time in the following 
studies. In addition, the biochemical and functional
consequences of thromboxane synthase inhibition are
evaluated in a clinically relevant model of platelet
activation in which endogenous synthesis of thromboxane is 
markedly enhanced.
2.Alternative Fatty Acid Substrates
Although arachidonic acid is the most common fatty acid
precursor of prostaglandins in membrane phospholipids,
prostaglandins can also be synthesized from alternative
fatty acid substrates. Dihomo- -linolenic acid
(eicosatrienoic acid) and eicosapentaenoic acid (EPA) have
three and five double bonds respectively instead of the
four double bonds present in arachidonic acid. These
alternative substrates are metabolized via the same
pathways as arachidonic acid. Two double bonds are lost
during the cyclooxygenase reaction and therefore
eicosapentaenoic acid (EPA) gives rise to prostaglandins
of the 3-series, for example PGG . PGH ,
3 3
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PGI2 and thromboxane A^ (311)(312). Similarly,
dihimo- Y  -linolenic acid is the substrate for
prostaglandins of the 1-series, such as PGG^,
PGH and thromboxane A (87) (Figure 1.11).
1 1
There may be substantial differences, however, between 
these alternative pathways and the arachidonic acid
cascade, both with respect to the affinity of the enzymes 
for the different substrates and the biological properties
of the resultant eicosanoids. Studies of cellular
metabolism in vitro have suggested that the products of 
EPA metabolism were either formed in smaller amounts or
were much less biologically potent than the corresponding 
arachidonic acid derivatives (311)(313)(314). Thus, for 
example, EPA has been shown in vitro to be a poor
substrate for platelet cyclooxygenase (315). Similarly, 
its analagous product, thromboxane A^, lacks the
biological potency of thromboxane A^ (311). On the 
other hand appears to possess similar
biological properties to prostacyclin in that it inhibits 
platelet aggregation and relaxes vascular smooth muscle in 
vitro (311).
There has been considerable interest in the possibility 
of dietary supplementation with fish oils rich in EPA and 
other omega-3 (N-3) fatty acids as an approach to reducing
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the biosynthesis of thromboxane A^. A reduction in
thromboxane A^ generation could occur as a result
either of a decrease in available arachidonic acid
substrate, or of competition by EPA with arachidonate for
cyclooxygenase or by increasing the formation of
relatively inactive thromboxane A^ at the expense of
thromboxane A . There have now been several studies 
2
of the effects of fish oil administration in man 
(313)(316-323). The principal constituent of the fish oils 
used, which contain mixtures of fatty acids, is EPA but 
significant concentrations of docosahexaenoic acid (DCHA) 
are also present. Preliminary evidence from these studies 
shows that the capacity of platelets to form thromboxane 
ex vivo is diminished during EPA feeding in 
healthy individuals (316 ) (317 ) (319 ). In addition, 
prostacyclin biosynthesis appears to be unaltered (312). A 
recent study by von Schacky and Weber has demonstrated 
that DCHA not only has intrinsic platelet-inhibitory 
properties, but that it can be retroconverted into EPA in 
vivo and may therefore contribute significantly to the 
putative anti-thrombotic effects of EPA (324). In 
addition, fish oil has been shown to exert effects 
distinct from those on platelet eicosanoid formation which 
may confer additional advantages in the prevention of 
atherosclerosis (325)(326).
90
SUMMARY AND SPECIFIC OBJECTIVES
The pathways of arachidonic acid metabolism in
platelets, leucocytes and endothelial cells have been
described and the biological effects of the major
metabolites in these and other tissues discussed. The
principal product of arachidonic acid in human platelets, 
thromboxane A^, is the most potent endogenous
platelet agonist known and a powerful vasoconstrictor. It 
has therefore been implicated in the pathogenesis of a
variety of diseases in which platelet activation and
vasospasm are believed to be important.
The studies described in this thesis were designed to 
fulfill the following specific objectives:
1. To investigate the effects on endogenous thromboxane 
and prostacyclin formation of different approaches to
selective inhibition of thromboxane synthesis in healthy 
individuals.
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2. To characterize endogenous biosynthesis of 
thromboxane in syndromes in which thromboxane-dependent 
platelet activation is thought to play an important role 
and in this way identify groups of patients for which this 
therapeutic strategy is likely to be most appropriate.
3. To examine the biochemical and functional 
consequences of selective inhibition of thromboxane 
synthesis in such patients.
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I.PROSTAGLANDIN METABOLITES
General Considerations
Sensitive and specific methods to measure the
biologically active eicosanoids are essential, not only
for our understanding of their role in health and disease
but also to critically evaluate the effects of drug
regimens designed to modify their synthesis. The
techniques used to quantitate the synthesis of the two
most potent eicosanoids, thromboxane A and
2
prostacyclin, are considered here.
The development of methods to measure thromboxane 
A^ and prostacyclin has been a problem for many 
reasons. Firstly, the normal physiological concentration 
of these compounds appears to be extremely low: certainly 
less than 5 pg/ml in plasma
(92 ) (93)(130 )(132)(181)( 327 )( 328 ). Highly sensitive assays 
are therefore required to measure their formation under 
basal conditions. Secondly, the biological half-lives of 
thromboxane A^ and prostacyclin are very short and 
they are rapidly cleared from the circulation (8)(127). 
For this reason most of the techniques employed quantitate
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their major metabolites rather than the parent compound. 
Thirdly, several studies have shown that samples obtained 
using invasive methods, including careful venepunctures 
and sampling from indwelling cannulae and catheters, are 
very likely to have falsely elevated values for 
thromboxane and prostacyclin production (263 )(264)( 329 ). 
This is due to the formation of arachidonate metabolites 
ex vivo during the sampling procedure and can be reduced 
by collecting samples immediately into an inhibitor or 
circumvented by measuring the major metabolites in urine 
(93 ) (130 )< 330 ). Finally, many other substances are present 
within the biological fluids being analysed, which may 
lead to non-specific interference with the assays used to 
measure the eicosanoids (259).
Three basic approaches to the analysis of human
thromboxane and prostacyclin synthesis have been
investigated: bioassays (8 ) (10)(331), radioimmunoassays
(328 ) (330 )( 331 ) and stable isotope dilution assays
employing gas chromatography/mass spectrometry (GC/MS)
(259). Although bioassays have the advantage of detecting
compounds with demonstrable biological activity, they are
also non-specific and relatively insensitive (331).
Radioimmunoassays have been developed for the
non-enzymatic hydration products of thromboxane A^
(thromboxane B ) and prostacyclin (6-keto-PGF )
2 lfe£
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in plasma. Many of the early studies measured levels 
of these metabolites by radioimmunoassay of several 
hundred picograms (173 )( 233 )( 260 )( 261)(262 ), thus greatly 
over-estimating their true values. This probably reflects 
a combination of the problems referred to above, including 
sampling artifacts, as well as cross-reactivity of the 
antibodies employed and the presence of impurities 
(130)(332). Although these difficulties have largely been 
overcome by using highly specific antibodies and rigorous 
sample purification (328 ) ( 333 ) ( 334 ), the problem of 
sampling artifact remains.
GC/MS was chosen as the best technique for assessing 
endogenous biosynthesis of thromboxane and prostacyclin in 
the following studies. It permits the accurate 
quantitation of the major metabolites of thromboxane and 
prostacyclin in urine and thus avoids the problem of 
sampling artifact and ex vivo formation of these 
metabolites. In addition, GC/MS is highly specific and the 
most sensitive methods will detect levels of eicosanoid 
metabolites in the subpicogram range (335). The principal 
disadvantage of this approach is that it is not possible 
to determine with certainty the tissue of origin of the 
measured metabolites. Nevertheless, this can be largely 
circumvented by measuring the different metabolites in the 
same urine samples, as discussed below. The use of
timed-aliquot urine collections also facilitates the study 
of changes in endogenous thromboxane and prostacyclin 
production over prolonged periods of time.
THROMBOXANE
Two different approaches to quantitating thromboxane 
synthesis have been utilized in the following studies:
(i) Measurement of platelet thromboxane formation ex
vivo (serum thromboxane B ).
2
Thromboxane B in serum was measured by
2
radioimmunoassay. This provides an index of thromboxane 
generation ex vivo and reflects the capacity of platelets 
to form thromboxane in clotting blood, largely in response 
to thrombin (336).
(ii) Measurement of thromboxane synthesis in vivo 
(urinary Tx-M and thromboxane
Endogenous biosynthesis was determined by measuring 
urinary metabolites of thromboxane. Previous work had
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already established that a major metabolite of thromboxane
B in urine is 2,3-dinor-thromboxane B (Tx-M)
2 2
(91) and a method for measuring this metabolite has been 
described in preliminary studies (266)(291). I utilized a 
modification of this method for the studies carried out in 
my thesis. In contrast to the original method, which used 
electron-impact GC/MS and required extensive purification 
of large sample volumes, the modification of Lawson et al 
employs capillary column gas chromatography with 
negative-ion chemical ionization mass spectrometry and can 
be applied to samples of 5ml or less (337). The principal 
innovation is the use of a bonded phase phenyl boronic 
acid column to selectively extract thromboxanes. This
eliminates three high-pressure liquid chromatography steps 
which were required in the original assay and greatly 
improves the recovery of the metabolites. It is 
consequently both specific and sensitive, allowing 
quantitation of Tx-M in the low picogram range. It can 
therefore be used to accurately assess the effects of 
inhibitors of thromboxane synthesis on endogenous
thromboxane formation. In addition, it permits the
concomitant measurement of urinary thromboxane B .
2
In contrast to the dinor metabolite (Tx-M), urinary
thromboxane B^ is thought to be mainly of renal 
origin under physiological conditions (338) and 
measurement of both metabolites may be useful in
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distinguishing between platelet and renal thromboxane 
biosynthesis.
Serum Thromboxane B   2
Venous blood (l-2ml) was collected via a 19-gauge
butterfly needle into a warmed glass tube, allowed to clot
and incubated at 37°C in a water bath for 45-60 minutes. 
The sample was centrifuged at 2,000g for 15 minutes and 
the serum was separated and stored at -20 °C for later 
analysis. Radioimmunoassay was performed as described by
Patrono et al (336) using an antibody generously provided 
by Dr RJ Workman (Vanderbilt University). Serial dilutions 
(1:25 - 1:625) of the unextracted serum were prepared in
duplicate in phosphate buffer and assayed at a final
dilution of 1:500 - 1:12,500. The assay used
USI-thromboxane B and a rabbit anti-thromboxane
2
B^ antibody which were added to each sample and 
incubated at 0cC for 60-90 minutes. After addition of
polyethylene glycol (21%) and centrifugation at 2,000g for 
15 minutes at 0°C, the fluid phase was removed and the 
radioactivity of the sedimented fraction counted.
10 2
The detection limit of the assay was 1 ng/ml. Normal
values ranged between 119 and 779 ng/ml (mean 366 +/- 33
ng/ml) and were unaffected by age or sex (see Appendix I).
As reported by others (339 ) ( 340), there was a positive
correlation between platelet count and serum thromboxane
generation (r=0.588;p<0.001) in normal subjects.
The contribution of platelet number to the overall
variation in serum thromboxane B observed in
2
healthy individuals has been shown to be minor and 
insufficient to warrant correction of serum levels for 
platelet count (339).
Urinary 2 ^ i n o r - t h r o m b o x a n e  (jrx-M, and
Thromboxane B 
 2"
Sample collection:
Urine was collected in plastic containers with no added 
preservative. Baseline samples were usually collected over 
a 24-hour period, but shorter (6 or 12-hour) collections 
were used to assess the effects of inhibitory therapy in 
order to detect transient changes in metabolite excretion. 
In every case concomitant measurement of urinary
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creatinine was carried out to correct for variations in 
urine volume and the possibility of incomplete 
collections. Whenever possible the containers were kept at 
4 °C during the collection.
Internal Standard:
Tx-M was measured using a stable isotope dilution assay 
as described by Lawson et al (337). Deuterated 
2,3-dinor-thromboxane (19,19,20,20-
aH -dinor thromboxane B ) provided by Drs F.
4 2
Fitzpatrick and J. Pike (Upjohn Company, Kalamazoo,
Michigan, USA) was used as the internal standard. A known 
amount of internal standard (2.5 ng/ml of urine) was added 
to each aliquot of urine as soon as possible after
collection and these "spiked" urine samples were stored at 
-20°C until later analysis. Samples could be stored in 
this way for several months without any significant loss 
of activity and the addition of the internal standard soon 
after collection ensured that any change occurring with
storage affected the standard and endogenous metabolite
equally.
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MethoximeDerivatization and Extraction:
A 5ml aliquot of "spiked" urine was thawed and mixed 
with 0.5g methoxyamine hydrochloride and 1.5ml acetate 
buffer and allowed to stand at room temperature for at
least 5 minutes to form the methoxime derivative (Figure
2-1). The sample was then applied to a phenylboronic acid
column which had been prepared with 2ml methanol and
converted to the trigonal neutral form with 0.1N
hydrochloric acid. Formation of the methoxime derivative 
with its open ring structure is essential for efficient 
bonding of Tx-M to the phenylboronic acid column (Figure 
2-2). The column was then rinsed with acid salt followed 
by methanol and the metabolite was eluted using 0. IN 
sodium hydroxide in methanol. The eluate was acidified 
with 10% formic acid and purified by application to a 
reverse-phase Sep-Pak cartridge which had been primed with 
methanol then distilled water. The column was washed with 
distilled water followed by methanol:water (1:3) and the 
metabolite was then eluted with ethyl acetate and 
evaporated to dryness under nitrogen.
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FIGURE 2.1 DERIVATIZATION OF Tx-Mt METHOXIKE FORMATION IN URINE.
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FIGURE 2.2 DERIVATIZATION OF Tx-M : BONDING TO THE PHENYLBORONIC ACID COLUMN.
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Further Purification and Derivatization:
The dried extract from the reverse-phase cartridge was 
dissolved in methanol, applied to a silicic acid thin 
layer chromatography plate and run in a solvent system of 
ethyl acetate, acetic acid and hexane (54:12:25, 
vol:vol:vol). Unlabelled 2,3-dinor-thromboxane
B^-methoxime run concurrently on a separate plate 
was used as the standard (Rf approximately 0.21). For each 
sample, the area of the plate corresponding to the Rf 
value of the standard was scraped (Figure 2-3), added to 
1.5ml ethyl acetate and, after centrifuging for 1 minute 
at 900rpm, the organic layer was removed and evaporated to 
dryness under nitrogen.
The sample was further derivatized as the 
pentafluorobenzyl ester by adding di-isopropylethylamine 
(lOul) and 12.5% pentafluorobenzyl bromide in acetonitrile 
(20ul) and heating for 30 minutes at 40°C. Derivatization 
is necessary in order to increase the sensitivity and 
specificity of the assay by improving the gas 
chromatography characteristics of the metabolite (259). 
The pentafluorobenzyl ester derivative was applied to a 
thin layer chromatography plate and run in a solvent 
system of isooctane and ethyl acetate (65:85, vol:vol)
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FIGURE 2.3
Thin layer chromatogram of authentic standards of 
2,3-dinor-thromboxane Bn and 6-keto-PG F„2 lot
2,3-dinor-thromboxane B0 6-keto-PGF„- 2  l
For each sample a 1-1.5 cm area of the plate corresponding to a concurrently 
run standard was scraped and extracted into ethyl acetate.
using the same standard as above which had been subjected 
to derivatization in the same way as the samples. The 
plate was scraped as before (Rf value approximately 0.11), 
added to ethyl acetate and the organic layer aspirated and 
evaporated to dryness. Final derivatization was achieved 
by adding bis (trimethylsilyl) trifluoroacetamide (lOul)
and pyridine (lOul) to form the trimethylsilyl ether.
Gas Chromatography-Mass Spectrometry:
The samples were analysed by gas chromatography-mass 
spectrometry using a Nermag 10-10C mass spectrometer 
linked to a Varian Vista 6000 gas chromatograph. The mass 
spectrometer was operated in the negative ion-chemical 
ionization mode. The mass spectra obtained in this mode 
are much simpler than those obtained by electron impact 
mass spectrometry. In addition, it is also highly
efficient and, as the principal fragmentation ions are in
the high mass range, there is good separation of Tx-M from 
any contaminating substances which may remain despite 
rigorous purification. Negative ion-chemical ionization is 
therefore both very specific and very sensitive (259).
Specificity was augmented by using capillary column gas 
chromatography (a 5 M DB-1 capillary column) to improve 
resolution. Selected ion monitoring was carried out at m/z 
(mass/charge ratio) 586 for endogenous Tx-M and m/z 590
(ie 4 mass units higher) for the tetradeuterated
internal standard. The negative ion-chemical ionization 
mass spectrum of the methoxime, trimethylsilyl ether,
pentafluorobenzyl ester derivative of Tx-M is shown in 
Figure 2-4. Selected ion monitoring for the same compound 
is shown in Figure 2-5. The top trace represents
endogenous Tx-M and the lower trace the internal standard.
Normal values were established first in young healthy
male subjects. These results and the effects of 
physiological variables on Tx-M excretion are given in 
Appendix I. Mean daily Tx-M excretion was 138 +/- 20 pg/mg 
creatinine with a range of 73 to 237 pg/mg creatinine. The
equivalent values expressed in ng/hour were 10.3 +/- 2.0
(range 4.8 to 24 ng/hour). Subsequent experiments showed 
that there was no difference between male and female 
subjects. Tx-M was significantly higher in healthy 
individuals over the age of 50 years (223 +/- 22 pg/mg
creatinine), despite normal creatinine excretion. The
relationship between age and Tx-M concentration was linear 
between the ages of 20 and 90 years in healthy subjects.
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FIGURE 2.4 NEGATIVE ION-CHEMICAL IONIZATION MASS SPECTRUM OF THE METHOXIME, 
TRIMETHYLSILYL ETHER, PENTAFLUOROBENZYL ESTER DERIVATIVE OF Tx-M.
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FIGURE 2.5 SELECTED ION MONITORING TRACE FOR THE METHOXIME, TRIMETHYLSILYL ETHER,
PENTAFLUOROBENZYL ESTER DERIVATIVE OF Tx-M AND THE TETRADEUTERATED INTERNAL STANDARD.
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Evidence that Tx-M derives predominantly from platelets
The levels of Tx-M measured in urine reflect total body
synthesis of thromboxane B . Tx-M is therefore
2
derived from both platelet and extraplatelet sources. In
platelets, however, thromboxane A is the principal
2
metabolite of arachidonic acid, whereas in most tissues 
which have the capacity for thromboxane synthesis, such as 
the kidney, other metabolites predominate (34)(35). 
Furthermore, as can be seen from the concentrations of 
thromboxane in serum, platelets have a huge
capacity for thromboxane generation in response to 
agonists such as thrombin. Before proceeding to study the 
biochemical and functional effects of different approaches 
to inhibition of thromboxane synthesis in detail, I 
carried out some preliminary experiments to address the 
hypothesis that urinary Tx-M is predominantly derived from 
platelets.
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1. Relationship between Tx-M excretion and platelet 
count:
Method: Tx-M was measured in 24 hour urine collections
from 28 healthy subjects aged 21-75 years. Platelet counts 
were performed in each subject on peripheral venous blood 
samples analysed on a Coulter counter.
Results: As shown in Figure 2.6, Tx-M was proportional
to platelet count over a wide range of counts (r=0.91; 
pCO.OOl).
FIGURE 2 . 6
R E L A T I O N S H I P  BETWEEN T x - M  AN D P L A T E L E T  C O U N T  
IN 28 H E A L T H Y  S U B J E C T S
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2. Effect of increased platelet turnover on Tx-M:
Method: 24-hour urine collections for measurement of
Tx-M were made in three patients with clinical syndromes 
in which platelet turnover is known to be increased. Two 
patients had immune thrombocytopenia and one (J.B.), in 
whom measurements were made on 2 separate occasions, had 
hypersplenism.
Results: The results are shown in Table 2.1. Bone
marrow findings on all the patients were consistent with 
thrombocytopenia due to peripheral platelet destruction 
with a shortened platelet lifespan. All three patients 
also had significantly elevated levels of urinary Tx-M.
TABLE 2.1 Tx-M EXCRETION IN PATIENTS WITH INCREASED PLATELET 
TURNOVER.
Patient
Tx-M
(pg/mg creatinine)
Platelet Count 
(x109/l)
JB 1478 63
1699 69
AR 449 42
MF 1492 109
PE 545 45
Ill
3. Tx-M excretion in patients with platelet activation 
in vivo:
Method: 10 patients with various conditions in which
platelet activation in vivo is thought to occur were 
studied. Tx-M was measured in 24-hour urine collections 
and in some patients plasma p-thromboglobulin was 
quantitated by radioimmunoassay as described below. In the 
patient with acute myocardial infarction serial urine 
collections were made before and after the event.
Results: The results are shown in Table 2.2. In this
small uncontrolled pilot study all patients were shown to
have elevated Tx-M excretion (compared to values measured
separately in normal subjects), despite normal platelet
counts in all but one. The exception was the patient
(R.B.) with primary polycythaemia who had mild
thrombocytosis. In those patients in whom
^-thromboglobulin concentrations were available, these
were also increased to a variable extent, consistent with
platelet activation in vivo. Serum thromboxane B ,
2
which is a capacity-related index and would not therefore 
be expected to be increased in the presence of platelet 
activation in vivo, was normal in all the subjects tested.
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4. Effect of aspirin on Tx-M:- pattern of inhibition
and recovery:
Method: A single dose of 650mg of aspirin was given to
3 healthy male volunteers. Urine was collected in 24-hour
aliquots before and at intervals for 11 days after aspirin 
administration.
Results: Tx-M fell following the aspirin and remained
inhibited for several days, returning to normal by 11 days
after dosing (Figure 2.7).
FIGURE 2.7
I N H I B I T I O N  AND R E C O V E R Y  OF T x - M  A F T E R  
S I N G L E  D O SE  A D M I N I S T R A T I O N  OF 650mg A S P I R I N
300 r—
r 200
£ 100
0 L_
B e f o r e  1 
d o s i n g
11
D a y s  a f t e r  d o s i n g
113
5. Review of other studies:
There is also evidence from other studies consistent 
with a mainly platelet origin for Tx-M. Levels of Tx-M 
declined by over 90% during chronic administration of high 
dose aspirin (291). Excretion of Tx-M remained depressed 
for several days after aspirin was discontinued, 
consistent with irreversible acetylation of platelet 
cyclooxygenase. By contrast, the recovery of Tx-M was much 
more rapid after reversible cyclooxygenase inhibition 
induced by indomethacin (266). Tx-M is also significantly 
inhibited after chronic administration of low-dose aspirin 
(291), whereas urinary thromboxane , which is 
believed to be primarily of renal origin under 
physiological conditions, remains unaltered (338). 
Finally, Tx-M has been shown to be markedly increased in 
another syndrome of platelet activation in vivo, 
thrombotic thrombocytopenic purpura, and to fall towards 
normal in response to prostacyclin infusion (341).
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Measurement of Urinary Thromboxane B — .---------------------*     2_
Urinary excretion of thromboxane B was measured
2
by a similar stable isotope dilution assay. The internal 
standard was tetradeuterated thromboxane B
2
(generously provided by Drs. Fitzpatrick and Pike, Upjohn
Company, Kalamazoo, Michigan). The purification and
derivatization steps were identical with those described
above for Tx-M with the exception that, since the relative
migration rates for thromboxane B and Tx-M
2
(respectively 0.33 and 0.21) are different, the
appropriate areas of the thin-layer chromatography plates 
were scraped at each step of the thin layer chromatography 
procedure.
Quantitation was established using the Nermag 10-10C
instrument operating in the negative ion mode monitoring
m/z 614 for endogenous thromboxane B and m/z 618
2
for the internal standard. A selected ion monitoring trace
for endogenous thromboxane B (too trace) and the
2
tetradeuterated standard (bottom trace) is shown in Figure 
2.8. Urinary thromboxane B^ ranged from 16 to 76 
pg/mg creatinine in healthy subjects with a mean of 46 +/- 
6 pg/mg creatinine. The equivalent values in ng/hour 
ranged from 0.5 to 7.3 with a mean of 2.8 +/- 0.7 ng/hour
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(see Appendix I).
Calculations:
The urinary excretion of thromboxane and Tx-Mr 
the dinor metabolite, is expressed in most of the 
experiments in pg/mg of urine creatinine. The amount of 
endogenous thromboxane or Tx-M is calculated from 
selected ion monitoring traces by comparing the peak 
height of the endogenous compound with that of the known 
amount of internal standard. The value obtained in pg/ml 
is then corrected for the total volume of urine collected 
and the concentration of creatinine. Correction of Tx-M or 
urinary thromboxane B^ for creatinine was 
particularly important when short timed collections were 
employed. In experiments in which differences in Tx-M 
excretion were sought between groups of subjects (eg 
patients with atherosclerosis versus healthy individuals) 
the rate of excretion in ng/hour was also determined.
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PROSTACYCLIN
Prostacyclin biosynthesis was determined by measuring
urinary 2,3-dinor-6-keto-PGF (PGI-M) using a
loC
stable isotope dilution assay. The method employed was a 
modification (335) of the original method described by
Falardeau et al (342).
Urinary PGI-M:
Sample collection:
Urine was collected into plain plastic containers. The 
collections were timed and, as for the thromboxane
metabolites, the amount of PGI-M measured was corrected in
each case for creatinine excretion.
Internal -Standard:
Tetradeuterated 2,3-dinor-6-keto-PGF (supplied
lQ4
by Drs Fitzpatrick and Pike of the Upjohn Company) was 
employed as the internal standard for this assay. The
117
standard was added at a concentration of 1 ng/ml of urine. 
Aliquots of urine were "spiked" with the internal standard 
as soon as possible after collection and the samples 
stored at -20°C for later analysis.
Derivatization and Purification:
After thawing, the "spiked" samples were subjected to 
extraction and back extraction under acidic and alkaline 
conditions. The extract was derivatized as the methoxime 
by addition of 0.5% methoxyamine hydrochloride in pyridine 
and heating for 60 minutes at 70®C. The samples were then 
evaporated to dryness under nitrogen and further
derivatizated as the pentafluorobenzyl ester. This was 
accomplished by addition of di-isopropylethylamine (lOul) 
and 12.5% pentafluorobenzyl bromide in acetonitrile (20ul) 
and heating for 30 minutes at 40^C.
Further purification was carried out by thin-layer
chromatography in a solvent system of 2% methanol in ethyl
acetate using as standard 6-keto-PGF derivatized
loC
as the methoxime penatfluorobenzyl ester (Rf approximately 
0.18). Derivatization was completed by formation of the 
trimethylsilyl ether by addition of bis (trimethylsilyl) 
trifluoroacetamide (lOul) and pyridine (lOul).
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Gas Chromatography-Mass Spectrometry:
Quantitation was accomplished using a Hewlett Packard 
5980 instrument operating in the negative ion-chemical 
ionization mode. Monitoring was at m/z 586 for endogenous
PGI-M (dg) and m/z 590 for the tetradeuterated
internal standard A representative trace is
shown in Figure 2.9. Calculation of the amount of PGI-M
present was achieved by comparing the measured peak
heights of endogenous PGI-M to that of the known amount of
internal standard, as for the thromboxane metabolites, and
correcting for urine volume and creatinine concentration.
The results were mainly expressed in pg/mg creatinine. In 
some experiments the data is also given in ng/hour.
In control experiments in healthy subjects PGI-M
excretion ranged from 55 to 142 pg/mg creatinine with a
mean of 101 +/- 9 pg/mg creatinine. The equivalent values 
in ng/hour ranged from 3.6 to 13.8 with a mean of 8.1 +/-
0.6 ng/hour (see Appendix I). There was no difference 
between men and women, but values were higher in older
subjects (mean PGI-M in subjects over 50 years: 197 +/- 21
pg/mg creatinine), despite normal creatinine excretion
119
(see Appendix I).
figure 2. SELECTED ION MONITORING TRACE OF THE METHOXIME, TRIMETHYLSILYL ETHER, 
PENTAFLUOROBENZYL ESTER DERIVATIVE OF PGI-M AND THE TETRADEUTERATED 
INTERNAL STANDARD.
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II.PLATELET FUNCTION
General Considerations
A variety of approaches to the assessment of platelet 
function have been developed. Although there are a number 
of animal models of platelet activation in vivo 
(203 ) (343)(344 )( 345), the skin bleeding time is the only 
reliable measure of haemostatic function in vivo in man. 
The bleeding time, however, is relatively non-specific as 
it is influenced by other factors in addition to platelets 
(346). Methods to specifically evaluate platelet function 
have mainly been directed towards their ability to respond 
to various stimuli in vitro. The most widely used 
technique, platelet aggregometry by the light transmission 
method, was described by Born in 1962 (347). Since that 
time various methods to measure platelet aggregation in 
whole blood have also been devised in the hope that such 
an approach would more closely represent the processes 
occurring in vivo (348 ) ( 349 ) . Alternatively, measurement 
of circulating platelet aggregates and of the 
platelet-specific proteins, p-thromboglobulin and platelet 
factor 4 released when platelets are activated, have been 
employed as markers of platelet activation in vivo in
several disease states (167 ) ( 265 ) ( 350 ).
BLEEDING TIME
In all of these studies the bleeding time was measured 
by the template method using the Simplate I device. This 
device has been shown to give reproducible results and to 
produce a significantly prolonged bleeding time after 
aspirin ingestion (351). The test was performed on the 
volar aspect of the forearm and care was taken to avoid 
blood vessels. The incision was consistently made 
perpendicular to the fold of the elbow. A sphygmomanometer 
cuff was kept inflated at a pressure of 40 mm Hg 
throughout the procedure. The blood emerging from the 
incision was removed every 30 seconds with a disc of 
filter paper until the bleeding stopped. In my hands the 
mean normal value for the bleeding time using this 
technique was 5.0 +/- 0.4 minutes in healthy individuals
with a range of 2.5-7.0 minutes (see Appendix II).
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PLATELET AGGREGATION
Platelet aggregation in most of the studies was 
measured in platelet-rich plasma by the light transmission 
method (347). In some experiments an impedance method was 
also used to examine platelet aggregation in whole blood 
(348). The principal advantages of the light transmission 
method are that it is a well validated method which has 
been in use for over 25 years and provides reproducible 
data. The availability of two- and four-channel machines 
has speeded up the procedure and allows more samples with 
different agonists to be tested within a short time of
collection. It does not, however, take account of the
possible contributions of erythrocytes and leucocytes to
the process of platelet aggregation and also, as a result 
of sample preparation, may select a particular 
subpopulation of platelets for study rather than 
reflecting the behaviour of the circulating platelet pool. 
Whole blood platelet aggregometry was developed in an 
attempt to remedy some of these problems and has the 
additional advantage of allowing the sample to be analysed 
within a few minutes of blood withdrawal ( 348 ) ( 352 ).
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Preparation of platelet-rich plasma;
Platelet-rich plasma (PRP) was prepared from venous 
blood collected into 3.8% sodium citrate (1:9 
citrate:blood). The citrated blood was transferred to 
plastic tubes and centrifuged at 150g for 15 minutes at 
20dC. The PRP was removed and platelet-poor plasma (PPP) 
prepared by further centrifugation of the remaining blood 
at 2,000g for 15 minutes. The platelet count of the PRP 
was determined using a Coulter counter and adjusted to 30 0 
x 10*/I by addition of appropriate quantities of PPP. 
Aliquots of 0.5 ml PRP were kept at 37°C and tested within 
2 hours of collection.
Aggreqometry:
Platelet aggregation was measured in a Payton 
dual-channel aggregometer. The agonists used were: 
collagen in a high dose (19 ug/ml, final concentration) 
and a low dose (1.9 ug/ml); arachidonic acid in various 
concentrations from 0.33-1.33 mM; and adrenaline 1-10 uM. 
All the reagents were freshly prepared on the day of 
study. In each case the sample of PRP was preincubated for 
1 minute and a stable baseline obtained on the chart
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recorder prior to addition of the agonist. The samples 
were stirred continuously using magnetic stir bars and 
recording was continued for 6 minutes.
The extent of platelet aggregation was quantified in
two ways (Figure 2.10). Firstly, by measuring the maximum
height in cm of the aggregation trace after 6 minutes
(T ), using the baseline tracing prior to agonist 
max 6
addition as zero, ie no light transmission. This
measurement takes no account of the rate at which platelet
aggregation is occurring. This may be calculated from the
slope of the aggregation trace but, in the absence of an
aggregometer designed to measure this parameter
automatically, it may be very inaccurate. An alternative
is to measure the lag time to achieving 50% of maximal
aggregation (LT , Figure 2.10), which has been
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shown to be a sensitive quantitative index of
arachidonate-induced aggregation (298). In all the studies
data for adrenaline-induced aggregation are expressed as
the T measuring the total height of the primary
max 6
and secondary wave together. For arachidonic acid and 
collagen-induced aggregation the l t 5q tended to give 
more sensitive and reproducible results. Normal values are 
given in Appendix II.
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FIGURE 2.10 CALCULATION OF THE LT (LAG TIME TO ACHIEVING 30% OF MAXIMAL 
AGGREGATION).
PPP
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Platelet aggregation in whole blood:
Platelet aggregation in whole blood was measured by 
impedance aggregometry using the Chrono-log Whole Blood 
Aggregometer. This measures an increase in electrical 
impedance across electrodes placed in the blood sample as 
platelets accumulate on them. Venous blood collected into 
l/10th volume 3.8% citrate was discharged in 1 ml aliquots 
into plastic cuvettes for immediate testing. After 
preincubation for 1-2 minutes to establish a stable 
baseline, the agonist was added and the resultant change 
in impedance monitored for 10 minutes. Collagen and 
arachidonic acid were used as agonists in these 
experiments in fixed doses of 9.5 ug/ml and 0.66mM 
respectively.
Results were expressed as the increase in impedance in 
ohms after 6 minutes. In common with some other 
investigators (353), I found this method less sensitive 
and less consistent than light transmission platelet 
aggregometry (see Appendix II). I therefore used the light 
transmission method for most of my experiments. 
Nevertheless, the whole blood technique offered particular 
advantages in assessing the effects of thromboxane 
synthase inhibitors and in some of these experiments both
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methods were employed.
PLATELET GRANULE PROTEINS
Measurement of the plasma levels of the 
platelet-specific granule proteins, p-thromboglobulin and 
platelet factor 4, provides a useful index of the presence 
of platelet activation in vivo ( 265) ( 354 ). Interpretation 
of the results may be confounded by the influence of in 
vitro platelet activation resulting in artificially 
elevated values (263)(265)(355). In addition, measurement 
of p-thromboglobulin is unreliable in renal failure as the 
plasma concentration may rise significantly without
enhanced platelet release in vivo (356). There is also 
considerable variation in both p-thromboglobulin and
platelet factor 4 assays between different laboratories 
(357) and normal ranges must therefore be established 
within individual laboratories.
The problems of in vitro activation can be minimized in 
several ways: by careful sampling, by employing an
appropriate anticoagulant containing platelet inhibitors, 
by rapid sample processing at 4 °C and, because of their
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markedly different plasma clearance rates, by measurement
of both granule proteins in the same sample (265)(354).
Although ^-thromboglobulin and platelet factor 4 are 
released in similar quantities, the clearance of platelet
factor is extremely rapid compared to that of
J3-thromboglobulin and the plasma concentration
consequently significantly lower (358). Thus, comparable 
elevations of platelet factor 4 and p-thromboglobulin 
measured in the same sample strongly suggest in vitro 
platelet release. In contrast, elevated levels of 
J3-thromboglobulin in the presence of normal or slightly 
increased levels of platelet factor 4 are consistent with 
in vivo platelet activation.
p-thromboglobulin and platelet factor 4 were measured 
in plasma by radioimmunoassay using commercially available 
kits. In each case the concentration of both granule 
proteins was determined in the same sample. Consequently 
identical procedures for sample collection and preparation 
were followed for both assays.
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ft-Thromboglobulin
Sample collection and preparation:
Blood was collected without stasis via a 19-gauge 
butterfly needle into a syringe containing an ice-cold 
anticoagulant mixture in a ratio of 4:1
blood:anticoagulant. The anticoagulant mixture was freshly 
prepared and consisted of acid citrate dextrose with lOuM 
indomethacin and luM PGE^ added to minimize in vitro 
platelet activation. A two-syringe technique was also used 
to clear the system of activating factors: blood drawn 
into the first syringe (l-2ml) was discarded, while the 
second sample collected into the anticoagulant mixture was 
retained for analysis. The samples were kept in melted ice 
and centrifuged within 30 minutes of withdrawal at 30,000g 
at 4 #C for 20 minutes. Platelet-poor plasma from the top 
layer was removed and stored at -20°C for later analysis.
Radioimmunoassay procedure:
Plasma p-thromboglobulin was measured using the 
Amersham radioimmunoassay kit following the standard
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procedure. The assay depends on competition between
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endogenous and I -labelled B-thromboglobulin for a
limited number of binding sites on a rabbit
p-thromboglobulin-specific antibody. Plasma (50ul) was
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incubated with I -B-thromboglobulin (200ul) and
specific antibody (200ul) for 60 minutes at room 
temperature. After ammonium sulphate precipitation, the 
precipitates were counted in a gamma counter and the
results calculated from a standard curve derived from 
concurrently run standards. Normal values ranged between 2 
and 24 ng/ml with a mean of 12.2 +/- 1 ng/ml (see Appendix 
II). Elevated values of p-thromboglobulin were excluded 
from analysis if increased levels of platelet factor 4 
were obtained in the same sample. Measurement of both 
granule proteins in samples from 38 patients identified 
values of platelet factor 4 in excess of 18 ng/ml as 
likely to be accounted for largely by in vitro platelet 
activation (see Appendix II).
Platelet Factor 4
Platelet factor 4 was measured using a radioimmunoassay 
kit from Abbott Laboratories following the standard 
procedure. Sample preparation was identical to that for
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p-thromboglobulin. I -labelled platelet factor 4
(250ul) and goat platelet factor 4 antiserum (250ul) were 
added to plasma samples and standards (50ul) and incubated 
at room temperature for 2 hours. After ammonium sulphate 
precipitation, the net radioactivity in the precipitate 
was determined in a gamma counter and the results 
calculated from a standard curve derived from concurrently 
run standards.
Normal values in healthy subjects ranged from 2-18
ng/ml with a mean of 7.7 +/- 0.7 ng/ml (see Appendix II).
Values in excess of 18 ng/ml in healthy subjects were
invariably associated with a marked increase in
p-thromboglobulin in the same sample suggesting that
platelet release had occurred in vitro during sample 
collection or preparation. Repeat samples on these
subjects always yielded results within the normal range 
which I had established. I therefore excluded all samples 
in which platelet factor 4 levels were greater than 18
ng/ml (see Appendix II), on the assumption that
significant platelet release had occurred in vitro, thus
increasing the likliehood that measured increases in 
p-thromboglobulin could be attributed to platelet
activation in vivo.
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CIRCULATING PLATELET AGGREGATES
The circulating platelet aggregate ratio (CPA) was 
measured according to the method of Wu and Hoak (350). 
Venous blood was collected via a 19 gauge butterfly needle 
without stasis. Blood samples (0.5 ml) were drawn directly 
into syringes containing either 2ml of buffered EDTA 
solution or 2ml of EDTA-formalin solution. The buffered 
EDTA solution was prepared by adding 3ml 0.077M EDTA to 
5ml phosphate-buffered saline and 10ml distilled water; 
5ml 4% formalin was added to the EDTA-formalin solution to 
a final volume of 20ml. Duplicate samples were taken on 
each occasion to control for in vitro platelet activation. 
The samples were gently mixed and decanted into 
siliconized tubes, then left to stand at room temperature 
for 15 minutes and centrifuged at 150g for 5 minutes to 
obtain platelet-rich plasma (PRP). Platelet counts in the 
PRP from each sample were carried out using a Coulter 
counter.
The CPA ratio was calculated as follows: counts in 
EDTA/counts in EDTA-formalin (data are therefore expressed 
as the inverse of that originally described by Wu and 
Hoak). The method is based on the principle that platelet
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aggregates will be fixed in the EDTA-formalin solution and 
will therefore sediment to the bottom of the tube with 
centrifugation. The presence of circulating platelet
aggregates is then reflected by a lower count in the PRP 
from the EDTA-formalin sample and hence an elevated CPA 
ratio. The CPA ratio in healthy subjects ranged from 
0.812-1.116 with a mean of 1.011 +/- 0.016 (see Appendix 
II).
ASSAYS OF DRUGS AND THEIR METABOLITES
ASPIRIN AND SALICYLATE:
The experiments using very low doses of aspirin (20mg 
or less) required a highly sensitive assay to detect 
plasma levels of aspirin and salicylate with accuracy. 
Methods using high performance liquid chromatography lack 
the sensitivity and specificty to characterize aspirin 
kinetics at doses below lOOmg ( 358 ) ( 359 ). I therefore used 
a stable isotope dilution assay employing gas 
chromatography/mass spectrometry which had a detection
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limit of 10 ng/ml. This method was developed by Pedersen 
and FitzGerald in the laboratory in which I carried out 
this work and is described in detail elsewhere (360). 
Heptadeuterated derivatives synthesized in the laboratory 
were used as internal standards.
Sample Preparation:
Venous blood was collected into heparin with sodium 
fluoride (to prevent deacetylation) and immediately 
centrifuged at 2,000g at 4®C. The plasma was removed and - 
stored at -20°C for later analysis.
Analytical Procedure:
Aliquots of plasma (300ul) were mixed with 5ml 0.06M pH 
6.5 phosphate buffer containing 0.1M tetrahexylammonium 
hydroxide and 5ml dichloromethane containing 25ul 
benzylbromide. Internal standard solution containing 
aspirin and salicylic acid-heptadeuterobenzyl esters (5ul) 
was then added to each sample and the samples were shaken 
in a mechanical shaker for 10 minutes. Following 
extraction and centrifugation at 2,000g for 10 minutes, 
the upper layer and colloid interface were removed and the 
organic phase evaporated to dryness under nitrogen. The 
sample was partitioned between hexane (2ml) and water 
(2ml) and the hexane phase transferred to a tube 
containing l-2g sodium sulphate, shaken to mix and
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decanted. After evaporation to dryness under nitrogen, the 
residue was dissolved in ethyl acetate (50ul) prior to gas 
chromatography.
Gas Chromatography/Mass Spectrometry:
Quantitation was accomplished with a Hewlett Packard 
5980 instrument operating in the electron impact mode. 
Selective ion monitoring was carried out at m/z 228 for 
endogenous aspirin and salicylic acid and m/z 235 for the 
heptadeuteratea internal standards. Using this method 
aspirin and salicylic acid could be detected in plasma 
after oral administration of a single 20mg dose of 
aspirin.
3-lH-imidazol-l-yl-methy)-2-methyl-lH-indole-l-propanoic 
Acid (UK 38,485):
In order to confirm drug absorption, plasma 
concentrations of UK 38,48 5 were determined in all the 
subjects studied. These analyses were kindly undertaken by 
Dr P. Gibson of Chapel Laboratories (Hythe, Kent) by 
arrangement with Dr J.F. Faulkner, Pfizer Central 
Research, Groton, Connecticut. The method employed high 
performance liquid chromatography. Briefly, UK 38,485 was
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isolated from plasma by precipitation with acetonitrile. 
The sample was then centrifuged at 2,000g for 5 minutes, 
evaporated to dryness under nitrogen and resuspended in 
tetramethylethylenediamene/citrate buffer. Quantitation 
was accomplished using a Spherisorb Phenyl column with a 
mobile phase of 75% methanol:25%
tetramethylethylenediamene/citrate buffer. UK 38,485 and 
the internal standard (UK 37,418) were detected by 
fluorescence at an excitation wavelength of 220nm and 
emission of 370nm. The limit of detection of the assay was 
lOng/ml.
Imidazo(1,5-2)pyridine-5-hexanoic Acid (CGS 13080):
Drug absorption was confirmed for CGS 13080 by 
measuring plasma levels in all the patients studied. The 
analyses were carried out by Dr Chan of the Ciba-Geigy 
Corporation, Summit, New Jersey. Plasma CGS 13080 was 
determined by high performance liquid chromatography. 
After purification using an Amberlite CG-50 cation 
exchange column, the samples were applied to a C18 
u-Bondpack column with a mobile phase of 0.01M 
sodium-l-pentanesulphonate, pH 3, containing 27% 
acetonitrile. Levels of CGS 13080 and an internal standard 
(CGS 13067) were measured by fluorescence at an excitation
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wavelength of 280nm. The limit of detection of the 
assay was 10 ng/ml.
IV.STATISTICAL METHODS
All the data in these studies were analysed by 
non-parametric methods, thereby avoiding assumptions as to 
the distribution of the variables under investigation
(361). Analysis of variance was carried out either by the 
method of Friedman or by that of Kruskall and Wallis 
according to the form of the data. Subsequent pairwise 
comparisons were then performed by the Wilcoxon
Matched-Pairs Signed-Ranks Test or the Mann-Whitney U Test 
as appropriate. The Lord's U Test was occasionally used 
where small sample size precluded other tests. The data 
are expressed throughout this work as the mean values +/-
the standard error of the mean (SEM) except where
otherwise stated.
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Chapter 3
SELECTIVE INHIBITION OF ENDOGENOUS THROMBOXANE 
FORMATION; Studies in Healthy Subjects
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Introduction
Recognition of the potent biological properties of
thromboxane A^ and of the role of platelets in
vascular occlusion has stimulated research into the
development of therapeutic regimens designed to inhibit
thromboxane-dependent platelet activation. Although
several different approaches have been investigated in
animal and clinical studies, the lack of a suitable assay
to quantify endogenous thromboxane production has made
interpretation of these sudies very difficult. The
principal pharmacological approaches to the inhibition of
thromboxane biosynthesis are: selective blockade of
thromboxane synthase and inhibition of cyclooxygenase by
aspirin. The following studies utilize the newly-modified
assay described in chapter 2 for 2,3-dinor thromboxane
B (Tx-M) to evaluate the effects of these drugs on 
2
endogenous thromboxane formation in healthy human 
subjects.
The synthesis of specific inhibitors of thromboxane 
synthase represented a theoretically attractive approach. 
These drugs not only block platelet microsomal synthesis
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of thromboxane from prostaglandin endoperoxides 
(274)(275)(276)(303), but also, in the presence of a 
source of prostacyclin synthase, enhance the generation of 
prostacyclin in vitro (62)(309). In diverse animal models 
of acute thrombosis (205)(211)(228) and other potentially 
thromboxane-mediated conditions ( 212) ( 216)(250 )( 251) the 
results have been promising. However, preliminary clinical 
studies in small groups of patients with similar 
conditions have generally failed to confirm these findings 
in man. There are likely to be many reasons for this. It 
may relate to the characteristics of the patients studied. 
For example, thromboxane A^ may play an 
insignificant role in the pathogenesis of some of the 
conditions in which the efficacy of thromboxane synthase 
inhibitors has been investigated. Alternatively, the 
principal reasons for their disappointing results in the 
clinical setting may be attributable to the pharmacology 
of the drugs themselves. In the first section of this 
chapter the pharmacology of a newly developed selective 
inhibitor of thromboxane synthase,
3-(lH-imidazol-l-yl-methyl) 2-methyl-l-H-indole-l-
propanoic acid (UK 38,485), is examined and the effects of 
thromboxane synthase inhibitors on endogenous thromboxane 
formation are investigated in humans for the first time.
In contrast to thromboxane synthase inhibitors, the
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value of aspirin in vascular occlusion has been under 
investigation for over thirty years
(229-232)(267-272)(362). Initial enthusiasm for this 
approach was tempered by the failure of all the major 
clinical trials of aspirin in the secondary prevention of 
myocardial infarction to produce statistically significant 
reductions in coronary mortality. In addition, inhibition 
of cyclooxygenase by aspirin was clearly shown to depress 
prostacyclin formation in vitro and in vivo (287-291), 
although the inhibitory effects appear to be reduced by 
administering lower doses ( 65)( 288 )( 290)(291)(333 ).
The ability of aspirin to inhibit endogenous 
thromboxane production has only been investigated in one 
previous study (291). Data from this study suggested that 
doses of aspirin between 80mg and 160mg daily inhibited 
endogenous thromboxane production by 80-90%, while the 
reduction in prostacyclin synthesis was significant at 
doses equal to or in excess of 160mg daily. On the basis 
of these results, I investigated the effects of a dose of 
aspirin predicted to substantially depress endogenous 
thromboxane formation without significantly reducing 
prostacyclin generation (120mg). The platelet-inhibititory 
properties and changes in thromboxane and prostacyclin 
biosynthesis induced by this calculated "selective" dose 
of aspirin are described in the second section of the
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chapter.
Another approach to achieving a selective reduction in 
thromboxane synthesis has been suggested by Bertele et al 
(363). They showed that in vitro the platelet-inhibitory 
effects of a thromboxane synthase inhibitor were 
significantly enhanced by combining it with a small amount 
of aspirin. The amount of aspirin used was insufficient to 
decrease the synthesis of the prostacyclin metabolite, 
6-keto-PGFle', by cultured endothelial cells. The third 
section of this chapter examines the effects of such a 
combination in vivo.
The different approaches used in these studies to 
achieve selective inhibition of thromboxane formation 
revealed a consistent discrepancy between the degree of 
inhibition of thromboxane generation in serum and 
of its major metabolite in urine, Tx-M. This suggests that 
the relationship between inhibition of thromboxane 
synthesis in vivo and the capacity of platelets to 
generate thromboxane ex vivo is not linear. Such an 
observation would have important implications for 
platelet-inhibitory therapy and is investigated further in 
the fourth section of the chapter.
In some clinical situations the achievement of absolute
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biochemical selectivity with respect to thromboxane versus 
prostacyclin biosynthesis may not be of functional 
importance. However, in the setting of platelet 
activation, in which endogenous thromboxane biosynthesis 
might be expected to be markedly enhanced and in which 
prostacyclin formation is known to increased (180), 
selectivity is likely to be of much greater significance. 
The experiments in the final section of this chapter 
explore a novel approach to achieving a truly selective 
mode of administration of aspirin by acetylation of 
platelet cyclooxygenase in the presystemic circulation.
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I.SELECTIVE INHIBITION OF THROMBOXANE SYNTHASE
Two principal classes of thromboxane synthase 
inhibitors are available on a restricted basis for human 
studies. The majority are analogues of imidazole and 
include dazoxiben (UK 37,248 ), 3-(lH-imidazol-l-yl-methyl) 
2-methyl-l-H-indole-l- propanoic acid (UK 38,485), 
imidazo-(1,5-2)-pyridine-5- hexanoic acid (CGS 13080) and 
sodium 5- (3'-pyridinylmethyl) benzofuran-2-carboxylate
(U-63557A). The other class of synthase inhibitors is made 
up of a small number of pyridine derivatives of which the 
best known is sodium-(E)-3- {4 — (3-pyridylmethyl)phenyl}
-2-methyl-2-propenoate (OKY-1581). All of these compounds 
have been shown to be selective on the basis of their 
inhibitory activity in vitro against the various enzymes 
of the arachidonic acid cascade. However, their 
pharmacological half-lives and their potency in different 
animal species and types of tissue, varies for the 
individual compounds ( 277 ) ( 303 )( 305)( 364 ).
An imidazole derivative, UK 38,485 (Figure 3.1), was 
chosen for these investigations as it had been shown in 
preliminary studies to have a longer biological half-life 
than other thromboxane synthase inhibitors available at
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FIGURE 3.1 CHEMICAL FORMULA OF:-
3-(1H-imidazol-l-yl-methy1)-2-methyl-1H-indole-l-propanoic acid 
(UK 38,485).
UK-38,485
W
ch2ch2cooh
that time (64)(310 )(364 ) (365)(366). It was anticipated 
that this might lead to enhanced platelet inhibitory 
properties, both by prolonging the duration of inhibition 
of thromboxane formation and, as a consequence of this, 
increasing the availability of prostaglandin endoperoxides 
for prostacyclin synthesis.
Study Design;
For the experiments described in the first three 
sections of this chapter, 12 healthy male volunteers aged 
21-46 years were studied on 5 separate occasions. This 
allowed me to evaluate the effects of inhibition of 
thromboxane synthase, of cyclooxygenase and of combined 
enzyme inhibition under very tightly controlled 
conditions: the studies were placebo-controlled,
randomized and double-blind. On each of the 5 study days, 
after an overnight fast, the volunteers received one of 
the following as a single dose: a) UK 38,485 lOOmg, b) UK
38.485 200mg, c) aspirin 120mg, d) aspirin 120mg plus UK
38.485 or e) placebo. The study days were separated by a 
minimum of 10 days and the volunteers had all refrained 
from ingestion of aspirin or aspirin-like drugs for at 
least 2 weeks prior to these investigations. UK 38,485 and 
placebo capsules were kindly provided by Dr P. Urquilla of
Pfizer Incorporated (Groton, Connecticut). The results of 
selective inhibition of thromboxane synthase by UK 38,485 
are described below; those for low-dose aspirin and the 
aspirin/UK 38,485 combination are described in sections II 
and III respectively.
Effect of UK 38,485 on Platelet Thromboxane Formation ex
vivo:
Platelet thromboxane generation ex vivo was measured as 
serum thromboxane prior to and 1,4,6,8 and 24
hours after drug administration. Serum thromboxane 
was unaffected by placebo (Figure 3.2). UK 38,485 
in both doses caused a rapid, reversible reduction in 
serum thromboxane B^ generation which was maximal 
one hour after dosing (Figure 3.2). Serum thromboxane 
B^ fell by 96 +/- 2% from 312 +/- 33 ng/ml to 12 +/- 
3 ng/ml one hour after 200mg UK 38,485. The corresponding 
reduction after the lOOmg dose was not significantly 
different, falling by 96 +/- 1% from 315 +/- 26 ng/ml to 
15 +/- 5 ng/ml. Serum thromboxane B^ generation
remained at less than 10% of pre-dosing levels for 6 hours 
after UK 38,485 200mg but had returned to over 70% of
pre-dosing values within 24 hours. Although at each
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FIGURE 3.2 EFFECT OF UK 38,485 ON SERUM THROMBOXANE B GENERATION IN HEALTHY 
SUBJECTS.
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sampling point the degree of inhibition of serum 
thromboxane was slightly greater for the 200mg compared to 
the lOOmg dose, at no time did this difference reach 
statistical significance.
Effect on Thromboxane Biosynthesis:
Endogenous thromboxane formation was determined by 
measuring the urinary excretion of a major urinary 
metabolite of thromboxane, 2,3-dinor-thromboxane B
2
(Tx-M), as described in Chapter 2. Urine was collected for 
24 hours and in three post-dosing aliquots: 0-6, 6-12 and 
12-24 hours. As there was no difference in platelet 
thromboxane formation ex vivo between the two doses of UK 
38,48 5, Tx-M excretion after the lOOmg dose was not 
assessed. There was a significant and reversible fall in 
Tx-M from 97 +/- 14 pg/mg creatinine to 56 +/- 6 pg/mg
creatinine (p<0.01) 6-12 hours after administration of UK
38,485 (Figure 3.3). This represented a peak reduction of 
37 +/- 9% from control values and contrasts with the peak
decrease in serum thromboxane of 96%.
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Effects on Prostacyclin Biosynthesis:
Prostacyclin biosynthesis was determined by measuring 
its major metabolite in urine, 2,3-dinor-6-keto-PGFlet 
(PGI-M), as described in Chapter 2. PGI-M was assayed in 
the same aliquots of urine collected for Tx-M estimation, 
ie. for 24 hours before and 0-6, 6-12 and 12-24 hours 
after drug administration. The results are shown in Table 
3.1. There was a transient but significant (p<0.05)
increase in PGI-M excretion after the higher dose of UK
38,485 which was maximal 6-12 hours after dosing and 
corresponded to the time of peak Tx-M depression. PGI-M
increased by 20% from control values from 119 +/- 18 pg/mg
creatinine to 143 +/- 19 pg/mg creatinine. No significant 
increase in PGI-M was apparent after lOOmg UK 38,485.
TABLE 3.1 EXCRETION OF 2.3-DIN0R-6-KET0-PGF (PG1-M) IN 12 HEALTHLY 
HALE SUBJECTS AFTER SINGLE DOSE ADMINISTRATION OF 
UK 38,485 (100mg and 200mg) OR PLACEBO.
Time after 
dosing 
(hours)
Placebo UK 38,485 100mg
UK 38,485 
200mg
-24 111+18 120±17 119±18
0-6 115±16 126+24 122±16
6-12 124±14 131±24 143+19*
12-24 128±15 126±16 131±19
Values are expressed in pg/mg creatinine (mean + SEM). 
* p <0.05 compared to placebo
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Effects on Platelet Function:
The effects on platelet function were assessed by 
measuring platelet aggregation in platelet-rich plasma 
(PRP) prior to and 1,4,6,8 and 24 hours after 
administration of placebo or UK 38,485. Arachidonic acid, 
collagen and adrenaline were used as agonists. In 6
patients whole blood aggregation in response to 
arachidonic acid and collagen was also tested. As a
measure of platelet function in vivo, template bleeding 
times were performed prior to and 1 hour after dosing 
(this time point being chosen to correspond with peak
inhibition of platelet thromboxane generation ex vivo).
UK 38,485 caused significant inhibition of platelet
aggregation in PRP in response to 0.66mM and 1.33mM
arachidonic acid for up to 8 hours following drug
administration (Tables 3.2 and 3.3). Inhibition of
aggregation was measured as a prolongation of the
LT (lag time to achieving 50% of maximal
50
aggregation), which has been shown to be a sensitive 
quantitative index of inhibition of arachidonate-induced 
aggregation (298) ( 367). There was no statistically
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TABLE 3.2 PLATELET AGGREGATION IN PRP IN RESPONSE TO ARACHIDONIC
ACID (1.33mM) AFTER SINGLE DOSE ADMINISTRATION OF
UK 38,485.
Time after 
dosing 
(hours)
LT^g (minutes)
Placebo
UK 38,485 
100mg
UK 38,485 
2Q0mg
0 0.70±0.07 0.74±0.06 0.80±0.09
1 0.68+0.04 2.10+0 .68* 2.10±0.68**
4 0.66±0.05 1,75±0.59* 2.53±0.74**
6 0.61±0.03 1.43±0.44* 1.51±0.42**
8 0.61±0.03 1.37±0.45* 1.57±0.52**
24 0.67±0.03 1.12+0.45 1.34±0.44
TABLE 3.3 PLATELET AGGREGATION IN PRP IN RESPONSE TO ARACHIDONIC 
ACID (0.66mM) AFTER SINGLE DOSE ADMINISTRATION OF 
UK 38,485.
Time after 
dosing 
(hours)
LT^g (minutes)
Placebo UK 38,485 100mg
UK 38,485 
200mg
0 0.97±0.13 0.98±0.11 0.91+0.07
1 0.90±0.14 2.67±0.72** 2.80±0.70**
4 0.82+0.11 2.59±0.73* 2.34±0.66*
6 0.80±0.06 2.62±0.73* 1.59±0.43*
8 0.91±0.11 1.85±0.58 2.02±0.57*
24 0.94+0.09 1.36±0.45 1.90+0.57
Values are mean ± SEM of determinations in 12 healthy male subjects.
LT^g : lag time to achieving 50% of maximal aggregation.
* p <0.05 vs placebo
** p <0.01 vs placebo
significant difference between the two doses of UK
38,485 in the degree of inhibition observed. Platelet 
aggregation induced by high dose collagen (19 ug/ml) was 
also reversibly inhibited by both doses of UK 38,485 as 
shown in Table 3.4. The degree of inhibition was minor and 
considerably less than that seen in response to
arachidonic acid, reaching statistical significance only 
at 4 and 6 hours after drug administration. The 200mg dose 
of UK 38,485 caused transient inhibition of aggregation in 
response to low-dose collagen (Table 3.5). This effect was 
not apparent after the lOOmg dose of UK 38,485. Platelet 
aggregation induced by adrenaline (luM, 5uM and lOuM) was 
unaffected by either dose of UK 38,485 (Tables 3.6, 3.7 
and 3.8).
The effects of UK 38,485 on platelet aggregation in 
whole blood were investigated in 6 subjects. Although the 
extent of aggregation (measured as the height of the
aggregation trace in cm above the baseline after 6
minutes) was reduced in response to 0.66mM arachidonic
acid, the difference failed to reach statistical
significance (Table 3.9). There was also no significant
inhibition of collagen-induced aggregation in whole blood 
(Table 3.10). The effect of UK 38,485 on the template 
bleeding time is shown in Figure 3.4. After the lower dose
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TABLE 3.4 PLATELET AGGREGATION IN PRP INDUCED BY COLLAGEN
(19|ig/ml) AFTER SINGLE DOSE ADMINISTRATION OF UK 38,485.
Time after 
dosing 
(hours)
LT50 (minutes)
Placebo UK 38,485 100mg
UK 38,485 
200mg
0 1.98±0.09 2.18+0.12 2.10±0.11
1 2.0±0.09 2.28±0.17 2.33±0.14
4 1.99+0.09 2.38±0.13* 2.84±0.14**
6 2.0+0.09 2.25+0.12 2.41+0.14**
8 2 .0±0.11 2.11±0.13 2 .12±0.12
24 2.22±0.09 2.08±0.09 2.28+0.14
Values are mean ± SEM of determinations in 12 healthy male subjects.
LTt-g : lag time to achieving 50% of maximal aggregation.
TABLE 3.5 PLATELET AGGREGATION IN PRP INDUCED BY COLLAGEN (1.9ng/ml) 
AFTER SINGLE DOSE ADMINISTRATION OF UK 38,485.
Time after 
dosing 
(hours)
LT^Q (minutes)
Placebo
UK 38,485 
100mg
UK 38,485 
200mg
0 4.44+0.24 4.96+0.31 5.04±0.29
1 4.64+0.24 4.98+0.33 4.82±0.19
4 4.54+0.27 5.23±0.34 5.34±0.25
6 4.64±0.19 5.19±0.30 3.45+0.23*
8 4.54±0.21 4.63±0.36 5.13±0.25
24 4.60±0.15 5.36±0.17 5.30+0.20
Values are mean ± SEM of determinations in 11 healthy male subjects, 
(one subject consistently failed to respond to low dose collagen).
LT : lag time to achieving 50?o of maximal aggregation.
* p <0.05 vs placebo
TABLE 3.6 PLATELET AGGREGATION IN PRP IN RESPONSE TO ADRENALINE
(10pM) AFTER SINGLE DOSE ADMINISTRATION OF UK 38,485
Time after 
dosing 
(hours)
TmaXg (cm)
Placebo UK 38,485 
100mg
UK 38,485 
200mg
0 16.1±0.B 16.4+0.7 16.6±0.6
1 17.0+0.5 16.0±0.7 17.0±0.4
4 17.3±0.6 17.1+0.4 16.4+0.4
6 17.8±0.6 15.9±0.5 17.1±0.5
8 17.8±0.7 16.7±0.7 18.2±0.6
24 17.0+0.5 16.8±0.8 17.9±0.6
TABLE 3.7 PLATELET AGGREGATION IN PRP IN RESPONSE TO ADRENALINE 
(5fiM) AFTER SINGLE DOSE ADMINISTRATION OF UK 38,485.
Time after
TmaXg (cm)
dosing
(hours) Placebo
UK 38,485 
100mg
UK 38,485 
200mg
0 16.5+0.5 16.9±0.6 15.7±1.4
1 16.5±0.4 16.4±0.3 14.9±1.0
4 16.8±0.4 17.0±0.5 15.7±0.8
6 16.8±0.6 15.9+0.6 15.3±0.8
8 17.2±0.5 16.8±0.6 14.0±1.5
24 17.9±0.5 16.7±0.5 16.8+1.2
Values are mean ± SEM of determinations in 12 healthy male subjects.
TmaXg : maximum height of aggregation trace 6 minutes after addition of 
agonist.
TABLE 3.8 PLATELET AGGREGATION IN PRP IN RESPONSE TO ADRENALINE 
(1jun) AFTER SINGLE DOSE ADMINISTRATION OF UK 38,485.
Time after 
dosing 
(hours)
TmaXg (cm)
Placebo
UK 38,485 
100mg
UK 38,485 
200mg
0 16.5±0.5 14.2±0.9 15.1±1.0
1 16.6+0.6 15.7±0.5 16.5±0.6
4 16.4±0.5 14.9+2.0 14.4±2.3
6 16.6±0.7 16.1±0.4 16.5±0.6
8 18.6+0.9 16.0±0.4 16.3+2.0
24 16.4±0.7 17.1±0.7 17.7±0.7
Values are mean ± SEM of determinations in 6 healthy male subjects.
Tmax. : maximum height of aggregation trace 6 minutes after addition 
of agonist
TABLE 3.9 PLATELET AGGREGATION IN WHOLE BLOOD IN RESPONSE TO
ARACHIDONIC ACID (0.66mM) AFTER SINGLE DOSE ADMINISTRATION
OF UK 38,485.
Time after
Change in impedance (ohms)
dosing
(hours) Placebo
UK 38,485 
100mg
UK 38,485 
200mg
0 14.5±1.1 10.9±1.2 10.7+1.2
1 14.5±2.8 9.2±3.0 8.1±0.8
4 4> l+ 9.9±2.1 6.7±1.1
6 12.1±2.1 10.3±2.1 9.3±0.7
8 13.0±1.0 12.7±1.8 10.7±1.1
TABLE 3.10 PLATELET AGGREGATION IN WHOLE BLOOD IN RESPONSE TO
COLLAGEN (9.5pg/ml) AFTER SINGLE DOSE ADMINISTRATION 
OF UK 38,485.
Time after 
dosing 
(hours)
Change in impedance (ohms)
Placebo
UK 38,485 
100mg
UK 38,485 
200mg
0 12.4±1.4 10.6±0.9 10.6±0.9
1 11.6±1.2 7.4±0.8 7.7+1.7
4 11.9±C.7 10.2±1.0 9.7±0.9
6 10.8±0.8 9.9±0.5 10.3±1.1
8 10.9±0.8 10.1±1.3 9.7+0.7
Values are. mean + SEM of determinations in 6 healthy male subjects.
There was no significant difference between placebo and UK 38,485 by 
analysis of variance before and after drug administration.
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the bleeding time was slightly prolonged from 5.1 +/- 0.3 
to 5.4 +/- 0.4 minutes and after the 200mg dose from 4.7
+/- 0.4 to 5.9 +/- 0.6 minutes. Although there was a
2-fold increase in bleeding time after the higher dose in 
4 of the subjects, in the group as a whole the increment 
was not statistically significant.
Plasma Drug Levels;
Plasma levels of UK 38,48 5 were obtained 1,4,6 and 8
hours after drug administration.. The results are shown in
. J f  ?  V *
Table 3.11. Plasma concentrations of UK 38,485 were
proportional to dose. Peak drug levels were measured one
hour after dosing: 200mg-: 3207 +/- 333 ng/ml (range
1954-4520) and lOOmg-: 1699 +/- 140 ng/ml (range 768-2670 
ng/ml). The decline in plasma levels of UK 38,48 5 was
rapid, less than 3% of the peak drug concentration being 
detectable after 6 hours. Plasma concentrations of UK 38, 
485 in the patient in whom only very minor inhibition of 
platelet aggregation was observed were similar to those 
for the whole group for each dose of UK 38,48 5 and at each 
time point.
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TABLE 3.11 PLASMA CONCENTRATIONS OF UK 38,485 (ng/ml)
Time after 
dosing (hours)
UK 38,485 
100mg
UK 38,485 
200mg
0 ND ND
1 1699±140 3207+333
4 99±13 225+46
6 38+11 66±8
8 16+8 26+4
Values are expressed as mean ± SEM in 12 healthy male subjects. 
Limit of sensitivity : 10ng/ml.
ND= Not detectable.
Discussion
A newly developed thromboxane synthase inhibitor, UK 
38,485, has been shown in this study to selectively and 
reversibly inhibit endogenous thromboxane formation in 
normal subjects. Despite approaching maximal inhibition of 
the capacity of platelets. from these individuals to 
synthesize thromboxane A^, the effects on platelet 
function were transient and relatively minor. Thus, while 
there was a slight increase in the bleeding time, this did 
not reach statistical significance. Similarly, although 
there was significant inhibition of arachidonic 
acid-induced platelet aggregation consistent with the 
reduction in platelet thromboxane generation, the 
responses to adrenaline and collagen were maintained. 
There was also no alteration in platelet aggregation in 
whole blood. This is consistent with the relatively small 
increase caused by UK 38,48 5 in endogenous prostacyclin 
synthesis, which was several orders of magnitude less than 
would result in systemically active concentrations of 
prostacyclin in the circulation (132) (155).
The effects of other thromboxane synthase inhibitors on
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human platelet behaviour have been investigated by several 
groups and shown to be minor in comparison to those of 
aspirin. Most have demonstrated similar dose-related 
inhibition of arachidonate and collagen-induced 
aggregation after administration either of other
imidazole-analogue synthase inhibitors, such as dazoxiben 
(64 ) (65)(309 )( 368 )( 369 )( 370 ), or of pyridine derivatives, 
for example, sodium (E)-3-(4- {3-pyridylmethyl}
phenyl)-2-methyl-2-propenoate (OKY 1581) (310 ) ( 371). The
effects of thromboxane synthase inhibition on the bleeding 
time have been variable. Lower doses have no effect 
(64 ) (308 ). Higher doses have been shown in some studies 
(64 ) (65)(369 ), but not in others (310) (371), to
significantly prolong the bleeding time by up to 100%.
The discrepancy between the marked inhibition of
platelet thromboxane formation ex vivo and the relatively 
weak platelet inhibitory properties has important clinical 
implications and may have several explanations. Firstly, 
accumulated prostaglandin enaoperoxides may reach 
sufficient concentrations, when their metabolism via 
thromboxane synthase is blocked, to substitute for the 
proaggregatory effects of thromboxane A^. The lack 
of effect on adrenaline- and low dose collagen-induced 
aggregation, which are largely prostaglandin-dependent, is 
consistent with this hypothesis. In addition, experiments
155
in vitro show that while platelets incubated with the
thromboxane ' synthase inhibitor dazoxiben continue to 
aggregate in response to arachidonic acid despite
virtually complete inhibition of thromboxane formation, 
the addition of small amounts of aspirin abolishes 
aggregation (363). Nevertheless, direct evidence of 
endoperoxide-mediated platelet aggregation in this setting 
is lacking in humans at present. Recent studies in a
canine model of coronary artery occlusion, however, do 
support the concept of endoperoxide-dependent platelet 
activation (345). In this model, Fitzgerald et al showed 
that the combination of an endoperoxide/thromboxane 
receptor antagonist with a synthase inhibitor, 
but not the synthase inhibitor alone, significantly
delayed the time taken for complete coronary occlusion to 
occur. Preliminary evidence for the efficacy of this 
combination has also been obtained with human platelets in 
vitro (372) ( 373 ).
An alternative explanation for the weak platelet
inhibitory activity seen after administration of
thromboxane synthase inhibitors may be provided by
comparing the effects of these drugs on the platelet
capacity to generate thromboxane ex vivo (measured as
serum thromboxane B ) and their effects on actual
2
thromboxane synthesis in vivo. This study investigated for
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the first time the effects of acute administration of a 
synthase inhibitor on thromboxane formation in vivo by 
measuring urinary excretion of the thromboxane metabolite, 
Tx-M. Interestingly, although the peak reduction in serum 
thromboxane generation ex vivo exceeded 95%, the mean 
maximal decrease in Tx-M, reflecting thromboxane synthesis 
in vivo, was less than 40%. Thus, incomplete inhibition of 
thromboxane biosynthesis may have contributed to the weak 
anti-platelet effects of UK 38,485. This observation was 
further investigated in studies described in this and
subsequent chapters.
Several investigators have reported interindividual
differences in the platelet inhibitory response to
thromboxane synthase inhibitors in vitro (307 ) ( 374 ). This
has led to the suggestion that subjects may be divided
into two distinct groups on the basis of their in vitro
platelet response to these drugs: "responders" and
"non-responders". Experiments in vitro have demonstrated a
relationship between "responder" status and the ability to
produce PGD (375 ) ( 376)(377 ). Measures which 
2
increase the generation of PGD induce
2
"non-responder" platelets to respond. Thus, it has been 
proposed that the anti-platelet effects of thromboxane 
synthase inhibitors are dependent upon inducing a
PGD^-mediated rise in intraplatelet cyclic AMP and
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that interindividual variation in this response explains 
the inconstant effects of these drugs on platelet 
function. However, the proportion of "non-responders" 
varies considerably in different studies, from around 33% 
(370X378) up to 75% (375) ( 376) and there is little
evidence of a clear division between "responders" and 
"non-responders" in vivo.
In my study, by using a sensitive measure of inhibition 
of platelet aggregation, the (298 ) ( 367 ), which
takes account of both the rate and extent of aggregation, 
I was able to demonstrate an impaired aggregation response 
in all 12 subjects after administration of the higher dose
of UK 38,485. Similarly, in experiments I carried out with
others in our laboratory, we showed that by prolonging the 
incubation time of platelet suspensions with a thromboxane 
synthase inhibitor (dazoxiben) in vitro, it was possible 
to progressively delay the onset of platelet aggregation
and ultimately completely inhibit aggregation (379). In 
further experiments, we found that this was accompanied by 
further inhibition of platelet thromboxane generation and 
conversion of apparent "non-responders" (in vitro) into
"responders". Thus, "responder" status would not be 
expected to be of major importance in determining the 
anti-platelet effects of thromboxane synthase inhibitors 
in vivo.
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The principal theoretical advantage of thromboxane 
synthase inhibitors over alternative approaches to the
inhibition of thromboxane biosynthesis is their capacity 
to increase prostacyclin formation. There is evidence from 
animal studies that such a mechanism is relevant in vivo.
In a canine model of partial circumflex coronary
obstruction, while a synthase inhibitor prevented blockage 
of the artery in 90% of dogs, this effect was inhibited by 
topical application of a prostacyclin synthase inhibitor
(203). In a . similar model,#- the. combination of a;
thromboxane synthase inhibitor with an
endoperoxide/thromboxane A^ receptor antagonist was
more effective in preventing coronary artery occlusion 
than the receptor antagonist alone (345). Thus,
prostacyclin appears to contribute to the efficacy of 
thromboxane synthase inhibitors in this setting".
The mechanisms by which these drugs enhance
prostacyclin synthesis are not fully understood. Since it
has been reported to occur in vivo with synthase
inhibitors which are structurally distinct from UK 38,485 
(64 ) ( 65), it is unlikely to be the result of a direct 
stimulatory effect of the drug itself. A more attractive
hypothesis is that the increment in prostacyclin
generation is a consequence of rediversion of
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prostaglandin endoperoxides to a source of prostacyclin 
synthase. This might occur in any tissue with the enzymes 
to synthesize both thromboxane and prostacyclin, such as 
the lung. Alternatively, platelet-derived endoperoxides 
might be utilized by endothelial cells to synthesize 
prostacyclin at sites of platelet-vessel wall 
interactions. There is good evidence that this takes place 
in vitro. Marcus et al clearly showed that aspirin-treated 
endothelial cells are able to synthesize prostacyclin from 
endoperoxides derived from platelets and that synthesis is 
enhanced in the presence of a thromboxane synthase 
inhibitor (62). Others have confirmed these findings (63), 
but direct evidence of such a mechanism occurring in vivo 
remains to be established in humans.
The biochemical and functional effects of a novel 
thromboxane synthase inhibitor have been described and 
discussed. In common with other synthase inhibitors, the 
effects on platelet function are relatively minor despite 
over 95% inhibition of thromboxane generation ex vivo. The 
results suggest that this is likely to be due in part to 
the accumulation of proaggregatory endoperoxides and their 
substitution for thromboxane A^ in the presence of 
thromboxane synthase blockade. However, the concomitant 
finding of a relatively small reduction in a major urinary 
metabolite of thromboxane, Tx-M, raises the possibility
160
that incomplete inhibition of thromboxane biosynthesis may 
also be a contributory factor. These observations are 
further investigated in the following studies.
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II. CYCLOOXYGENASE INHIBITION BY LOW-DOSE ASPIRIN
The dose of aspirin used in this study, 120mg, was
selected with the aim of achieving maximal inhibition of
thromboxane formation without significantly reducing
prostacyclin synthesis. Patrono et al showed that the
relationship between the dose of aspirin administered and
the resultant degree of inhibition of serum thromboxane
generation was linear (297). They found a 50% inhibitory
dose for single dose administration of 26mg. Thus, a dose
of 180mg would be required to reduce serum thromboxane by
over 99%. However, there is clear evidence that even in
doses lower than this, aspirin inhibits prostacyclin
synthesis by human vascular tissue in vitro
(288)(289)(290) and at doses of 160mg or greater it will
significantly inhibit endogenous prostacyclin biosynthesis
(291). Single doses of lOOmg have been shown to depress
serum thromboxane B by around 95% ( 333 ) ( 336 ). I
2
therefore chose a dose of 120mg in order to increase the 
degree of inhibition of thromboxane generation attained,
while still leaving prostacyclin synthesis relatively
unaltered. The effects of single dose administration of
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low-dose aspirin on endogenous thromboxane biosynthesis 
had not been previously investigated and thus could not be 
allowed for in calculating the most appropriate dose of 
aspirin to employ.
Effects of Low-dose Aspirin on Thromboxane Formation in 
vivo and ex vivo;
Platelet thromboxane formation ex vivo was determined 
in serum before and 1,4,6,8 and 24 hours after single dose 
administration of 120mg of aspirin. Thromboxane synthesis 
in vivo was measured as Tx-M excretion in the 24 hours 
prior to dosing and in three aliquots for 24 hours 
following aspirin administration (0-6, 6-12 and 12-24
hours ).
Serum thromboxane fell by a mean of 94 +/- 2 % 
one hour after dosing from 349 +/- 37 to 18 +/- 4 ng/ml 
and remained inhibited for the 24 hour study period 
(Figure 3.5). Aspirin also caused a significant reduction 
in Tx-M excretion from 134 +/- 21 to 92 +/- 17 pg/mg
creatinine (p<0.01) which, in contrast to the thromboxane 
synthase inhibitor, persisted for 24 hours after drug 
administration (Figure 3.5). However, peak depression of
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Figure 3.5 EFFECTS OF LOW-DOSE ASPIRIN (120mg) ON SERUM THROMBOXANE B„ 
GENERATION AND Tx-M EXCRETION IN HEALTHY SUBJECTS.
ng/m l Serum Thromboxane B,
400 i -
pg /m g
cre a tin in e
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TABLE 3.12 EXCRETION OF Tx-M, SERUM THROMBOXANE B AND PLASMA
SALICYLATE AFTER SINGLE DOSE ADMINISTRATION OF SODIUM 
SALICYLATE 120mg.
Prior to 
dosing
Afte 
Time (hrs)
r dosing
Concentration
Plasma salicylate 
(pg/ml)
ND 3 7.6+1.2
Serum thromboxane B„ 
(ng/ml)
345+75 3 313+29
Tx-M 75±13 0-6 85±28
(pg/mg creatinine 6-12 78±10
12-24 72+7
Values are mean ± SEM of determinations in 3 healthy male subjects. 
ND = Not detectable.
Tx-M, which was observed in the 6-12 hour aliquot after 
dosing, was only 28 +/- 8 % from pre-dosing values despite 
almost maximal inhibition of serum thromboxane B
2
formation throughout the study period. To exclude the 
possibility that the change in Tx-M excretion resulted 
from altered renal handling of Tx-M rather than inhibition 
of cycloxygenase (380), the effects of an identical oral 
dose (120mg) of sodium salicylate were investigated in 
three of the subjects. Sodium salicylate is subject to the 
same renal tubular excretory mechanism as aspirin (381) 
but has no or only very weak inhibitory activity against 
platelet cycloxygenase (6)( 382 ) ( 383 ). In contrast to 
aspirin, 120mg of sodium salicylate did not alter Tx-M 
excretion or the capacity of platelets to form thromboxane
B (Table 3.12).
2
Effect on Prostacyclin Biosynthesis;
Urinary excretion of the prostacyclin metabolite PGI-M 
was measured prior to dosing and in three aliquots 
following dosing with aspirin 120mg (0-6, 6-12 and 12-24 
hours). Analysis of Tx-M and PGI-M in the same samples 
allowed direct comparison of the inhibitory effects of
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this dose of aspirin on endogenous biosynthesis of both 
thromboxane and prostacyclin in the 12 subjects studied.
As shown in Figure 3.6, even in this low dose aspirin 
caused a small but statistically significant reduction in 
PGI-M. The decrease in prostacyclin metabolite was, 
however, transient. PGI-M excretion fell from 100 +/- 10 
to 70 +/- 11 pg/mg creatinine 0-6 hours after aspirin
administration (p<0.01) and returned to normal levels in 
the second two aliquots collected (104 +/- 22 and 110 +/- 
16 pg/mg creatinine in the 6-12 and 12-24 hour samples 
respectively). The mean maximum reduction in PGI-M (25 +/- 
11%) was similar to that for Tx-M (28 +./- 8%), but the 
inhibitory effects on Tx-M were more prolonged, no 
recovery being seen within the 24 hour study period 
(Figure 3.6).
Effects on Platelet Function;
Platelet aggregation in PRP in response to arachidonic 
acid, collagen and adrenaline was assessed before and 
1,4,6,8 and 24 hours after aspirin administration. The 
bleeding time was measured immediately prior to dosing and
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PERCENTAGE REDUCTION IN PGI-M AND Tx-M EXCRETION AFTER ADMINISTRATION 
OF LOW-DOSE ASPIRIN TO HEALTHY SUBJECTS.
PGI -M T x - M
T
X X
-24 0-6 6-12 12-24 -24 0-6 6-12 12-24
T im e  a f t e r  d o s i n g  ( h o u r s )
one hour following 120mg aspirin. Aspirin completely 
abolished platelet aggregation induced by arachidonic acid 
and low-dose collagen throughout the 24 hour study period 
(Table 3.13). In addition, aspirin inhibited the secondary 
wave of adrenaline-induced aggregation and significantly 
impaired, although did not abolish, platelet aggregation 
in response to high-dose collagen (Table 3.13). Aspirin 
120mg also caused a small but significant prolongation of 
the bleeding time from 5.1 +/- 0.4 to 7.4 +/- 0.5 minutes
(p<0.01).
Discussion
The effects of single dose administration of 120mg of 
aspirin on endogenous thromboxane and prostacyclin 
biosynthesis and platelet function have been investigated 
in healthy subjects. Platelet thromboxane 
formation in serum was rapidly inhibited by 120mg of 
aspirin by a mean of 94%. Despite sustained inhibition of 
the platelet capacity for thromboxane generation ex vivo 
for at least 24 hours, the corresponding reduction in 
Tx-M, reflecting actual thromboxane synthesis in vivo, was
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less than 30%. The failure of sodium salicylate to alter 
Tx-M excretion suggests that the reduction in Tx-M was 
indeed due to cyclooxygenase inhibition. However two 
possible explanations for the significantly smaller 
depression in Tx-M compared to serum thromboxane should be 
considered.
Firstly, since Tx-M reflects total body synthesis of 
thromboxane, it is derived from both platelet and
extraplatelet sources, for example from macrophages, the 
kidney and possibly the lung ( 25 ) ( 33 ) (34 ) (72)( 77 ). Thus, 
the significant amounts of Tx-M excreted after aspirin 
administration may represent thromboxane synthesis from 
cells other than platelets on which aspirin has had less 
profound inhibitory effects. Previous experiments (see 
Chapter 2), however, suggested that in healthy subjects 
Tx-M is predominantly derived from platelets. In addition, 
patients with thrombocytosis and increased platelet
turnover had markedly elevated Tx-M excretion. The pattern 
of recovery of inhibition of Tx-M in the present studies 
is also consistent with inhibition of platelet-derived
Tx-M. Levels of Tx-M rapidly returned towards normal after
the reversible thromboxane synthase inhibitor. In 
contrast, after low-dose aspirin (and after the higher 
dose administered in the preliminary investigations in 
Chapter 2), Tx-M remained inhibited for at least 24 hours.
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Others have shown a similarly reversible depression in 
Tx-M following administration of indomethacin, a 
reversible cyclooxygenase inhibitor (266). It therefore
seems unlikely that the discrepancy between the degree of
inhibition of Tx-M and serum thromboxane is entirely
accounted for by non-platelet thromboxane synthesis,
although a small proportion of the residual Tx-M may 
originate from such sources.
An alternative explanation is that Tx-M and serum
thromboxane B formation are not related in a linear 
2
fashion. There is some evidence to suggest that the 
relationship between inhibition of the platelet capacity 
for thromboxane generation ex vivo and
thromboxane-dependent platelet activation, for example, is 
not linear (291) ( 384 ) ( 385). In the same way, the results 
of this study suggest that the relationship between the 
extent of inhibition of serum thromboxane B
2
formation and of Tx-M excretion may also be non-linear. 
Such an observation, although not previously recognized, 
would not be surprising since it is well known that the 
capacity of tissues to synthesize icosanoids in response 
to physical and chemical stimuli far exceeds their actual 
production rates in vivo ( 92 )( 132 )( 181 ) ( 288 ) ( 336 ).
The dose of aspirin used in this study had significant
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anti-platelet activity by conventional criteria. Platelet 
aggregation induced by arachidonic acid, collagen and 
adrenaline was inhibited and the bleeding time was 
prolonged by almost 50%. However, a major potential
disadvantage of even this low dose of aspirin is the
inhibitory effect it exerted on prostacyclin biosynthesis. 
A single dose of 120mg depressed prostacyclin synthesis in 
vivo by 30%. The fall in prostacyclin was transient and is 
consistent with rapid de novo synthesis of endothelial 
cyclooxygenase following aspirin exposure as has been 
shown to occur in cultured endothelial cells (287)(294). 
The rapid recovery of PGI-M after single dose
administration of aspirin contrasts with the delay of 
several days seen with chronic administration of much 
larger doses (291). This may reflect inhibition of
prostacyclin synthesis by vascular smooth muscle. Chronic 
dosing might be expected to facilitate acetylation of 
vascular smooth muscle cyclooxygenase which is likely to 
have limited exposure to pharmacologically active
concentrations of aspirin after a single low dose.
Prostacyclin formation by endothelial cells appears to 
recover more quickly than in vascular smooth muscle cells 
(287 ) ( 386), perhaps due to additional inhibitory effects 
of aspirin on smooth muscle prostacyclin synthesis which 
can only be overcome by cell division (387).
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The inhibitory effects of aspirin on the capacity of 
human venous tissue to generate prostacyclin ex vivo may 
be even greater for equivalent doses of aspirin than the 
effects on endogenous biosynthesis. Using a bioassay, 
Hanley et al have shown significantly reduced prostacyclin 
formation (around 60% inhibition) after either a single 
81mg dose of aspirin (289) or after three 40mg doses 
administered up to 72 hours apart (388). Preston and his 
colleagues administered a single 300mg dose of aspirin to 
4 healthy subjects and demonstrated 61-100% inhibition of 
venous prostacyclin synthesis ex vivo 2-8 hours after 
dosing (288). In a separate study, they found that the 
inhibitory effects persisted for at least 72 hours and 
that a similar degree of inhibition of prostacyclin 
generation could be obtained by administering four 40mg 
doses of aspirin 24 hours apart (389). Since these studies 
were carried out, Weksler and her colleagues have reported 
in a recent paper that even 20mg aspirin administered on a 
chronic basis to patients with atherosclerosis is 
sufficient to reduce both aortic and saphenous vein 
prostacyclin production by 50% (386).
In summary, it seems unlikely that a truly selective 
dose of aspirin administered on a daily or even alternate 
day basis can be identified. Chronic administration of 
even 20mg daily will result in some inhibition of
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prostacyclin production (291X386). The increase in 
aspirin dose which would be required to achieve maximal 
inhibition of thromboxane synthesis in vivo is likely to 
further compromise the biochemical selectivity of low-dose 
aspirin and lead to a substantial reduction in 
prostacyclin biosynthesis.
Although the functional implications of this are 
unclear at present, endogenous prostacyclin biosynthesis 
has recently been shown to be significantly enhanced in 
patients with severe atherosclerotic peripheral vascular 
disease who had evidence of platelet activation in vivo 
(180). In such patients, prostacyclin may therefore 
function as a locally-acting regulator of
platelet-vascular homeostasis. Under these circumstances, 
preservation of prostacyclin synthesis is likely to be of 
particular importance and alternative pharmacological 
approaches require to be investigated.
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III. COMBINED INHIBITION OF PLATELET CYCLOOXYGENASE AND
THROMBOXANE SYNTHASE
Combined inhibition of cyclooxygenase and thromboxane 
synthase represents a possible solution to the dilemma of 
developing a regimen which will maximally inhibit 
endogenous throjnboxape generation without compromising 
prostacyclin formation. Such a combination is effective in 
vitro (363). In the study described above, aspirin in a 
dose of 120mg failed to inhibit thromboxane synthesis in 
vivo by more than 30% and, even in this dose, also caused 
a transient decline in prostacyclin biosynthesis. Addition 
of a thromboxane synthase inhibitor, which acts at a site 
distinct from aspirin in the synthetic cascade, should 
allow a greater degree of inhibition of thromboxane 
synthesis and will have no effect on vascular 
cyclooxygenase. Furthermore, if this hypothesis is 
correct, then further inhibition of platelet thromboxane 
synthesis in vivo, should be accompanied by accumulation 
of prostaglandin endoperoxides which can in turn be 
utilized by vascular tissue to generate prostacyclin. The 
effects of this approach on prostanoid formation and
platelet function in healthy subjects are discussed below. 
The thromboxane synthase inhibitor, UK 38,485, was given 
in a dose of 200mg which was shown to significantly 
increase prostacyclin synthesis in vivo when administered 
alone. The dose of aspirin coadministered with UK 38,485 
was 120mg, which allowed direct comparison between the 
effects of the combined regimen and either drug alone.
Effects on Thromboxane Synthesis in vivo and ex vivo:
The effects on thromboxane synthesis in vivo of 
combined inhibition of cyclooxygenase and thromboxane
synthase by single dose administration of aspirin (120mg) 
together with UK 38,485 (200mg) were assessed by measuring 
urinary Tx-M prior to dosing and in three post-dosing 
aliquots: 0-6, 6-12 and 12-24 hours. Tx-M excretion fell
by a mean of 58 +/- 7 % from 95 +/- 12 to 37 +/- 6 pg/mg
creatinine (Table 3.14). This reduction in Tx-M was 
significantly greater (p<0.01) than that seen after 
administration of either drug alone. No recovery of Tx-M 
excretion was seen during the 24-hour study period.
Serum thromboxane B was used as an index of
2
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TABLE 3.14 Tx-M EXCRETION AFTER COMBINED CYCLOOXYGENASE AND
THROMBOXANE SYNTHASE INHIBITION.
Time after 
dosing 
(hours)
Aspirin 120mg 
+
UK 38,485 200mg
Aspirin
120mg
UK 38,485 
200mg
-24 95±12 134+21 97±14
0-6 65+9* 108±18* 85+10
6-12 47±11*i 92±17* 56±6*
12-24 37±6*ii 104±17* 76±9
Values are expressed in pg/mg creatinine (mean ± SEM) in 12 healthy 
male subjects.
* p <0.01 compared to control values.
I p <0.05 compared to aspirin 120mg or UK 38,485 200mg.
II p <0.01 compared to aspirin 120mg or UK 38,485 200mg.
TABLE 3.15 SERUM THROMBOXANE B„ AFTER COMBINED CYCLOOXYGENASE AND 
THROMBOXANE SYNTHASE INHIBITION.
Time after 
dosing 
(hours)
Aspirin 120mg 
+
UK 38,485 200mg
Aspirin
120mg
UK 38,485 
200mg
0 380±19 349±37 312±33
1 8±4 (98±1)^** 18±4 (94±1) 12+3 (96±2)
4 8±4 (98±1)i** 19+4 (94+1) 14±4 (96±1)
6 8±3 (98±1)i#* 24±7 (92±2) 31±6 (90±2)
8 14+4 (96±1)** 25±7 (29±3) 69±12 (78+4)
24 29±7 (92±2)f* 26+7 (90±3) 129±23 (92+7)
Values are expressed as mean ± SEM in ng/ml (?o inhibition from 
pre-dose control) in 12 healthy male subjects.
I p<0.05 aspirin/UK 38,485 versus aspirin 120mg.
** p<0.01 aspirin/UK 38,485 versus UK 38,485 200mg.
thromboxane synthesis ex vivo and was measured in samples 
taken before and 1,4,6,8 and 24 hours after drug 
ingestion. The aspirin/UK 38,485 combination depressed 
serum thromboxane generation by a mean of 98 +/-
1 % from 380■+/- 19 to 8 +/- 4 ng/ml one hour after dosing
(Table 3.15). Serum thromboxane remained markedly 
inhibited throughout the 24-hour study period. The degree 
of inhibition was significantly greater than that achieved 
after either drug alone: p<0.01 1, 4, 6, 8 and 24 hours
after dosing (aspirin/UK 38,485 versus UK 38,485 200mg) 
and p<0.05 1,4 and 6 hours after dosing (aspirin/UK 38,485 
versus aspirin 120mg).
Effects on Prostacyclin Biosynthesis:
The combination of aspirin with UK 38,485 had no effect 
on prostacyclin biosynthesis as assessed by PGI-M 
excretion measured in the three aliquots (0-6,6-12 and 
12-24 hours) after drug administration (Table 3.16). This 
contrasted with the significant increase in PGI-M caused 
by UK 38,485 administered alone and a similar decrease in 
PGI-M after aspirin.
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TABLE 3.16 PGI-M EXCRETION AFTER COMBINED CYCLOOXYGENASE AND
THROMBOXANE SYNTHASE INHIBITION.
TIME AFTER 
DOSING 
(hours)
Aspirin 120mg 
+
UK 38,485 200mg
Aspirin
120mg
UK 38,485 
200mg
-24 116±20 100±10 119+18
0-6 92±14 70+11** 122±16
6-12 111+23 104±22 143+19*
12-24 108±14 110+16 131+19
Values are expressed in pg/mg creatinine (mean ± SEM) in 12 healthy 
male subjects.
* p<0.05.
** p<0.01
Effects on Platelet Function:
The aspirin/UK 38,485 combination completely inhibited 
arachidonate-induced platelet aggregation and abolished 
the secondary wave of adrenaline-induced aggregation for 
the 24 hours of the study (Table 3.17). Platelet 
aggregation in response to high-dose collagen was 
significantly impaired to a similar degree to that seen 
for aspirin alone (Table 3.17). The bleeding time was also 
prolonged when measured one hour after dosing, from 4.7 
+/- 0.4 to 7.2 +/- 0.6 minutes (p<0.01), but this was not
significantly different from the increase seen after 
aspirin alone (p>0.02).
Plasma Drug Levels:
Plasma drug levels of UK 38,485 were measured 1,4,6 and 
8 hours after drug administration. Adequate plasma levels 
were achieved in all the subjects and no difference was 
apparent in the concentration of UK 38, 485 when it was 
co-administered with aspirin compared to those measured 
after UK 38,485 alone (Table 3.18).
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TABLE 3.17 EFFECTS ON PLATELET FUNCTION OF COMBINED CYCLOOXYGENASE 
AND THROMBOXANE SYNTHASE INHIBITION BY SINGLE DOSE 
ADMINISTRATION OF ASPIRIN 120mg PLUS UK 38,485 200tog.
Time after 
dosing 
(hours)
PLATELET AGGREGATION IN PRP
Bleeding
time
(minutes)Arachidonic 
Acid (1.33mM)
Collagen
(19|ig/ml)
Adrenaline
(10|iM)
0 0.76±0.06 2.00±0.08 15.9+0.4 4.7±0.4
1 NA 2.48±0.11* PA 7.2±0.6*
4 NA 2.51±0.14* PA NT
6 NA 2.50±0.13* PA NT
8 NA 2.46+0.09* PA NT
24 NA 2.40±0.13* PA NT
Values are mean + SEM of determinations in 12 healthy male subjects. 
Aggregation induced by arachidonic acid and collagen is measured as 
the lag time to achieving 50?o of maximal aggregation (LT™, in 
minutes). Adrenaline-induced aggregation is measured as the height 
of the aggregation trace 6 minutes after addition of adrenaline 
(Tmax^, in cm).
* p <0.01.
NA = no aggregation.
PA = primary aggregation.
NT = not tested.
TABLE 3.18 PLASMA CONCENTRATIONS OF UK 38,485 ADMINISTERED IN 
COMBINATION WITH ASPIRIN OR ALONE.
Time after dosing 
(hours)
UK 38,485 (200mg) 
+ Aspirin 120mg
UK 38,485 (200mg)
1 2992±320 3207±333
4 199±22 225±46
6 66+7 66±8
8 28±3 26±4
Values are expressed in ng/ml (mean ± SEM) in 12 healthy male subjects.
Discussion
The combination of low-dose aspirin (120mg) with a
thromboxane synthase inhibitor has been shown to inhibit
thromboxane synthesis in vivo and ex vivo to a
significantly greater extent than either drug administered
alone. Although the difference in inhibition of serum
thromboxane B formation was small (94% for aspirin 
2
alone versus 98% for the combination), it was sufficient 
to enhance the extent of inhibition of actual thromboxane 
synthesis in vivo from 28% to almost 60%.
This observation provides additional evidence that the
relationship between inhibition of serum thromboxane
B and Tx-M is not, in fact, linear. It also 
2
suggests that in patients with enhanced thromboxane 
biosynthesis, in whom treatment with such drugs might be 
expected to be of the most clinical benefit, inhibition of 
platelet capacity to generate thromboxane must be 
virtually complete before thromboxane synthesis in vivo is 
significantly reduced. Since maximal inhibition of 
platelet thromboxane production is apparently required to
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prevent thromboxane-dependent platelet activation ex vivo 
(291) and in vitro (384), this has important clinical 
implications.
Despite the significantly greater decline in Tx-M after 
the aspirin/thromboxane synthase inhibitor combination, I 
was unable to demonstrate an enhancement of the 
anti-platelet effects of this regimen compared to those of 
aspirin. However, this is likely mainly to reflect 
platelet aggregation occurring by
prostaglandin-independent mechanisms, since the response 
to high-dose collagen, though impaired, was largely 
maintained.
It is particularly interesting that the reduction in 
prostacyclin biosynthesis which was evident with low-dose 
aspirin, was no longer significant when the same dose of 
aspirin was administered in combination with UK 38,485. It 
is attractive to speculate that, as inhibition of 
endogenous thromboxane formation was incomplete after a 
single dose of 120mg of aspirin, the apparent lack of 
effect on prostacyclin biosynthesis may reflect the net 
effect of rediversion of residual platelet endoperoxides 
to endothelial prostacyclin synthase. Thus, addition of a 
thromboxane synthase inhibitor appears to compensate for 
the inhibitory activity of aspirin against vascular
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cyclooxygenase.
This study has therefore identified a potentially 
useful clinical approach to selective inhibition of 
thromboxane formation, although its effects during chronic 
administration remain to be determined. The discrepancy 
between the degree of inhibition of Tx-M and serum 
thromboxane was again apparent. In view of the
implications of this observation for platelet-inhibitory 
therapy in patients with thromboxane-dependent platelet 
activation in vivo, the relationship between inhibition of 
thromboxane synthesis in vivo and ex vivo is investigated 
further in the next section.
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IV.FURTHER STUDIES ON THE RELATIONSHIP BETWEEN 
INHIBITION OF THROMBOXANE B^ GENERATION 
IN SERUM AND Tx-M; Evidence that it is non-linear
It is well recognized that the capacity of tissues to
generate icosanoids in response to physical and chemical
stimuli far exceeds their actual biosynthetic rates in
vivo (132 ) (181)(288 )(390). Thus, although the capacity of
platelets to generate thromboxane in clotting blood in
response mainly to thrombin results in serum thromboxane
levels of 300-400 ng/ml (336), the maximal
endogenous concentration of thromboxane B in plasma
2
has been estimated at under 2 pg/ml (92). It follows, 
therefore, that the normal rates of thromboxane synthesis 
observed in vivo can be accounted for by activation of 
platelets to less than 0.1% of their capacity.
The studies described above suggest that there may also 
be a discrepancy between the degree of inhibition after 
aspirin or thromboxane synthase inhibitors of the platelet 
capacity for thromboxane generation in serum and of 
endogenous thromboxane biosynthesis. This observation may 
provide insight into the action of these drugs in human
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syndromes of platelet activation. It also has important 
implications in the design of platelet-inhibitory therapy 
in such conditions since preservation of even a very small 
residual capacity to synthesize thromboxane may still, in 
response to stimuli in vivo, result in biologically-active 
levels of thromboxane.
In order to explore this further, I have examined the 
relationship between different degrees of inhibition of 
serum thromboxane and the corresponding reduction 
in Tx-M excretion. In addition to using data obtained from 
the studies described above, I investigated the effect of 
a smaller dose of aspirin (20mg administered as 4 separate 
5mg doses). This regimen was chosen to achieve an 
intermediate degree of inhibition of serum thromboxane 
B^. The work of Patrono et al suggested that 
repeated dosing with 5 mg of aspirin should reduce serum 
thromboxane formation by around 50% (297).
Study Design;
The effects on thromboxane synthesis in vivo and ex 
vivo of four different regimens which inhibit thromboxane 
formation were studied by measuring the maximal depression
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of Tx-M excretion and serum thromboxane B in
2
healthy volunteers. Regimens 1,2 and 3, which are 
described in detail in sections I, II and III, were as 
follows: 1. UK 38,485 200mg, 2. aspirin 120mg and 3. 
aspirin 120mg plus UK 38,485, the drugs being administered 
as single doses in each case. Regimen 4 consisted of 20mg 
of aspirin administered orally as four 5mg doses taken two 
hours apart. Twelve healthy male subjects were studied in 
all parts of the study except in regimen 4 in which 4 
subjects participated.
Results:
The small dose of aspirin (4x5mg) reduced serum
thromboxane B by a maximum of 48 +/- 2 % from 365 
2
+/- 21 to 190 +/- 8 ng/ml 2 hours after the final dose.
The corresponding fall in Tx-M was considerably smaller: 
from 134 +/- 21 to 112 +/- 22 pg/mg creatinine,
representing a decline of 14 +/- 4 %. These results are 
plotted together with those from regimens 1, 2 and 3 on 
Figure 3.7.
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FIGURE 3.7 RELATIONSHIP BETWEEN INTIBITION OF SERUM THMfiOXWE GENERATION 
EX VIVO AM) Tx-H EXCRETION.
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This shows that the relationship between peak
inhibition of thromboxane generation ex vivo and peak
inhibition of Tx-M departed markedly from the line of
identity. Thus, as maximal blockade of the capacity to 
generate thromboxane ex vivo was approached, minor
increments in the degree of inhibition achieved resulted
in a disproportionately greater depression of thromboxane
synthesis in vivo. This conclusion is supported by data
derived from the only published study (carried out some
years previously in the laboratory in which I worked) 
which is also included on the graph. In this study,
complete inhibition of both serum thromboxane B
2
(99%) and Tx-M excretion (97%) was obtained following 
chronic administration of 2,600mg of aspirin daily (291).
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Discussion:
Using several different regimens to achieve varying 
degrees of inhibition of thromboxane formation, I have 
shown that the relationship between the reduction in the 
capacity of platelets to generate thromboxane ex vivo and 
the reduction in thromboxane synthesis in vivo is 
non-linear. Indeed it departs markedly from the line of 
identity. The results show that minor increments (from 94% 
to 98%) in the extent of inhibition of serum thromboxane 
give rise to much greater reductions in Tx-M 
excretion. The functional implications of this observation 
are illustrated by evidence that even a residual 10% 
capacity to generate thromboxane appears to be enough to 
fully sustain thromboxane-dependent platelet activation 
(384 H391). In addition, previous work has shown that it 
is possible to obtain further measurable inhibition of 
platelet function by increasing the inhibition of platelet 
thromboxane formation ex vivo from 95 to 99% (291).
Measurements of the platelet capacity to generate 
thromboxane are frequently used as a guide to dosing with 
platelet-inhibitory drugs (130 )( 290 )( 386 )( 392)( 393 ) ( 394 ). 
The results of this study, however, indicate that this
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will not accurately reflect the inhibition of actual 
thromboxane biosynthesis by platelets and consequently the 
effect on thromboxane-dependent platelet activation. It is 
clear that even when inhibition of serum thromboxane 
is substantial (90-95%), thromboxane synthesis in? 
vivo is largely maintained. Thus, in patients in which 
platelet activation in vivo plays an active role, it is 
likely that therapy should be directed towards achieving 
virtually complete inhibition of serum thromboxane 
generation. Lesser degrees of inhibition would 
not be expected to substantially influence
thromboxane-dependent platelet activation in such 
patients.
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V .PRESYSTEMIC ACETYLATION OF PLATELET CYCLOOXYGENASE
An alternative approach to achieving selective 
inhibition of thromboxane formation was suggested by the 
observation that after oral administration of aspirin 
platelet thromboxane generation ex vivo appeared to fall 
significantly 10-15 minutes before aspirin was detectable 
in the plasma (395). Such an observation was consistent 
with acetylation by aspirin of platelet cyclooxygenase in 
the presystemic circulation. Aspirin is known to undergo 
substantial presystemic hydrolysis to salicylic acid in 
the intestine and liver before it enters the systemic 
circulation (396). During aspirin absorption from the gut 
platelets are therefore exposed, as they pass through the 
gut capillaries, to much higher concentrations of aspirin 
than in the systemic circulation. This raised the 
possiblity that administration of an extremely low dose of 
aspirin might be sufficient to inhibit thromboxane 
formation in platelets as they passed through the 
presystemic circulation but, as hepatic extraction of such 
a small amount of aspirin should be virtually complete, 
pharmacologically active concentrations of aspirin would
not be achieved in the systemic circulation. Thus, the 
bulk of the vascular endothelium would not be exposed to 
aspirin and prostacyclin synthesis would be preserved.
Some support for the hypothesis that platelets were 
exposed to significant concentrations of aspirin in the 
presystemic circulation was provided by earlier studies 
investigating the pharmacology of enteric-coated 
"slow-release" aspirin preparations. These had shown 
inhibition of platelet cyclooxygenase and/or platelet 
aggregation in the absence of detectable plasma 
concentrations of aspirin in some subjects
(382 ) (397 ) (398 ) ( 399 ) ( 400 ). The evidence remains
presumptive, however, as the methods used to measure 
aspirin in these studies were relatively insensitive and 
the effects on vascular cyclooxygenase were not 
investigated.
A model was therefore devised to test the hypothesis 
that repeated administration of extremely low doses of 
aspirin would result in cumulative inhibition of platelet 
cyclooxygenase in the presystemic circulation. Thus, even 
with chronic dosing regimens, the inhibitory effects of 
aspirin would be confined to platelets. The effects of 
such a regimen on vascular cyclooxygenase were assessed by 
measuring endogenous prostacyclin biosynthesis and a new
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highly-sensitive GC/MS assay for aspirin and salicylate 
(360) was utilized to evaluate aspirin absorption and 
metabolism.
Design of the Model;
The model was designed to deliver extremely low doses 
of aspirin into the portal circulation over a prolonged 
period in healthy human subjects (Figure 3.8). The lowest 
possible dose (lmg) was chosen in order to minimize the 
chance of any aspirin reaching the systemic circulation.
FIGURE 3.8
PRESYSTEMIC ACTION OF LOW DOSE ASPIRIN
LIVER
HEART
ACETYLATION OF 
PLATELETS IN 
PRE-SYSTEMIC 
CIRCULATION
BODY
187
Six male volunteers were studied. After an overnight 
fast single lmg capsules of aspirin (prepared by 
Vanderbilt University Medical School pharmacy) were
administered orally every 30 minutes to a total of 20 
doses, thus mimicking a "slow-release" formulation. The 
aspirin was taken with a small amount of water and no 
meals were allowed during the study. The subjects had all 
refrained from ingesting aspirin or aspirin-like drugs for 
at least two weeks prior to the study.
Blood samples for measurement of serum thromboxane
and plasma aspirin and salicylate were taken
immediately prior to and 5, 10, 15 and 30 minutes after
the first dose of aspirin and then immediately prior to
each subsequent dose. An additional sample was collected
30 minutes following the final dose which corresponded to
10 hours after the first dose of aspirin. In 4 of the
subjects blood was also taken for platelet aggregation
studies before and 2, 6 and 9 hours after the first dose
of aspirin. Urine was collected for 24 hours before the
study and in two post-dosing aliquots (0-12 hours and
12-24 hours) for measurement of the dinor metabolites of
prostacyclin (PGI-M) and thromboxane (Tx-M). In addition,
to assess the recovery of platelet thromboxane generation,
serum thromboxane B was measured 1, 3, 7 and 10
2
days following the commencement of the study. For
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comparative purposes the 6 subjects received, on a 
separate occasion, a single 20mg dose of aspirin 
administered orally after an overnight fast.
Effects on Platelet Thromboxane Formation;
Serum thromboxane fell significantly within 5
minutes of the first lmg dose of aspirin from 267 +/- 54
to 221 +/- 45 ng/ml (p<0.05). This represented a mean
reduction of 15 +/- 4 % (Figure 3.9). The maximal
reduction in serum thromboxane formation after lmg of
aspirin (22 +/- 9 %) was seen 30 minutes following drug
administration. There was a further, but much smaller,
reduction in serum thromboxane generation after
the second lmg dose to a mean of 75 +/- 8 % of pre-dosing
values 60 minutes after the start of the study (Figure
3.9). With administration of subsequent lmg doses, serum
thromboxane B fell in a linear fashion by a maximum 
2
of 55 +/- 4 % to 118 +/- 23 ng/ml 30 minutes after the 
final lmg dose of aspirin (Figure 3.10). In contrast to
the "slow-release regimen" (SR-1), the single 20mg dose of 
aspirin (LD) depressed serum thromboxane by a maximum of 
33 +/- 7 % (Figure 3.10). Tx-M excretion following the
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FIGURE 3.9 SERUM THROMBOXANE B AFTER ADMINISTRATION OF SIMULATED "SLOW-RELEASE"
LOW DOSE ASPIRIN.
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FIGURE 3.10 SERUM THROMBOXANE B AFTER ADMINISTRATION OF A SIGNLE DOSE OF ASPIRIN
AND REPEATED ADMINISTRATION OF 20 1mg DOSES OF ASPIRIN.
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"slow-release" aspirin regimen fell by a mean of 19 +/ 11
% from 197 +/- 47 to 168 +/- 20 pg/mg creatinine but this 
difference failed to reach statistical significance (Table 
3.19).
TABLE 3.19 URINARY EXCRETION OF PROSTAGLANDIN METABOLITES (Tx-M 
AND PGI-M) AFTER ADMINISTRATION OF A "SLOW-RELEASE”
LOW-DOSE ASPIRIN REGIMEN (5R-1).
Tx-M PGI-M
(pg/mg c ■eatinine)
Before Aspirin:
After Aspirin
0-12 hours: 
12-24 hours:
197+47
229±18
168±20
127+35
133±24 
118±34
Values are mean ± SEM of determinations in 6 healthy male subjects.
Effect on Platelet Function:
Platelet aggregation in PRP was tested in response to 
0.66mM arachidonic acid and 5uM adrenaline in 4 subjects 
after the SR-1 aspirin regimen. In one of the subjects 
(PI.) the secondary wave of adrenaline-induced aggregation 
disappeared and arachidonate-induced aggregation was
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completely abolished after only 4mg of aspirin (Figure 
3.11). In the remaining subjects there was some impairment 
of platelet aggregation after 4mg, but it was not until 9 
hours following the first dose of aspirin (after a total 
of 18mg had been ingested), that significant inhibition of 
aggregation was seen in all subjects in response to both 
agonists (Table 3.20).
Evidence for a Presystemic Site of Action:
Plasma Aspirin and Salicylate Levels:
Aspirin was not detected in peripheral venous plasma at 
any time following administration of the SR-1 aspirin 
regimen, despite sampling every 5-15 minutes for the first 
hour and at 1/2-hourly intervals thereafter. The lower 
limit of sensitivity of the assay was 10 ng/ml. Absorption 
of aspirin was confirmed, however, by the demonstration of 
salicylate in venous plasma at the corresponding time 
points. After administration of the single 20mg dose (LD) 
of aspirin, the peak plasma aspirin concentration was 220 
+/- 30 ng/ml measured 30 minutes after dosing.
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FIGURE 3.11 ARACHIDONATE-INDUCED PLATELET AGGREGATION AFTER 
ADMINISTRATION OF 4 1mg DOSES OF ASPIRIN.
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Effect on Prostacyclin Biosynthesis:
PGI-M excretion was 127 +/- 35 pg/mg creatinine prior 
to dosing with the SR-1 aspirin regimen and was not
significantly different in the 2 post-dosing aliquots
(Table 3.19).
Pattern of Recovery of Serum Thromboxane B^:
The pattern of recovery of serum thromboxane B^
formation after the SR-1 aspirin regimen is shown in
Figure 3.12. The lowest value of serum thromboxane, which
was measured 30 minutes after the final lmg dose,
represents 100% inhibition (ie 0% recovery) and full
recovery to predosing values is thus equivalent to 0%
inhibition. Recovery of the platelet capacity for
thromboxane synthesis began within 24 hours: at 14 hours
after the last dose serum thromboxane B had
2
recovered by just over 30% to 204 +/- 66 ng/ml and reached
normal values 9 days later.
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FIGURE 3.12 RECOVERY OF SERUM THROMBOXANE B AFTER ADMINISTRATION OF SIMULATED
"SLOW-RELEASE" LOW-DOSE ASPIRIN.
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Discussion
The purpose of this study was to establish a human 
model of selective inhibition of thromboxane synthesis 
using extremely low doses of aspirin to inactivate 
platelet .cyclooxygenase in the presystemic circulation. 
Since aspirin undergoes substantial presystemic hydrolysis 
to salicylate in the intestine and liver (396), very small 
doses of aspirin are likely to be almost completely 
metabolized. Thus, negligible amounts of intact aspirin 
should reach the systemic circulation. In this way 
vascular cyclooxygenase would remain unexposed to 
inhibitory concentrations of aspirin and prostacyclin 
biosynthesis would consequently be preserved. A simulated 
"slow-release" mode of administration was used to deliver 
extremely small quantities of aspirin into the portal 
circulation in a controlled manner. While a single 
low-dose enteric-coated aspirin formulation would have 
been much more convenient, such a preparation was not 
available in a low enough dose. Perhaps more importantly, 
erratic absorption of enteric-coated aspirin preparations 
(359)(382)(397)(39 9)(401)(402) with the possibility of 
intermittently larger increments in aspirin
bioavailability was likely to make interpretation of the
results very difficult.
In order to ensure that hepatic extraction of aspirin
would be virtually complete and minimize the chance of
significant amounts of aspirin reaching the systemic
circulation, the smallest practicable dose was employed in
this study. The results show that even in doses as low as
lmg aspirin is able to induce measurable inhibition of the
capacity of platelets to generate thromboxane. Since it
irreversibly acetylates the cyclooxygenase enzyme and
platelets are unable to synthesize new enzyme, the
inhibitory effects of aspirin on platelet thromboxane
generation are cumulative on repeated dosing
(296)(297)(333). Thus, although serum thromboxane
fell by a mean of 22% after a single lmg dose of aspirin,
there was a progressive decline in thromboxane generation
with repeated administration of lmg until it had fallen by
55% after a total of 20mg. This contrasted with a maximal
reduction in serum thromboxane B after a single
2
20mg dose of 33%.
That the effects of the "slow-release" aspirin regimen 
were the result of presystemic acetylation of platelet 
cyclooxygenase was suggested by three lines of evidence. 
Firstly, significant cumulative inhibition of serum 
thromboxane B^ generation and thromboxane-dependent
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platelet aggregation was achieved in the absence of
detectable plasma concentrations of aspirin. Secondly,
prostacyclin biosynthesis was unaltered. Thirdly, the 
recovery of the platelet capacity to generate thromboxane 
was accelerated.
Several previous studies have shown that despite
undetectable plasma levels of aspirin, enteric-coated 
slow-release preparations of aspirin may inhibit platelet 
cycloxygenase activity (382)(397)(399). Others have been 
able to demonstrate significant inhibition of platelet
aggregation in the absence of measurable concentrations of 
aspirin in peripheral plasma (382)(398)(400). However, the 
doses used in these studies have generally been high
(650-1300mg) and in every study the methods used to 
quantitate plasma concentrations of aspirin have been
relatively insensitive, with detection levels 10-100 fold 
less than the assay employed in the present investigation. 
Indeed, similar doses of slow-release aspirin have been 
reported by several other workers to give rise to 
significant plasma aspirin concentrations
( 402 ) ( 403 )( 404 ) ( 405 )( 406 )( 407 ).It is difficult, therefore, 
to interpret the significance of "undetectable" levels of 
aspirin in these earlier studies, particularly when in
some cases the reported assays were unable to measure
aspirin in peripheral blood even after a conventional
320mg tablet of compressed aspirin (399). In the present 
study plasma salicylate levels confirmed absorption of 
each lmg dose of aspirin and as an additional control
aspirin was readily detectable in peripheral plasma after 
single dose administration of 20mg of aspirin.
Further evidence in support of a presystemic site of
action for the "slow-release" aspirin regimen employed in 
the present study is provided by the lack of effect of
this regimen on endogenous prostacyclin biosynthesis. This 
is not conclusive evidence, however, as single dose 
administration of 20mg of aspirin has also been shown to 
have no significant effect on prostacyclin formation in 
vivo (65). Since chronic administration of such a dose 
does inhibit prostacyclin synthesis in vivo (291) and ex 
vivo (386), confirmation of the ability of very low doses 
given in a "slow-release" form to preserve prostacyclin 
biosynthesis requires to be tested in chronic dosing
studies. Nevertheless, since there was no evidence of
accumulation of aspirin after 20 lmg doses given at 
half-hourly intervals, it is very unlikely that 
prostacyclin synthesis would be depressed even with
long-term administration. Although significant
accumulation of salicylate is likely to occur with chronic
dosing, this has been shown to have no inhibitory effects 
on endogenous prostacyclin production even in very high
doses (53 mg/kg) (383).
The accelerated rate of recovery of serum thromboxane
generation observed in all the subjects in the
present study was also consistent with the model of
presystemic acetylation of platelet cyclooxygenase by the
"slow-release" aspirin regimen. It is generally believed
that the normal 48-hour lag in the recovery of platelet
capacity for thromboxane synthesis (286)(296)(408)(409) is
due to acetylation of megakaryocyte cyclooxygenase by
aspirin (410). The substantial recovery of serum
thromboxane B occurring within 15 hours of the last 
2
dose of aspirin is therefore highly suggestive of a 
failure to acetylate megakaryocytes which would not be 
exposed to inhibitory concentrations of aspirin.
Despite an overall reduction of thromboxane generation 
in serum of more than 50% after the simulated 
"slow-release" aspirin regimen, the decline in Tx-M 
excretion was much smaller, less than 20%, and failed to 
reach statistical significance. This is consistent with 
the studies described above in which the relationship 
between these two indices was shown to be non-linear. In 
addition it may reflect the partial recovery of platelet 
thromboxane generation which began within the initial 24 
hour study period. The reduction in platelet thromboxane
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generation was, however, sufficient to produce measurable
inhibition of platelet function, in most individuals after
only 4-12 mg of aspirin. Others have recently reported
that chronic administration of lmg aspirin daily to
healthy volunteers for several weeks is sufficient to
render platelets more sensitive to the anti-aggregatory
effects of prostacyclin in vitro (411) and to induce small
(15%) but significant reductions in serum thromboxane
B (412). ^
2
This study haS used" repeated dral administration of ant■ 
extremely low dose of aspirin to establish a model of 
selective inhibition of thromboxane formation by
acetylation of platelet cyclooxygenase in the presystemic 
circulation. Such a regimen was not only selective with 
respect to its effect on prostacyclin production, but also 
achieved a greater degree of inhibition of platelet
thromboxane generation than did an equivalent amount of
aspirin administered as a single dose. The potential 
clinical benefit of such an approach would depend on the 
feasability of developing a sustained-release preparation 
which was able t o . deliver an appropriate low dose of 
aspirin at a controlled rate, although a similar objective 
might be possible using continuous infusion of aspirin in 
minute amounts. These regimens could therefore be used to 
more rapidly attain complete inhibition of platelet
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thromboxane synthesis which, as discussed above, is likely 
to be necessary to prevent thromboxane-dependent platelet 
activation in a clinical setting. They would have the
additional : benefit of protecting not only vascular
cyclooxygenase from the potentially harmful effects of
aspirin, but also other sources of the enzyme,
particularly renal and gastric cyclooxygenase, which may 
otherwise limit the therapeutic use of aspirin (413).
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CONCLUSION
The biochemical and functional effects of several 
different approaches to achieving selective inhibition of 
thromboxane formation have been investigated in healthy 
subjects. An important objective was to identify a regimen 
which satisfied the dual criteria of maximising the 
reduction in thromboxane synthesis without a 
coorresponding fall in prostacyclin production. The 
various regimens studied demonstrated varying degrees of 
selectivity.
The thromboxane synthase inhibitor efficiently blocked 
platelet thromboxane synthesis ex vivo and, in the higher 
dose, also significantly increased prostacyclin 
biosynthesis. Nevertheless, the effects on platelet 
function were relatively minor and actual . thromboxane 
synthesis in vivo fell by less than 40%. The significantly 
greater platelet-inhibitory activity of the low-dose 
aspirin regimen (120mg) and in vitro studies of platelet 
behaviour with thromboxane synthase inhibitors suggest 
that accumulated prostaglandin endoperoxides substitute
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for the proaggregatory effects of thromboxane when 
arachidonate metabolism via thromboxane synthase is
blocked. Even in this dose, which is within the range 
conventionally accepted as "low-dose aspirin", aspirin 
caused a transient but significant reduction in endogenous 
prostacyclin formation and the corresponding decline in 
thromboxane biosynthesis was far from optimal (around 
30%). These results indicate that, despite contentions to 
the contrary, a truly selective single dose of aspirin is 
not achievable.
However, two new and potentially useful approaches were 
identified which were both highly selective and caused 
measurable inhibition of platelet function in all the
subjects studied. The combination of low-dose aspirin with 
a thromboxane synthase inhibitor appeared to offset the 
principal disadvantages of either drug administered alone. 
Thus, the fall in prostacyclin seen after low-dose aspirin 
was no longer apparent with the combined regimen and there 
was substantial and prolonged inhibition of platelet 
function. Furthermore, the inhibitory effect on endogenous 
thromboxane formation appeared to be additive (a reduction 
of almost 60%) in response to enzyme blockade at two 
different steps in its biosynthetic pathway. The other 
novel regimen employed repeated administration of
extremely low doses of aspirin to achieve selective
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presystemic acetylation of platelet cyclooxygenase. These 
latter two approaches remain to be fully evaluated, 
^however, to determine the optimum formulations and dosing 
schedules for chronic drug administration.
The studies described in this chapter were the first to 
investigate the effects of these drugs on actual 
thromboxane synthesis in vivo using a modified, 
non-invasive, highly sensitive and specific assay for a 
major urinary metabolite of thromboxane,
2,3-dinor-thromboxane (Tx-M). As a result, they
highlighted a previously unrecognized but important 
observation with significant implications for platelet 
inhibitory therapy. It is apparent that the relationship 
between inhibition of the platelet capacity for 
thromboxane generation, as reflected by serum thromboxane 
formation ex vivo, and actual thromboxane synthesis in 
vivo is not linear. Thus, since the capacity of platelets 
to produce thromboxane in response to diverse physical and 
chemical stimuli far exceeds the actual rates of 
thromboxane synthesis in vivo, inhibition of this capacity 
is likely to have to be virtually complete to prevent 
thromboxane-dependent platelet activation. It is also 
clear that the therapeutic potential of stategies designed 
to inhibit endogenous thromboxane formation will therefore 
have to be investigated in human models of platelet
activation in vivo in which thromboxane-dependent 
platelet activation plays a significant role. The studies 
in the following chapters focus on the identification of 
appropriate models and evaluate the effects of thromboxane 
synthesis inhibition in one of them.
I acknowledge the help of Ms Johniene Doran with some 
of the platelet function tests carried out in these 
studies.
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INTRODUCTION
Thromboxane has been implicated as an
important mediator in diverse human diseases in which
platelet activation and/or vasospasm are known to occur
(see Table 1.1). While this is an attactive hypothesis,
documented evidence of enhanced thromboxane biosynthesis
in such conditions has been lacking. As discussed in
chapter one, this is largely due to methodological
problems which are inherent to the measurement of such
evanescent compounds, particularly when invasive sampling
procedures are employed (130). However, measurement of a
major urinary metabolite of thromboxane, Tx-M, circumvents 
most of these difficulties and has recently allowed the
rate of secretion of thromboxane into the circulation to
be calculated (92). Under physiological conditions in
humans it appears to be very low- in the order of 1-2
pg/ml (92). This is not surprising since eicosanoids are
not stored within cells but are synthesized following a
stimulus which releases arachidonic acid from the cell
membrane. Thus, in healthy individuals in the absence of
stimuli which trigger platelet activation endogenous
production of thromboxane would be expected to be low.
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Conversely, thromboxane biosynthesis would be predicted to 
be increased in the presence of platelet activation in 
vivo.
The following series of studies also employs
quantitation of Tx-M in urine to investigates endogenous
thromboxane biosynthesis in various syndromes in which
platelet activation in vivo is believed to occur. I
elected to study in detail three groups of conditions 
which, on the basis of preliminary experiments outlined in
chapter 2, were associated with elevations of Tx-M
excretion and platelet activation in vivo: severe
atherosclerosis, systemic sclerosis with Raynaud"s
phenomenon and myeloproliferative disorders. The presence
of platelet activation in these patients was determined
using a number of markers of platelet function, including
measurement of platelet granule proteins, circulating 
platelet aggregates and platelet aggregation. Although the
interpretation of all of these methods may be confounded
by the influence of ex vivo activation (263)(265)(355),
this was controlled for by obtaining matching data from
healthy subjects for each group of patients.
Several animal models of platelet activation have been
established and have provided a useful approach to the 
evaluation of platelet-inhibitory therapy
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(203 )(343)(344 ) ( 346). In man no equivalent model has been
defined. The aim of these studies was not only to enhance
our understanding of the pathogenesis of such conditions,
but also to identify appropriate clinical targets for
therapeutic stategies designed to inhibit
thromboxane-dependent platelet activation.
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I.SEVERE ATHEROSCLEROSIS
The role of platelets in the pathogenesis of
atherosclerosis remains controversial. Nevertheless,
evidence from pathological, biochemical and clinical
studies supports the contention that platelet activation
is an important factor in acute thrombotic events and in
the evolution of diffuse atherosclerotic disease
(190)(193)(194)(414). Direct evidence from post-mortem
studies shows that platelets constitute the major
component of occlusive thrombi in atherosclerotic vessels
(191X415) and that in acutely thrombosed arteries the
thrombus which has precipitated luminal occlusion consists
largely of aggregated platelets (192). In addition to 
their involvement in occlusive thrombi, platelets may
contribute to the formation of the proliferative lesions
of atherosclerosis by producing growth factors which
stimulate smooth muscle cell proliferation (416)(417). The
measurement of diverse biochemical indices of platelet
activation in vivo provides supportive evidence for the
involvement of platelets and their products in patients
with longstanding atherosclerotic disease
(233)(350)(354)( 418)( 419)(420 ).
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The following study was designed to investigate
thromboxane biosynthesis in a well-defined group of 
patients with severe atherosclerosis and evidence of
platelet activation in vivo. The patients all had advanced 
diffuse obliterative arterial disease of the lower limb 
and were selected on the basis of preset criteria
indicative of platelet activation. This group of patients
was considered unsuitable for reconstructive vascular
surgery and, since it had not at the time been shown to be
of proven value, was not on treatment. They therefore
represented an appropriate stable model of severe
atherosclerosis in which to test the hypothesis that
platelet activation in vivo is associated with enhanced
endogenous formation of thromboxane.
Study Design
Patient selection;
The nine patients studied (8 men and one woman, aged 
49-75 years) were selected from the peripheral vascular 
disease clinics of Vanderbilt University Medical School
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and the Veterans Administration Hospital, Nashville,
Tennessee. All had angiographically confirmed obstructive
arterial disease of the lower limbs with pain at rest
and/or ischaemic ulcers (grades III and IV). They met
preset criteria for the presence of platelet activation in 
vivo: plasma B-thromboglobulin > 20 ng/ml and a
circulating platelet aggregate (CPA) ratio of more tha or
equal to 1.3. Since previous work has shown that spurious
increases in B-thromboglobulin can be identified by the
presence of concomitantly high levels of platelet factor 4
(265), samples with platelet factor 4 levels above 18 
ng/ml were excluded. These values were predetermined on
the basis of the range of values obtained in over 30
healthy individuals over a wide age range (21-88 years) 
(see Appendix II). Five of the patients had
insulin-dependent diabetes and seven had
electrocardiographic evidence of myocardial ischaemia, 
although only one was taking anti-anginal medication
(occasional sublingual glyceryl trinitrate). Seven of the
nine patients studied were chronic cigarette smokers. None
had taken aspirin or other nonsteroidal anti-inflammatory 
drugs for at least 10 days before the study.
As shown in Appendix 1, excretion of the urinary 
metabolites of thromboxane and prostacyclin increases
significantly with advancing age. Therefore to serve as
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age-matched controls, ten apparently healthy volunteers
(age 50-75 years) working in the above hospitals or
attending a local Geriatric Centre were studied in
parallel. None was on regular therapy and all denied a 
significant past history of disease, in particular
cerebrovascular, cardiovascular, peripheral vascular or
renal disease.
Analytical methods;
The methods used were as described in chapter 2. Venous
blood was collected without stasis via a 19-gauge
butterfly needle. Plasma was obtained for measurement of
B-thromboglobulin and platelet factor 4 by
radioimmunoassay and for the determination of the
circulating platelet aggregate ratio by the modified
method of Wu and Hoak (350). Serum thromboxane B
2
was measured by radioimmunoassay to confirm that no
aspirin had recently been taken. In addition, the bleeding
time was measured using the template method. Urine was
collected in 24-hour aliquots for quantitation of the
major urinary metabolites of prostacyclin
(2,3-dinor-6-keto-PGF PGI-M) and thromboxane
1CK
(2,3-dinor-thromboxane B Tx-M) by gas
chromatography/mass spectrometry using the stable isotope
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dilution assays described in chapter 2.
Evidence for Platelet Activation in vivo:
All the patients fulfilled the preset criteria
consistent with the presence of platelet activation in
vivo. Plasma B-thromboglobulin was markedly elevated at
113 +/- 22 ng/ml compared to 13 +/- 3 ng/ml in the healthy
control subjects (p<0.001) (Figure 4.1). In addition, the 
CPA ratio was significantly higher in the patients
compared to the controls (1.4 +/- 0.01 vs 1.0 +/- 0.02; 
p<0.05) The levels of platelet factor 4 measured in the
same samples were within the normal range: 11.7 +/- 0.5
versus 11.0 +/- 2 ng/ml (patients vs controls). The
atherosclerotic patients also had a significantly shorter 
bleeding time (2.9 +/- 0.2 vs 5.0 +/- 0.4 minutes;
p<0.001) (Figure 4.1).
Figure 4.2 shows the urinary excretion of PGI-M for the
atherosclerotic patients and the healthy age-matched
controls. Normal values for healthy young subjects are
included for comparison. Prostacyclin biosynthesis was 
significantly enhanced in the patients compared to the
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FIGURE 4.1 INDICES OF PLATELET ACTIVATION IN VIVO IN PATIENTS WITH SEVERE 
ATHEROSCLEROSIS.
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FIGURE 4.2 PGI-M EXCRETION IN PATIENTS WITH SEVERE ATHEROSCLEROSIS AND HEALTHY 
CONTROL SUBJECTS.
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FIGURE 4.3 Tx-M EXCRETION IN PATIENTS WITH SEVERE ATHEROSCLEROSIS AND HEALTHY 
CONTROL SUBJECTS.
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age-matched controls (323 +/- 89 vs 197 +/- 21 pg/mg
creatinine? p<0.05)f providing further indirect evidence
of platelet activation in vivo in this model. Serum and 
urine creatinine were within normal limits in all the 
subjects studied.
\
Thromboxane Biosynthesis (Tx-M):
Urinary excretion of Tx-M was markedly increased in the 
patients with severe atherosclerosis compared to healthy 
controls (Figure 4.1). Normal values for healthy young 
controls are shown for comparison (Figure 4.3). Tx-M in 
the patients ranged from 484 to 1816 pg/mg creatinine with 
a mean of 912 +/- 99 pg/mg creatinine. This was
significantly greater (pCO.OOl) than mean Tx-M excretion 
in the healthy age-matched controls (223 +/- 22 pg/mg
creatinine). However, there was no significant difference 
between patients and age-matched controls in thromboxane
B 2 generation in serum (300 +/- 46 vs 340 +/- 45
ng/ml? patients vs controls) or in the peripheral blood 
platelet counts (292 +/- 19 vs 298 +/- 32 x lO'/l).
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Discussion
This study has demonstrated markedly enhanced
endogenous formation of thromboxane in patients with
advanced atherosclerosis in whom there was also evidence 
of platelet activation in vivo. Although, as I showed in
the earlier studies, Tx-M is mainly derived from platelets
in healthy individuals, the source of the increase in Tx-M
was not directly addressed in this study. However, the
following lines of evidence suggest that it is most likely 
to be of platelet origin. Firstly, the increase in Tx-M
was accompanied by other markers of platelet activation in
vivo, including a substantially elevated plasma 
concentration of B-thromboglobulin and the presence of
circulating platelet aggregates. Secondly, prostacyclin
biosynthesis was also enhanced in these patients.
Increased prostacyclin production has previously been
demonstrated in patients with severe atherosclerosis and
platelet activation and is thought to reflect enhanced
platelet-vascular interactions in this setting (180). In 
addition, the concomitant increase in PGI-M suggests that
the observed enhancement of Tx-M excretion is not simply 
the result of enhanced metabolism to the dinor metabolite 
of a normal amount of thromboxane (the fractional
216
conversion of prostacyclin to its dinor metabolite is
normal in this setting {180}). Since renal function was
normal in both patients and controls, it also seems
unlikely that altered renal handling of the metabolite
accounted for the marked discrepancy between the levels of 
Tx-M in the two groups of subjects.
In order to clarify the relationship between enhanced
synthesis of Tx-M and platelet activation in vivo, it is
necessary to examine the effects on Tx-M both of inducing
and of inhibiting platelet activation. Previous work in
animal models of acute thrombosis has shown increases in
plasma thromboxane in response to various
stimuli, including arachidonate-induced myocardial
ischaemia (202) or sudden death (211) and experimentally
stenosed coronary artery occlusion (206). More recently,
Fitzgerald et al have developed a canine model of
platelet-dependent coronary occlusion in which complete
obstruction of the coronary artery is accompanied by a
marked increase in urinary Tx-M (421). In addition,
coronary occlusion is prevented or significantly delayed
by administration of specific endoperoxide/thromboxane
receptor antagonists. Since then the same workers 
have also reported phasic increases in Tx-M excretion in 
patients with unstable angina during episodes of acute 
chest pain (422), a situation in which platelet thrombi
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have been demonstrated in the coronary vessels (423).
Thus, Tx-M appears to be a sensitive, non-invasive
index of platelet activation in vivo which may be elevated
in chronic disease, such as severe atherosclerosis, and 
increase further in response to an acute stimulus. The
effects of inhibiting endogenous thromboxane formation in
such patients, either directly using a specific inhibitor 
of thromboxane synthesis or indirectly by using an
inhibitor of platelet activation which has no specific
activity on the thromboxane biosynthetic pathway remain to
be investigated. One preliminary report, in which platelet
activation was inhibited indirectly using prostacyclin,
did show a decline in Tx-M excretion from initially
elevated levels in a patient with thrombotic 
thrombocytopenic purpura (341). The present study has
identified a clinically relevant, stable model of in vivo 
platelet activation in which to investigate the effects of 
platelet-inhibitory therapy on thromboxane biosynthesis.
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II.SYSTEMIC SCLEROSIS WITH RAYNAUD'S PHENOMENON
Raynaud's phenomenon is characterised by episodic
exaggerated constriction of the small digital arterioles
and arteries in response to cold or emotional stress
(424). In patients with Raynaud's phenomenon associated
with systemic sclerosis marked structural changes have
been demonstrated in the blood vessels, particularly
intimal hyperplasia and severe fibrosis (425)(426). In
addition, other investigators have found evidence of 
platelet activation in vivo in patients with this disease,
including the presence of circulating platelet aggregates
and elevated plasma B-thromboglobulin levels
(427)(428)(429). It was therefore attractive to speculate
that such patients might provide a further human model of
platelet activation in vivo in which thromboxane
biosynthesis was likely to be enhanced.
The aims of this study were firstly to measure Tx-M 
excretion in a group of patients with longstanding 
systemic sclerosis complicated by Raynaud's phenomenon who 
had evidence of in vivo platelet activation; and secondly, 
to determine whether induction of an acute attack in
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response to exposure to cold was accompanied by a 
further increase in Tx-M formation.
Study Design:
Patient selection;
The ten patients studied (9 women and one man, aged
36-60 years) all had systemic sclerosis complicated by
symptomatic Raynaud's phenomenon and were attending the
outpatient clinic at Vanderbilt University Medical Center. 
Each patient fulfilled the criteria of the American
Rheumatism Association for a diagnosis of systemic
sclerosis (430), all were non-smokers and none had taken
non-steroidal anti-inflammatory drugs within the two weeks 
prior to the study. Any patients with a clinical history
or laboratory evidence of ischaemic heart disease (ECG) or
renal impairment (serum creatinine > 133 umol/1) were
excluded from the study.
Ten healthy age- and sex-matched volunteers served as
controls. The patients and the control subjects were 
studied before and after central cooling had been induced
with a cooling blanket (Aquamatic-K-thermia, Gorman-Rupp,
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Belville, Ohio). Cooling was continued for 30 minutes or 
until Raynaud's phenomenon developed, which was observed 
in all the patients. Care was taken to ensure that the
maximum fall in the subject's normal oral temperature did
not exceed 3*F.
Analytical methods:
Blood was taken for measurement of plasma 
B-thromboglobulin and platelet factor 4, the circulating 
platelet aggregate (CPA) ratio, serum thromboxane B^
and platelet aggregation in response to arachidonic acid.
B-thromboglobulin, platelet factor 4 and serum thromboxane
B 2 were measured by radioimmunoassay as described in 
chapter 2 and the CPA ratio was determined using a 
modification of the method of Wu and Hoak (350). Platelet 
aggregation was studied in PRP using the light 
transmission method. The threshold aggregating
concentration for arachidonic acid was determined (defined 
as the minimum concentration producing a greater than 70% 
increase in light transmission). Endogenous biosynthesis 
of thromboxane and prostacyclin was assessed by measuring 
their major metabolites in urine, Tx-M
(2,3-dinor-thromboxane B^) ana PGI-M
(2,3-dinor-6-keto-PGF )r by gas chromatography/mass
Its
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spectrometry. To determine the effect of cooling, urine
was collected from both patients and controls for 24 hours
prior to cooling and in an aliquot corresponding to the
time of cooling for measurement of Tx-M and PGI-M. Blood
was also taken at the end of the period of cooling for
plasma B-thromboglobulin, platelet factor 4 and platelet 
aggregation studies.
Evidence for Platelet Activation in vivo:
Basal excretion of Tx-M was significantly increased
(p<0.001) in the patients with systemic sclerosis and
Raynaud's- phenomenon (486 +/- 88 pg/mg creatinine)
compared to the healthy control subjects (162 +/- 38 pg/mg
creatinine) (Figure 4.4). PGI-M excretion was also
significantly higher (p<0.005) in the patients compared
with the controls (248 +/- 39 vs 112 +/- 10 pg/mg
creatinine). • There was a marked increase in plasma 
B-thromboglobulin in the patients with systemic sclerosis
(57 +/- 16 vs 14 +/- 2 ng/ml; p<0.005). However, plasma
platelet factor 4 levels were also significantly higher in 
the patients (43 +/- 14 vs 6 +/- 1 ng/ml? p<0.005)
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suggesting that there was considerable platelet activation 
occurring ex vivo. Since normal platelet factor 4 levels 
were obtained in the control samples processed in an
identical manner, and since the CPA ratio was also
increased in the patients (1.43 +/- 0.11 vs 1.04'+/-
0.03), this is consistent with platelet activation taking
place during the actual blood sampling.
FIGURE 4.4 URINARY EXCRETION OF Tx-M AND PGI-M IN PATIENTS WITH SYSTEMIC SCLEROSIS 
AND RAYNAUD'S PtEN0»EN0N.
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The influence of ex vivo activation may therefore also 
have contributed to the significantly lower threshold
concentration for platelet aggregation in response to
arachidonic acid in the patients (0.16 +/-■ 0.04 vs 0.38
+/- 0.06 mM; p<0.005). The capacity of platelets to
generate thromboxane in serum was normal in the patients
(301 +/- 72 vs 276 +/- 71 ng/ml) and all the subjects
studied had normal platelet counts.
Effect of Cooling:
Typical clinical signs of Raynaud*s phenomenon
developed in the digits of all the patients with systemic 
sclerosis during cooling. There was a concomitant
significant increase (p<0.05) in Tx-M excretion from 416
+/- 80 to 1007 +/- 212 pg/mg creatinine during cooling
(Figure 4.5). There was also a smaller increase in PGI-M
excretion from 248 +/- 39 to 362 +/- 81 pg/mg creatinine
(Figure 4.6), but this failed to reach statistical
significance. In the healthy control subjects there was no
significant effect of cooling on the excretion of either
metabolite. Plasma concentrations of B-thromboglobulin and
platelet factor 4 were unaltered by cooling in either the
patients or controls (Figure 4.7) and the threshold
aggregating concentration of arachidonic acid was also
unchanged in the patients (0.16 +/- 0/04 mM before vs 0.21
+/- 0.03 mM after cooling) and in the control subjects
(0.38 +/- 0.06mM before vs 0.43 +/- 0.07 mM after
cooling).
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FIGURE A .5  EFFECT OF COOLING ON Tx-M EXCRETION IN  PATIENTS WITH SYSTEMIC SCLEROSIS AND
RAYNAUD'S PHENOMENON.
2,3 -  D INOR-Tx B2 
(pg/mg crea tin in e )
1000 U U  BEFORE COOLING 
EZZJ DURING COOLING
800 -
6 0 0
4 0 0
200
HEALTHY
CONTROLS
SYSTEMIC
SCLEROSIS
FIGURE A .6  EFFECT OF COOLING ON PGI-M EXCRETION IN  PATIENTS WITH SYSTEMIC SCLEROSIS 
AND RAYNAUD’ S PHENOMENON.
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PLATELET FACTOR 4 IN PATIENTS WITH SYSTEMIC SCLEROSIS AND RAYNAUD'S 
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Discussion
This study has shown that in patients with systemic 
sclerosis complicated by Raynaud's phenomenon endogenous
biosynthesis of thromboxane is enhanced. Moreover, a 
further increase in thromboxane synthesis occurred when 
the syndome was precipitated by exposure to cold. Such an
observation is consistent with the presence of platelet 
activation m  vrvo and suggests*1 that m  patients with ®
systemic sclerosis, platelets are activated on application 
of a cold stimulus sufficient to induce Raynaud's
phenomenon. The concomitant increase in prostacyclin
biosynthesis, as seen in the patients with severe
atherosclerosis, supports this hypothesis.
Several previous studies have reported enhanced
platelet reactivity in patients with systemic sclerosis
and Raynaud's phenomenon. Keenan and Porter demonstrated
increased numbers of platelet -adrenergic receptors 
(431) while others have found that platelets from such
patients are more responsive to platelet agonists 
(427)(429). In addition, various studies have demonstrated
significant elevations of B-thromboglobulin and the
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circulating platelet aggregate ratio ( 427 ) ( 428 ) ( 429 ), as 
in the present study. However, the coincidental increase
in platelet factor 4 seen in this study highlights the
difficulty in interpreting indices of platelet activation
obtained using invasive sampling procedures. It seems
likely that the increase in B-thromboglobulin is at least
in part attributable to platelet activation ex vivo during
blood sampling, particularly in such a group of patients
in which venous access is impaired as a result of the 
disease process. In this setting, plasma thromboxane
levels, although reported to be increased in patients with 
Raynaud's phenomenon (393), are likely to be extremely 
misleading and illustrate the advantage of measuring
urinary metabolites as a non-invasive approach to
investigating eicosanoid biosynthesis (130).
The pathogenesis of systemic sclerosis and of Raynaud's
phenomenon is not clearly understood. Platelets have been 
implicated, both in contributing to acute occlusive
episodes (184)(431) and in evolution of the chronic
disease process (425)(426)(432).While treatment with
platelet inhibitors such as prostacyclin and PGEl has been 
reported to be successful (433)(434)(435), this may
reflect the vasodilator activity of these compounds. This
study does not directly address the role of platelets in
these conditions, but does provide evidence that platelet
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activation is occurring and is enhanced on exposure to
cold. It therefore identifies a second model of platelet
activation in vivo in which thromboxane formation is
increased and which represents an appropriate target for 
therapeutic intervention with regimens designed to inhibit
thromboxane synthesis.
III.MYELOPROLIFERATIVE DISORDERS
It is well recognized that the myeloproliferative
disorders are associated with an increased incidence of 
thrombosis, particularly in the microvascular circulation
(436)(437). Qualitative abnormalities of platelet
behaviour are common in such patients and may result 
either in defective platelet function or in enhanced
platelet reactivity. Numerous types of abnormality have 
been described, including altered arachidonate metabolism 
(195)(196)(438) and several studies have demonstrated
evidence of platelet activation in vivo in a variable
proportion of patients (439)(440)(441)(442).
The following study investigates endogenous
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biosynthesis of thromboxane in a small group of 
patients with myeloproliferative disorders. The aim was to 
characterize a further model of platelet activation in 
vivo and to assess from this preliminary data whether 
measurement of Tx-M excretion was likely to represent a 
useful guide to selecting those patients for whom 
platelet-inhibitory therapy would be beneficial.
Study Design 
Patient selection:
Six male patients aged 42-76 years and six healthy age- 
and sex-matched controls were studied. All of the patients
were attending the haematology outpatient clinic of the 
Veterans Administration Hospital, Nashville, Tennessee. 
Five of the patients had stable phase chronic granulocytic
leukaemia (4 were Philadelphia chromosome-positive, 1 was
not tested) and one patient had polycythaemia rubra vera. 
Diagnoses were made on the basis of bone marrow aspirates,
trephine biopsies and neutrophil alkaline phosphatase 
scores in each case, with additional blood volume studies
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in the patient with polycythaemia vera. Although an
attempt was made to include further patients with
polycythaemia vera and essential thrombocythaemia in the 
study, almost all of such patients were already on
anti-platelet therapy or were unsuitable for study for
other reasons (eg renal impairment).
Analytical methods:
Endogenous biosynthesis of thromboxane and prostacyclin
was determined by measuring Tx-M and PGI-M excretion in 
urine by gas chromatography mass spectrometry as described
in chapter 2. Blood samples corresponding to the time of
urine collection were taken for plasma B-thromboglobulin
and platelet factor 4 and for serum thromboxane B2
which were measured by radioimmunoassay. The circulating
platelet aggregate ratio was calculated using a 
modification of the method of Wu and Hoak (350) and the
bleeding time was determined by the template method.
Results
The results are shown in Table 4.1. Thromboxane
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biosynthesis was increased in the patients with
myeloproliferative disorders compared to the healthy 
control subjects (412 +/- 115 vs 208 +/- 43 pg/mg
creatinine; p<0.05>. Serum thromboxane B., generation
was also significantly greater (p<0.05) in the patients
compared to the healthy controls (394 +/- 47 vs 283 +/- 43
ng/ml). However, unlike the patients with atherosclerosis
or systemic sclerosis, the peripheral blood platelet
counts were considerably higher in the myeloproliferative
patients compared to their controls (543 +/- 84 vs 252 +/-
24 x lO'/l? p<0.05). Since there is a linear relationship 
between platelet count and both Tx-M and serum thromboxane
(see Appendix I), the values of these parameters were 
corrected to a platelet count of 252 x lO'/l to allow
direct comparison with the values obtained in the control
subjects. This reduced Tx-M excretion in the 
myeloproliferative patients to 194 +/- 74 pg/mg creatinine
and serum thromboxane to 221 +/- 43 ng/ml, which
were not significantly different from the values in the
healthy controls.
There was also no difference in PGI-M excretion between 
patients and controls. Although plasma levels of 
B-thromboglobulin were increased in the patients (42 +/- 9 
vs 10 +/- 3 ng/ml; p<0.05), this was accompanied by a
similar elevation of platelet factor 4. The CPA ratio was
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TABLE 4.1 EICOSANOID SYNTHESIS AND PLATELET FUNCTION IN PATIENTS 
WITH MYELOPROLIFERATIVE DISORDERS.
Patients Controls
Tx-M
(pg/mg creatinine)
412±115* 208±43
PGI-M
(pg/mg creatinine)
162±43 220±31
Serum thromboxane B? 
(ng/ml)
394±47* 283±43
Platelet count 
(x 10^/1)
543±84* 252±24
G-thromboglobulin
(ng/ml)
42±9* 10±3
Platelet factor 4 
(ng/ml)
32±12 11±4
Bleeding time 
(minutes)
3.5±0.4 3.5±0.4
Values are mean ± SEM of determinations in 6 patients and 6 healthy 
controls.
* p <0.05
slightly higher in the myeloproliferative patients
(1.11 +/- 0.04 vs 1.01 +/- 0.04) but this difference was
not statistically significant. There was also no
difference in the bleeding time between the two groups
studied.
Discussion
The recognition that the myeloproliferative syndromes 
are associated with an increased frequency of thrombotic
complications and may exhibit platelet hyperaggregability
and platelet activation in vivo (439)(440)(441)(442)
suggested that such patients might also have an enhanced
rate of thromboxane synthesis. The results of the present 
study show that although endogenous thromboxane
biosynthesis was significantly enhanced in the patients 
with myeloproliferative disorders, this appears mainly to
be a consequence of the higher platelet counts found in
the patients. Thus, if the level of Tx-M was adjusted to
take account of the higher platelet counts in the
patients, . there was no longer a significant difference
between patients and controls. In addition, in contrast to
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the other two models of platelet activation described in 
this chapter, there was no increase in endogenous
prostacyclin formation. Similarly, while plasma
B-thromboglobulin was elevated in the patients, the 
concomitant increase in platelet factor 4 suggests that
this was more likely to be due to the higher platelet
counts (443) and/or platelet activation occurring during 
blood sampling (265) rather than the presence of platelet
activation in vivo.
There are several reasons for the failure to 
demonstrate convincing evidence of platelet activation in 
vivo in this study. Firstly, the numbers studied were 
small which reflected the difficulty in identifying
patients not already on platelet-inhibitory therapy and 
without other major clinical problems. Secondly, the group
of patients studied consisted mainly of individuals with
chronic granulocytic leukaemia who are known to have a
lower incidence of thrombotic complications than the other
myeloproliferative states (436). In addition, none of the
patients investigated had a definite history of previous
thrombotic episodes and this may therefore have been a low 
risk population in what is recognized to be a very 
heterogeneous group of disorders. Finally, the higher
platelet counts in these patients made it difficult to 
accurately interpret the measured indices in terms of the
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presence or absence of platelet activation in vivo.
It is likely that clarification of the role of 
thromboxane in the pathogenesis of the thrombotic 
complications of the myeloproliferative syndromes will 
require further studies in selected patients with 
documented microvascular insufficiency. The results of the 
present study suggest that as a group the 
myeloproliferative disorders may not represent a useful 
model of platelet activation in vivo and underline the 
importance of identifying appropriate models for the 
investigation of the mechanisms of human disease.
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CONCLUSION
These studies have shown that in two distinct human
syndromes of platelet activation in vivo endogenous 
biosynthesis of thromboxane is significantly enhanced. 
Moreover, an additional stimulus to platelet activation
(the precipitation of Raynaud's phenomenon on exposure to
cold) in the patients with systemic sclerosis resulted in 
a further increment in thromboxane formation in vivo. The
identification of these syndromes of thromboxane-dependent 
platelet activation provides clinically-relevant models in 
which to investigate the pharmacology and efficacy of
therapeutic regimens directed towards the inhibition of
thromboxane synthesis.
The utility of Tx-M as an index of platelet activation
in vivo, both in the setting of chronic disease and in 
response to acute changes, was also confirmed in these
studies. Since samples are obtained non-invasively, the
values measured are not influenced by ex vivo platelet
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activation which can lead to marked artifactual elevations 
in other parameters such as B-thromboglobulin and plasma 
thromboxane (130)(263)(264)(265). The results of
a recent study in patients with unstable angina, in whom
episodes of ischaemic chest pain , were accompanied by
phasic increases in Tx-M excretion (422), supports the
contention that this approach will be useful in evaluating
the role of platelets in the wide variety of conditions in
which they have been implicated.
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Chapter 5
SELECTIVE INHIBITION OF ENDOGENOUS THROMBOXANE FORMATION 
: Studies in a Human Model of Platelet Activation in vivo
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INTRODUCTION
Platelet-inhibitory therapy has been advocated for the
treatment and prevention of a wide spectrum of diseases in
which platelet activation is believed to play a role. 
Aspirin was the first drug to be evaluated in large
clinical studies and appeared to be of some benefit, 
particularly in cerebrovascular and cardiovascular
atherosclerosis
(229-232)(267-270)(272)(273)(362)(444)(445). Nevertheless, 
the results of individual controlled trials in these
conditions were much less dramatic than had been
anticipated on the basis of aspirin's ability in vitro to
inhibit platelet function and thromboxane synthesis (446).
While there are clearly many reasons for this, the 
recognition that aspirin also caused a significant
reduction in the synthesis of a potent endogenous
inhibitor of platelet function, prostacyclin, stimulated
the search for pharmacological agents which selectively
inhibited thromboxane formation.
Several approaches to selective inhibition of
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thromboxane synthesis were investigated in healthy 
individuals in chapter 3. However, the effects of
platelet-inhibitory therapy in patients with platelet
activation in vivo would be expected to be quite
different. For example, in normal healthy subjects the
rate of endogenous thromboxane biosynthesis is extremely 
low (92) and, as I have shown, a single dose of aspirin
will significantly reduce it. In the presence of in vivo 
platelet activation when thromboxane formation is
increased, it may consequently be more difficult to
inhibit endogenous thromboxane production. In addition,
since the platelet capacity for thromboxane generation 
greatly exceeds the actual biosynthetic rates even in the
presence of platelet activation in vivo, it is likely that
in these patients inhibition of thromboxane synthesis will
have to be virtually complete before thromboxane-dependent
platelet aggregation is abolished. Furthermore,
prostacyclin biosynthesis is also increased in such
patients. Since prostacyclin not only inhibits the
aggregation of platelets by all recognized agonists, but
is also a potent vasodilator and disaggregates previously
aggregated platelets (15), it may function as an important
regulator of platelet-vascular homeostasis in the presence
of vessel narrowing or occlusion, lending further support 
to the argument in favour of selective regimens. For these
reasons, the potential therapeutic benefit of such
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regimens needs to be evaluated by investigating their 
functional and biochemical effects in diseases in which 
platelet activation in vivo and associated enhanced 
biosynthesis of thromboxane have been shown to occur.
The following studies have been carried out in patients
with severe atherosclerosis who had evidence of platelet
activation in vivo and increased thromboxane biosynthesis.
The patients were chosen, on the basis of the work
described in chapter 4, to represent a stable model of 
thromboxane-dependent platelet activation in vivo which
could be evaluated over a period of months. The effects of
two different methods of inhibiting endogenous thromboxane
formation have been investigated- a direct approach 
employing specific blockade of thromboxane synthase, and
an indirect approach in which chronic administration of 
fish-oil was used to inhibit platelet activation and 
consequently reduce reduce thromboxane biosynthesis. 
Thromboxane synthase inhibitors are the only drugs known 
to enhance endogenous biosynthesis of prostacyclin and may
therefore offer a particular advantage in the setting of
vaso-occlusive disease. Dietary supplementation with 
fish-oils rich in eicosapentaenoic acid has been shown in
healthy individuals to diminish the capacity of platelets
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to form thromboxane B (316)(317)(319) and to 
inhibit platelet function (316)(317)(322)(321)( 447)(448 ). 
In addition, preliminary evidence suggests that
prostacyclin biosynthesis is preserved and that 
prostaglandin I which has similar biological
properties to prostacyclin, is formed (449) and may 
contribute to the anti-platelet effects of this approach.
I.SELECTIVE INHIBITION OF THROMBOXANE SYNTHASE
Although, they appear to have relatively weak
anti-platelet activity in vitro, there is considerable
evidence that thromboxane synthase inhibitors can
significantly reduce mortality and morbidity in several
animal models of thrombosis (202)(228) and vascular
occlusion (203-206). Dazoxiben has been shown to eliminate
or attenuate cyclical flow reductions in stenotic canine
coronary arteries (206) and in another canine model to
delay the time for occlusive thrombi to form at sites of
electrical injury in coronary vessels (205). Furthermore, 
in the studies of Aiken et al (203) and Fitzgerald et al
(345) the efficacy of thromboxane synthase inhibitors in 
this setting appeared to be due at least in part to the
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ability of these drugs to enhance prostacyclin formation.
Platelet granule constituents, including
platelet-derived growth factor, 5-hydroxytryptamine, the 
adenine nucleotides and platelet activating factor,
released when platelets are activated are potent stimuli 
for prostacyclin formation (114)(116)(117)(118). The
observation that basal prostacyclin biosynthesis is
significantly higher in patients with platelet activation
in vivo, raises the possibility that transfer of
platelet-derived prostaglandin endoperoxides to
prostacyclin synthase might be facilitated in such
patients. Thus, the potential of thromboxane synthase
inhibitors to increase prostacyclin biosynthesis may be 
even greater. Nevertheless, these drugs have never been
evaluated in a human model of vaso-occlusive disease in
which documented evidence of thromboxane-dependent
platelet activation in vivo provides the rationale for
such an approach. Previous clinical studies have generally
yielded very disappointing results (379). However, the
studies have largely been confined to heterogeneous groups
of patients in which the role of thromboxane has not been
clearly defined and the effects on thromboxane and
prostacyclin biosynthesis have not been assessed.
This study examines the biochemical and functional
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effects of thromboxane synthase inhibition in a human
model of platelet activation. The aim was to determine 
whether platelet activation persisted during chronic 
administration of these drugs and whether prostacyclin
formation was further enhanced. The thromboxane synthase
inhibitor selected for the study was imidazo
(1,5-2)pyridine-5-hexanoic acid (CGS 13080) which, in 
healthy individuals, induces a greater increase in
prostacyclin biosynthesis than the other two compounds of 
this class on which data are available (Figure 5.1).
STUDY DESIGN:
Patient selection;
Nine patients (8 men and one woman, aged 49-75 years) 
with angiographically-confirmed peripheral arterial
disease of the lower limb were studied. The patients had
severe generalized disease (grade III or IV) with pain at 
rest and/or ischaemic ulcers. Each patient fulfilled
predetermined criteria consistent with the presence of 
platelet activation in vivo and are described in detail in 
chapter 4. The criteria for inclusion were a plasma
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FIGURE 5.1 PGI-M EXCRETION AFTER ORAL ADMINISTRATION OF VARIOUS THROMBOXANE
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B-thromboglobulin concentration of > 20ng/ml (in
association with a normal platelet factor 4 level of < 18
ng/ml) and a circulating platelet aggregate (CPA) ratio of
more than or equal to 1.3. In addition, all the patients
had increased excretion of the major urinary metabolites 
of prostacyclin (PGI-M) and thromboxane (Tx-M) and a
shortened bleeding time. Of the nine patients, five were
insulin-dependent diabetics, seven had
electrocardiographic evidence of chronic myocardial
ischaemia and seven were cigarette smokers. Four of the
patients had foot ulcers at the beginning of the study and 
one further patient developed an ulcer during the course
of the study.
Protocol:
The study was randomized, double-blind and
placebo-controlled. The patients received either CGS 13080
lOOmg, CGS 13080 200mg or two matching placebo capsules as
a single dose followed 24 hours later by a regimen of one 
dose every 6 hours for 6 days. The drug and placebo 
capsules were kindly provided by Dr Nancy Feliciano of the
Ciba-Geigy Corporation, Summit, New Jersey. The order of
the three treatment regimens was randomized according to a 
crossover design, each of the treatments being separated
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by 7-day drug-free intervals so that each patient was
studied over a period of approximately 6 weeks. All of the
patients refrained from taking aspirin or other
non-steroidal anti-inflammatory drugs during and for at
least 10 days prior to the commencement of the study.
After an overnight fast and cessation of cigarette 
smoking for a minimum of 30 minutes, blood was drawn from 
a fresh venepuncture for determination of serum
thromboxane B plasma B-thromboglobulin, platelet
factor 4 and the CPA ratio before and 1,4,6,8 and 24 hours
after the single dose and before and after the final dose
of each 6-day regimen. Blood was collected for platelet
aggregation studies and for the measurement of plasma drug
levels at the same times and for full blood counts and a 
routine automated chemistry screen before dosing on each
of the study days of the three treatment periods. The 
bleeding time was estimated before and one hour after the 
first and last dose of each treatment. Twenty-four hour
urine collections for measurement of the major urinary
metabolites of thromboxane (Tx-M) and prostacyclin (PGI-M)
were made before and in three aliquots after (0-6, 6-12
and 12-24 hours) the single dose and the final dose of the 
chronic dosing period.
On a separate occasion four of the patients were
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administered 325mg aspirin as a single dose. Blood was 
drawn for measurement of serum thromboxane B^ and 
platelet aggregation in response to arachidonic acid, 
collagen and adrenaline before and one hour after dosing.
Clinical evaluation:
Before the study and at the end of each treatment
period, the patients were assessed clinically by physical 
examination and objectively by Doppler flow measurements
of ankle systolic pressure, by analysis of the waveform of 
arterial flow and by calculation of the ankle/brachial 
systolic pressure index (450). Measurements were made in
patients at rest with a unidirectional Doppler ultrasound
velocity detector (Park Electronics, Aloha, Oregon) and a 
mercury sphygmomanometer. A visual analogue scale was used
to monitor pain at rest. This consisted of a 10cm line
labelled "no pain" and "the worst pain I have ever 
experienced" at opposite poles.
Analytical methods:
The presence of platelet activation was determined by 
measuring plasma B-thromboglobulin and platelet factor 4
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by radioimmunoassay as described in chapter 2 and the
CPA ratio by a modification of the method of Wu and Hoak
(350). In addition, Tx-M and PGI-M were quantitated by 
stable isotope dilution assays employing gas
chromatography/mass spectrometry. Urinary thromboxane
was also measured by a stable isotope dilution
assay, as described in chapter 2, using gas
chromatography/mass spectrometry and thromboxane
generation in serum was determined by radioimmunoassay.
Platelet function was assessed by measuring the bleeding 
time by the template method and by platelet aggregation
studies in PRP in response to arachidonic acid (0.33mM and
1.33mM), collagen (1.9 ug/ml and 19 ug/ml) and adrenaline
(5 and lOuM) and in whole blood in response to arachidonic
acid (0.66mM) and collagen (9.5 ug/ml). Plasma
concentrations of CGS 13080 were determined by Dr Chan of
the Ciba-Geigy Corporation using high-pressure liquid
chromatography.
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RESULTS:
Evidence of Platelet Activation in vivo:
The patients all fulfilled the preset criteria 
consistent with platelet activation in vivo. Plasma 
B-thromboglobulin was elevated at 113 +/- 22 ng/ml with 
normal concentrations of platelet factor 4 (12 +/- 0.5 
ng/ml). The CPA ratio was increased at 1.4 +/- 0.01 and 
the bleeding time was shortened at 2.9 +/- 0.2 minutes. 
Urinary excretion of both Tx-M and PGI-M was enhanced at 
912 +/- 99 and 323 +/- 89 pg/mg creatinine respectively.
Effects on Thromboxane Synthesis in vivo and ex vivo:
Tx-M excetion was unaltered after administration of 
placebo and did not differ significantly on the control 
days that preceded each treatment period. After 
administration of a single dose, CGS 13080 caused a 
significant, reversible fall in Tx-M by a maximum of 66 
+/- 4 % from 716 +/- 213 to 240 +/- 81 pg/mg creatinine
6-12 hours after dosing (Figure 5.2). Although Tx-M 
excretion remained depressed during chronic dosing,
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FIGURE 5.2 EXCRETION OF Tx-M AND PGI-M AFTER ADMINISTRATION OF CGS 13080 TO
PATIENTS WITH ATHEROSCLEROSIS.
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significant biosynthesis of thromboxane persisted and no 
further decrement in Tx-M occurred with administration of
the final dose. There was no significant difference 
between the lOOmg and 200mg dose with respect to the
effects observed on Tx-M excretion after short- and
long-term dosing (Table 5.1). In the four patients in whom
the urinary excretion of both thromboxane and
Tx-M was measured, a similar degree of depression of both 
metabolites was noted (Table 5.2). In addition, basal
levels of urinary thromboxane were markedly
elevated compared with those observed in healthy subjects
(247 +/- 86 vs 46 +/- 14 pg/mg creatinine).
Administration of placebo did not significantly alter 
serum thromboxane B^ levels from predosing values.
After single-dose administration of CGS 13080, serum
thromboxane B^ generation ex vivo was reversibly
inhibited, with peak inhibition measured one hour after
dosing (Figure 5.3). Recovery of serum thromboxane was
linear and gave a calculated "biological" half-life (50%
recovery to predosing values) of between 6 and 8 hours.
The level of serum thromboxane B^ immediately before
the last dose (140 +/- 54 ng/ml), which was measured 8
hours after the previous dose, was not significantly
different from that measured after the first dose (115 +/-
38 ng/ml). Thus, no cumulative inhibition of serum
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TABLE 5.1 Tx-M EXCRETION AFTER ADMINISTRATION OF CGS 13080 TO
PATIENTS WITH ATHEROSCLEROSIS.
CGS 13080 
100mg
CGS 13080 
200mg
Prior to first dose: 737+271 716±213
After first dose
0-6 hours: 460±224 351+143*
6-12 hours: 390±212* 240±81**
12-24 hours: 441+197* 458+158*
Prior to last dose: 213±109** 106±32**
After last dose
0-6 hours: 234±99** 152+53**
6-12 hours: 245±117** 195+59**
12-24 hours: 379±147* 372+79*
Values are expressed in pg/mg creatinine (mean ± SEM) in samples 
from 9 patients.
* p <0.05
** p <0.01
TABLE 5.2 URINARY EXCRETION OF Tx-M AND THROMBOXANE B (TxB_) after 
CHRONIC ADMINISTRATION OF CGS 13080 200mg TO PATIENTS 
WITH ATHEROSCLEROSIS.
%  inhibition from predose control
Tx-M TxB2
Prior to last dose: 84.7±5 89.4±1
After last dose
0-6 hours: 78.0±6 88.2±7
6-12 hours: ' 71.6+7 72.7+4
12-24 hours: 52.1±12 . 52.3±7
Values are mean ± SEM of determinations in 4 patients.
FIGURE 5.3 EFFECT OF CGS 13080 ON SERUM THROMBOXANE B GENERATION IN PATIENTS
WITH ATHEROSCLEROSIS.
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thromboxane occurred during chronic dosing. As observed
with Tx-M excretion, there was no difference in the
effects of the two doses of CGS 13080 on serum thromboxane 
formation, suggesting their proximity on the
dose-response curve.
Effect on Prostacyclin Biosynthesis:
There was no change in PGI-M excretion with placebo. 
Coincident with the fall in Tx-M after 200mg of CGS 13080, 
PGI-M excretion increased significantly (p<0.05) from 291 
+/- 54 to 538 +/- 150 and 442 +/- 150 pg/mg creatinine in
the 0-6 and 6-12 hour aliquots. Similar increments in 
PGI-M were obtained after the lOOmg dose (Table 5.3). 
PGI-M remained significantly elevated during chronic 
dosing but no further increase occurred after the final 
dose of CGS 13080 (Figure 5.2).
Effects on Platelet Function;
Plasma B-thromboglobulin and platelet factor 4 were 
unchanged by placebo. There was no significant depression 
of B-thromboglobulin after single-dose administration of 
either dose of CGS 13080 (Figure 5.4). During chronic
TABLE 5.3 PGI-M EXCRETION AFTER ADMINISTRATION OF CGS 13080 TO
PATIENTS WITH ATHEROSCLEROSIS.
CGS 13080 
1Q0mg
CGS 13080 
200mg
Prior to first dose: 287+24 291±54
After first dose
0-6 hours: 444±110* 538±150*
6-12 hours: 441+148* 442±150*
12-24 hours: 402±151 399±139
Prior to last dose: 367±66* 419±105*
After last dose
0-6 hours: 494±92* 364±63
6-12 hours: 406±62* 353±77
12-24 hours: 371+67 334±66
Values are expressed in pg/mg creatinine (mean ± SEM) in samples 
from 9 patients.
* p <0.05
( n g / i
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dosing, however, B-thromboglobulin levels fell
significantly, although they remained more than three 
times normal: 61 +/- 21 ng/ml (200mg) and 45 +/- 15 ng/ml
(lOOmg) vs 13 +/- 3 ng/ml (age-matched control subjects). 
Platelet factor 4 levels were within the normal range and 
were unaltered by CGS 13080 (Figure 5.4).
The CPA ratio (Figure 5.5) and bleeding time (Figure 
5.6) were not significantly different before and after 
administration of CGS 13080 or placebo. There was no
change in platelet aggregation in PRP in response to
arachidonic acid (Figure 5.7), adrenaline and collagen 
(Figure 5.8). Platelet aggregation in whole blood was also
unaltered. By contrast, administration of aspirin
significantly inhibited platelet function in these
patients (Table 5.4).
Plasma Drug Levels:
Plasma concentrations of CGS 13080 are shown in Table
5.5. These confirmed bioavailability of the compound and 
the relationship of plasma concentration to dose within 
each of the patients.
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FIGURE 5.5 EFFECT OF CGS 13080 ON THE CIRCULATING PLATELET AGGREGATE RATIO IN
PATIENTS WITH ATHEROSCLEROSIS.
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FIGURE 5.6 EFFECT OF CGS 13080 ON THE BLEEDING TIKE IN PATIENTS WITH 
ATHEROSCLEROSIS.
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FIGURE 5.7 EFFECT OF CGS 13080 ON THE BLEEDING TINE IN PATIENTS WITH
ATHEROSCLEROSIS.
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FIGURE 5 . 8  PLATELET AGGREGATION IN RESPONSE TO COLLAGEN AFTER ADMINISTRATION 
OF CGS 13080  TO PATIENTS WITH ATHEROSCLEROSIS.
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TABLE 5.4 EFFECT OF ASPIRIN 325 mg ON PLATELET AGGREGATION
BLEEDING TIME AND SERUM THROMBOXANE B_ IN PATIENTS WITH 
ATHEROSCLEROSIS.
Before aspirin After aspirin
Platelet aggregation* 
in response to:
Arachidonic acid 1.33mM 87±1.5 NA
0.33mM 87±0.9 NA
Collagen 19p.g/ml 92±2 85±4
1.9p.g/ml 61 ±20 NA
Adrenaline 10(iM 88±2.5 PA
5pM 89±0.8 PA
Serum thromboxane B? 332±62 13+7
(ng/ml)
Bleeding time 3.6+0.6 5.1±0.8
(minutes)
* Platelet aggregation in PRP is expressed as a percentage of 
maximal aggregation 6 minutes after addition of the agonist.
Values are mean ± SEM of determinations in 4 patients.
NA : no aggregation
PA : primary wave of aggregation
TABLE 5.5 PLASMA CONCENTRATIONS OF CGS 13080(ng/ml) AFTER SINGLE
DOSE AND CHRONIC ADMINISTRATION TO PATIENTS WITH
ATHEROSCLEROSIS.
Time after 
dosing 
(hours)
CGS 13080 100mg CGS 13080 200mg
First
Dose
Last dose of 
100mg qid regimen
First
Dose
Last dose of 
200mg qid regimen
0 ND 53±26 ND 260±213
1 2333±279 1704+397 2476±593 3010±590
4 149±36 128±30 299±122 437±111
6 31±8 49±19 98±53 102+33
8 ND 21+9 20±9 64±23
24 ND ND ND ND
Significant concentrations of CGS 13080 were not
detectable in plasma 8 hours after single-dose 
administration and in eight of the nine patients there was 
no evidence of accumulation during administration of
multiple doses. One patient did, however, exhibit marked
accumulation of the drug with long-term dosing,
particularly at the higher dose, and this correlated with
a greater degree of inhibition of serum thromboxane 
3^/ Tx-M excretion and plasma B-thromboglobulin 
(Figure 5.9) than observed in the other patients.
Clinical Evaluation:
There was no significant alteration in the Doppler 
measurements of absolute ankle systolic pressure, the 
arterial wave form or the ankle/brachial systolic pressure 
index (Figure 5.10). The scores measured on the visual
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FIGURE 5.9 RELATIONSHIP BETWEEN PLASMA CONCENTRATIONS OF CGS 13080 AND THE
EFFECTS ON INDICES OF THROMBOXANE SYNTHESIS AND PLATELET FUNCTION.
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analogue scale used to assess pain at rest were not
significantly diferent with placebo or CGS 13080. At the
beginning of the study the routine biochemistry screen and 
full blood counts, including the platelet counts (mean 268
+/- 17 x 10*/l), of all the patients were within normal 
limits and did not change significantly during the study.
Discussion
This study was designed to investigate the biochemical
and functional effects of administration of a
representative thromboxane synthase inhibitor in patients
with platelet activation in vivo and increased endogenous
thromboxane biosynthesis. Single-dose administration of
CGS 13080 resulted in more than 95% inhibition of serum
thromboxane formation ex vivo one hour after dosing, with
a biological half-life of 6-8 hours, which is comparable
to that achieved with other thromboxane synthase
inhibitors (64) (366) and with this compound in healthy
volunteers (65) (365). The corresponding reduction in Tx-M
excretion after a single dose was 66%. Thus, the 
thromboxane synthase inhibitor caused a considerably
greater fall in Tx-M in the patients with platelet
activation in vivo than that seen in healthy individuals
(see chapter 3). During chronic dosing, however, trough
levels of serum thromboxane B- and Tx-M remained at
2
approximately 50% and 25% respectively of predosing 
values. Since even a 10% residual capacity to generate 
thromboxane appears to be enough to fully sustain 
thromboxane-dependent platelet function in vitro (384), 
the degree of inhibition of Tx-M achieved in this study 
would be unlikely to abolish platelet activation in these 
patients.
Using a variety of methods to characterize platelet 
function ex vivo and in vivo, the study has clearly 
demonstrated that platelet activation does persist in this 
population during chronic administration of a thromboxane 
synthase inhibitor. There was also no objective evidence 
of clinical improvement during the study. There was no 
change in the bleeding time, in platelet aggregation in 
response to three different agonists or in the CPA ratio, 
and although B-thromboglobulin fell, it still remained 
more than three times normal. This is in contrast to 
studies in healthy volunteers in whom CGS 13080
significantly prolonged the bleeding time and inhibited 
platelet aggregation ex vivo (65). Nevertheless, that 
platelet activation was reduced to a significant degree is 
suggested both by the fall in B-thromboglobulin and by the
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disproportionately greater depression of Tx-M excretion 
induced by the thromboxane synthase inhibitor compared to 
that seen in healthy individuals without evidence of 
platelet activation in vivo.
The failure to induce complete, cumulative inhibition 
of thromboxane generation during chronic drug
administration may have several explanations. Firstly, the
dosing interval in this investigation, as in previous
clinical studies with this class of compounds
(393)(394)(451), was based, not on the plasma drug
half-life of 45 minutes (365), but on the much longer
biological half-life. While cumulation to a steady-state
effect would be expected in three to four half-lives when 
the dosing interval is based on the plasma drug half-life, 
this assumption cannot be made for the biological
half-life. Indeed, 6 to 8 hours after dosing, plasma
levels of CGS 13080 were barely detectable and it is thus 
not surprising that cumulative inhibition of thromboxane
formation did not occur during this study. While such a
discrepancy (between the biological and pharmacological
half-lives) might be anticipated on the basis of 
established plasma drug kinetic-dynamic relationships
(452), other factors, such as the presence of active
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metabolites or slow elimination of the drug from deep
compartments, may have contributed to this observation.
However, the same discrepancy can be seen with several 
structurally distinct thromboxane synthase inhibitors
(64 ) (65)(366). In no case have biologically active
metabolites of these compounds been identified. This 
suggests that incomplete inhibition of thromboxane
biosynthesis during the dosing interval is likely to have
occurred in clinical trials of synthase inhibitors other
than CGS 13080 since none have employed a dosing interval
of less than 6 hours.
Other factors which may contribute to the persistence
of platelet activation in vivo in these patients are the
effects of accumulated prostaglandin endoperoxides and
platelet activation secondary to non-eicosanoid dependent
mechanisms. Aspirin, which reduces formation of both
thromboxane and the prostaglandin endoperoxides,
significantly prolonged the bleeding time in these
patients and inhibited platelet aggregation. This
observation, and the lack of effect of the synthase 
inhibitor on measured indices of platelet function one
hour after dosing when inhibition of platelet thromboxane
formation ex vivo was more than 95%, suggest that
substitution for the proaggregatory effects of thromboxane
accumulated endoperoxides may play a role
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during inhibition of thromboxane synthase in vivo. Support 
for this hypothesis is provided by a canine model in which
the combination of an endoperoxide/thromboxane
receptor antagonist and a thromboxane synthase inhibitor
delays the time to coronary occlusion despite maximal
inhibition of platelet thromboxane synthesis by the
synthase inhibitor alone (345). However, that incomplete
inhibition of thromboxane formation throughout the chronic
dosing period is likely to be a major factor in the
continuing platelet activation observed in this study is
supported by the data from the single patient in whom
significant drug accumulation occurred. In this patient,
cumulative inhibition of thromboxane formation in vivo and
ex vivo was virtually complete, coincident with a
significantly greater fall in B-thromboglobulin.
It is of interest that the pattern of inhibition and
recovery of urinary thromboxane was almost
identical to that for the dinor metabolite, Tx-M. In
contrast to Tx-M which is mainly derived from platelets,
urinary thromboxane B i s believed to reflect
primarily renal thromboxane formation under physiological
conditions (338). Data from a rat glomerular preparation
in vitro has shown that glomerular thromboxane synthase
appears to be considerably more sensitive to the effects
of the synthase inhibitor, dazoxiben, than platelet
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thromboxane synthase (453). However, the similar degree of
inhibition of urinary thromboxane B and Tx-M seen
2
in the present study suggest that this is unlikely to be 
true in humans. An alternative explanation of these
findings is that in the setting of platelet activation in 
vivo, unlike in healthy individuals, a significant
proportion of urinary thromboxane B2 may be derived 
from enhanced platelet thromboxane synthesis. Indeed,
basal levels of urinary thromboxane were elevated 
in the patients in this study to a similar extent to those 
of Tx-M. The matching pattern of inhibition and recovery 
of these two metabolites is also consistent with this 
interpretation.
Endogenous biosynthesis of prostacyclin increased by
approximately two-fold in response to a single dose of the 
thromboxane synthase inhibitor, which is consistent with
endoperoxide rediversion to a source of prostacyclin
synthase (62) (63). The initial significant increment in
prostacyclin appeared not to be maintained during chronic
dosing and there was no further increase after the final
dose. These changes mirrored the fall in endogenous
thromboxane formation and provide additional evidence that
alterations in prostacyclin formation are dependent upon
increased provision of endoperoxide substrate after
inhibition of thromboxane synthase. While the percentage
259
increment in prostacyclin biosynthesis was similar to that 
observed with the same drug in healthy individuals (65),
the absolute increment in metabolite excretion was at
least twice as great in the patients. This suggests that
transfer of prostaglandin endoperoxides is enhanced in the
presence of platelet activation in vivo. Despite elevated
basal excretion of prostacyclin in these patients, the
magnitude of the increase in prostacyclin after
administration of the synthase inhibitor is substantially
less than the maximum capacity of vascular tissue to
generate prostacyclin (130) ( 288)(290) and would not result 
in levels sufficient to exert systemic effects (132).
Nevertheless, endogenous prostacyclin, which has the
ability not only to inhibit platelet aggregation in
response to all agonists but also to disaggregate 
previously aggregated platelets (15), may contribute to
the efficacy of thromboxane synthase inhibitors by its
actions at a local level.
The present study has demonstrated that administration
of a thromboxane synthase inhibitor in a dosage schedule
representative of those used in clinical trials caused
reversible inhibition of thromboxane formation in patients 
with platelet activation in vivo and enhanced endogenous
biosynthesis of thromboxane. Cumulative, complete
inhibition of thromboxane biosynthesis did not, however,
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occur and platelet activation persisted during chronic 
drug administration. The results of this study indicate 
that, as suggested by the investigations in healthy
individuals, realization of the therapeutic potential of 
thromboxane synthase inhibitors is likely to depend on:
prolongation of drug action and combination with
antagonists of the endoperoxide/thromboxane
receptor. In addition, they highlight the importance of
achieving complete inhibition of thromboxane formation in 
order to prevent continuing platelet activation in vivo in
such patients.
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II.INHIBITION OF THROMBOXANE BIOSYNTHESIS BY FISH-OIL
ADMINISTRATION
Epidemiological studies of Greenland Eskimos and 
mainland Danes have suggested that a diet rich in marine 
lipids may be associated with a reduction in the incidence 
of occlusive vascular disease (278)(454). More recently, 
studies based on dietary history indicate that even a 
small intake of fish may have reduced the incidence of 
coronary vascular disease in both European and North 
American study populations (455)(456). Fish-oil contains 
the N-3 polyunsaturated fatty acid, eicosapentaenoic acid. 
Whereas thromboxane A^ is the predominant product of 
arachidonic acid formed in platelets, the corresponding 
product when eicosapentaenoic acid is utilized as 
substrate is thromboxane A^ (see Figure 1.11), which 
is virtually biologically inert (8) (311). The mechanism of 
the reduced risk of atherosclerotic cardiovascular disease 
in populations consuming a diet rich in marine oils has 
therefore been postulated to reflect competition between 
eicosapentaenoic and arachidonic acid as potential 
substrates for cyclooxygenase with a resultant fall in the
rate of thromboxane A^ generation. Although
substrate competition might also be expected to reduce the
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amount of prostacyclin (PGI2 ) synthesized, in 
fact studies in healthy volunteers suggest that endogenous 
prostacyclin production is preserved during chronic
fish-oil administration (312)(457). In addition, 
PGI^f which is formed in small amounts during 
dietary supplementation with eicosapentaenoic acid 
(457)(312), is, like prostacyclin, a potent vasodilator 
and platelet inhibitor (311).
Studies of fish-oil administration in normal volunteers
have reported variable effects on platelet function in
these individuals (315-318)(321-323)(447). However, this
is likely to reflect an inadequate intake of fish-oil in
these studies as the majority have shown a much lower
ratio of eicosapentaenoate to arachidonate in the platelet
membrane lipids (315-318)(321)(322)(447) than that
reported in Eskimos (279). The present study was designed
to investigate the mechanisms underlying the effects of
fish-oil on platelet and vascular function in patients
with platelet activation in vivo and increased
biosynthesis of thromboxane. The study had two principal
aims. Firstly, to simulate an Eskimo diet in these
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patients and relate the biosynthesis of thromboxane and
prostacyclin to indices of platelet function in vivo; and 
secondly, in additional studies in two of the patients, to
determine whether inhibition of thromboxane formation
could be sustained by lower, more palatable doses of
fish-oil.
STUDY DESIGN;
Patient selection:
Six men (aged 51-69 years) with advanced 
atherosclerotic peripheral vascular disease participated
in the study. The patients were selected from amongst 
those attending the vascular clinic of the Veterans
Administration Hospital, Nashville, Tennessee. All the
patients had angiographically-confirmed peripheral
arterial disease and met predetemined criteria consistent 
with the presence of platelet activation in vivo: plasma 
B-thromboglobulin > 20 ng/ml, with a normal platelet
factor 4 level (below 18 ng/ml), and an elevated CPA 
ratio. Five of the six patients had taken part in the
preceding study investigating the effects of the
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thromboxane synthase inhibitor, CGS 13080. Two of the
patients had diabetes mellitus and 4 were chronic 
cigarette smokers. Four had electrocardiographic evidence
of chronic myocardial ischaemia but none was on 
anti-anginal medication. All the patients abstained from
aspirin or other non-steroidal anti-inflammatory drugs 
prior to and during the study.
Protocol:
All the participants were given 50ml (lOg of 
eicosapentaenoate) of Max-EPA fish oil (kindly provided by
Dr Desmond Davies, R.P. Scherer Company. Troy, Michigan)
daily for four weeks as a supplement to their usual diet.
To address further the relationship between the dose of
fish-oil and the effect on thromboxane biosynthesis, two 
of the patients were given a lower dose (lg daily) for 6
months after the study with the higher dose (lOg per day) 
had been completed. Compliance was checked by documenting
changes, in the erythrocyte lipid composition of all the
patients.
Urine was collected in 24-hour aliquots prior to the 
study and at weekly intervals during supplementation for 
measurement of 2,3-dinor thromboxane (Tx-M) and
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2,3-dinor-6-keto-PGF (PGI-M) and to determine
whether the corresponding metabolites of thromboxane
A (2,3-dinor-17-ene-thromboxane B ) and
prostaglandin I (2,3-dinor-6-keto-17-ene-PGFn , )
3 loC '
) were excreted. Blood was drawn before the study and 
weekly during the study for measurement of serum
thromboxane B B-thromboglobulin, platelet factor
4, the circulating platelet aggregate ratio, platelet
aggregation studies, serum a-tocopherol and the full blood
count. In addition, incorporation of eicosapentaenoic acid
into red cell phospholipid fractions and routine clotting
studies (prothrombin time, kaolin cephalin clotting time
and thrombin time) and serum chemistry were determined
prior to and during the last week of supplementation. The
bleeding time was measured before and at weekly intervals 
during supplementation and three months after Max-EPA had
been discontinued. The patients were also evaluated 
clinically by direct questioning regarding the severity of
their symptoms and by physical examination.
Analytical Methods:
The presence of platelet activation in vivo was 
assessed by measurement of plasma B-thromboglobulin and 
platelet factor 4 by radioimmunoassay and of the CPA
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ration by a modification of the method of Wu and Hoak 
(350). In addition, Tx-M and PGI-M were determined by a 
stable isotope dilution assay employing gas
chromatography/mass spectrometry as described in chapter
2. The dinor metabolites of thromboxane B
3
(Tx B^-m ) and prostaglandin I (PGI^-M)
were quantified simultaneously by selected ion monitoring 
at 2 mass units lower (m/z 584) because of the extra 
double bond (457). Representative selected ion monitoring 
traces before and after fish-oil supplementation are shown 
in Figure 5.11). Platelet aggregation in PRP was tested in 
response to arachidonic acid (0.66mM) and serum 
thromboxane B^ was determined by radioimmunoassay.
The bleeding time was measured by the template method.
Analysis of erythrocyte phospholipids and serum
Ot-tocopherol were kindly performed by Patricia Price of
the Department of Pharmacology, Vanderbilt University.
Serum e£-tocopherol was measured by high-performance liquid
chromatography (458). Erythrocyte phospholipids were 
extracted according to the Folch procedure (458), purified 
by thin-layer chromatography by a modification of 
Skipski1s method (460)(461) and analysed with a gas
chromatograph equipped with an integrator (Varian 2100,
Varian Corporation, Palo Alto, California) on a 2-metre 
column of internal diameter 2mm packed with 10% SP 2340 on
FIGURE 5.11 SELECTED ION MONITORING TRACES OF URINARY EICOSANOID METABOLITES 
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Supelcoport (Supelco, Beliefonte, Pennsylvania).
RESULTS:
Evidence of Platelet Activation in vivo:
The patients all had evidence of platelet activation in
vivo. B-thromboglobulin was elevated at 60 +/- 17 ng/ml
(normal: 13 +/- 3 ng/ml) with a normal platelet factor 4
level (8 +/- 1 ng/ml). The CPA ratio was also increased at
1.30 +/- 0.08 (normal: 1.0 +/- 0.02) and the bleeding time
was shortened at 3.3 +/- 0.2 minutes (normal: 5.0 +/- 0.4 
minutes). Urinary excretion of both Tx-M and PGI-M was
enhanced at 1406 +/- 245 and 364 +/- 71 pg/mg creatinine
respectively (normal: 223 +/- 22 pg/mg creatinine for Tx-M 
and 197 +/- 21 pg/mg creatinine for PGI-M). The normal
values are derived from a population of healthy
individuals of the same age (see Appendix I).
Effects on Thromboxane Synthesis in vivo and ex vivo:
There was a rapid and marked fall in Tx-M excretion
during the first week of fish-oil ingestion fron 1406 +/- 
245 to 840 +/- 101 pg/mg creatinine (p<0.05). Tx-M
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continued to fall during the study by a maximum of 58 +/-
8 % to 588 +/- 142 pg/mg creatinine (p<0.01) by the end of
the fourth week (Figure 5.12). No detectable excretion of
the dinor metabolite of thromboxane B _
3'
TxB -M , occurred before or during the first week of 
the study period, but a minor accumulation was found by 
the end of the fourth week (49 +/- 7 pg/mg creatinine; 
p<0.001) (Figure 5.11). There was also a significant
reduction (p<0.05) in serum thromboxane generation during 
supplementation from 429 +/- 38 to 242 +/- 91 ng/ml, a
fall of 44 +/- 10 %. This accompanied a slight reduction
in the platelet count in all the patients during the study 
from 268 +/- 15 to 240 +/- 21 x 10^/1 Table 5.6), which
failed to reach statistical significance.
The effects on Tx-M excretion of the lower dose of 
fish-oil in the two patients who were given lg daily for
six months are shown in Figure 5.13. There was a gradual
return in Tx-M excretion, which had fallen during the 
higher dose of fish-oil, back to the elevated pretreatment
values. This was accompanied by a decline in the
eicosapentaenoate content of their erythrocyte
phosphatidylcholines from 8.9% immediately after the high
dose of fish-oil to 3.3% and 1.4% at three and six months
respectively of supplementation (pretreatment < 0.5%).
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FIGURE 5.12 URINARY EXCRETION OF METABOLITES OF THROMBOXANES AND PROSTACYCLINS 
BEFORE AMD DURING FISH-OIL INGESTION (10g daily) IN PATIENTS WITH 
ATHEROSCLEROSIS.
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TABLE 5-6 EFFECT OF FISH-OIL ON INDICES OF PLATELET FUNCTION IN 
PATIENTS WITH ATHEROSCLEROSIS AND PLATELET ACTIVATION 
IN VIVO.
CPA
Ratio
Platelet Count 
(x109/l)
Platelet aggregation in 
response to 0.66mM arach­
idonic acid 
(LT^g, minutes)
Before
treatment: 1.28±0.08 268±15 0.58+0.04
Treatment:
Wee k 1 1.05+0.02* 280±19 0.47^0.05
Week 2 1.26±0.09 252±22 0.56+0.04
Week 3 1.05±C.03 240±21* 0.46±0.03
Week 4 1.16+0.07 254±34 0.56±0.05
After
treatment: 1.27±0.08 291+14 0.51±0.01
*  p  < 0 . 0 5
Values are mean ± SEM of determinations in 6 male oatients.
FIGURE 5.13 Tx-M EXCRETION AFTER ADMINISTRATION OF A
LOWER (1g) DOSE OF FISH OIL TO TWO PATIENTS 
WITH ATHEROSCLEROSIS.
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Effects on Prostacyclin Biosynthesis:
PGI-M excretion fell within the first week of 
supplementation from 364 +/- 71 to 269 +/- 54 pg/mg
creatinine (Figure 5.12). This initial decline continued 
throughout the study period to reach a significant 
(p<0.05) mean decrement of 42% at 212 +/- 57 pg/mg
creatinine at the end of the fourth week. A small quantity
of PGI^_m  was detected in all the patients before 
fish-oil ingestion (7 +/- 1 pg/mg creatinine) and
increased significantly (p<0.01) during supplementation to 
a peak of 30 +/- 9 pg/mg creatinine by the fourth week.
Effects on Platelet Function;
The bleeding time was significantly prolonged (p<0.01)
in all the patients by the end of the first week of
treatment from 3.3 +/- 0.2 to 4.6 +/- 0.4 minutes and
remained so for the duration of supplementation (Figure
5.14). Three months after supplementation the bleeding
time had returned to pretreatment values (3.4 +/- 0.6
minutes). Plasma concentrations of B-thromboglobulin also 
fell during the study from 60 +/- 17 to 35 +/- 35 ng/ml at
the end of the fourth week. The effect of fish-oil
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FIGURE 5.14 EFFECT OF FISH-OIL ON Tit BLEEDING Tilt IN PATIENTS WITH ATHEROSCLEROSIS.
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FIGURE 5.15 EFFECT OF FISH-OIL ON PLASMA B-THRttCOGLOBULIN IN PATIENTS WITH 
ATHEROSCLEROSIS.
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ingestion was shown to be significant by analysis of
variance (p<0.001), but became significant by pairwise
comparisons (p<0.05) only at the third week (Figure 5.15).
There was no change in plasma levels of platelet factor 4
or in arachidonate-induced platelet aggregation during the
study (Table 5.6). The CPA ratio fell from 1.3 +/- 0.08 to
1.05 +/- 0.02 at the end of the first week of
supplementation but the values fluctuated during treatment
and were significant (p<0.05) only after the first and 
third weeks of the study (Table 5.6).
Effects on Erythrocyte Fatty Acids:
There was extensive incorporation of N-3 fatty acids 
into erythrocyte phospholipids during dietary
supplementation with eicosapentaenoate (Table 5.7). By the 
end of the fourth week, the ratio of eicosapentaenoic to 
arachidonic acid had risen from 0.08 to 1.24 in
erythrocyte phosphatidylcholines and from <0.02 to 0.23
and 0.06 in phosphatidyl ethanolamines and phosphatidyl
(serines plus inositols) respectively. In common with the
effects on thromboxane and prostacyclin biosynthesis and 
platelet function, the changes largely occurred during the
first week of treatment. The baseline values were similar
to those reported in other studies (280)(281)(323)( 457 ),
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but showed more extensive incorporation of
e i c o s a p e n t a e n o a t e  c o n s i s t e n t  w i t h  t h e  h i g h e r  d o s e  u s e d  in
t h i s  S t u d y .  TABLE 5.7 INCORPORATION of eicosa PENTAENOIC ACID (EPA) AND
ARACHIDONIC ACID (AA) INTO ERYTHROCYTE PHOSPHOLIPIDS IN 
PATIENTS WITH ATHEROSCLEROSIS AND PLATELET ACTIVATION 
IN VIVO.
Phospholipid
Before Treatment After Treatment
AA EPA AA EPA EPA/AA AA Ratio
Phosphatidylcholines
Phosphatidylethanolamines
Phosphatidyl(serines plus 
inositols)
6.5±0.8 <0.5 
24.3±0.8 <0.5 
27.6±0.5 <0.5
5.0±0.4 6.2+1.0 1.24 
19.5+0.3 4.5±0.2 0.23 
25.7±C.9 1.5+0.2 0.06
Values are expressed as percentages of total fatty acids 
(mean ± SEM) in 6 male patients.
Clinical Evaluation;
All the patients tolerated the fish-oil without adverse
effects. There was no objective evidence of symptomatic 
improvement in any of the subjects during the study nor
were there any alterations in pedal blood flow, including 
skin colour, temperature, capillary refill time and time
extent of postural changes in skin colour using
Buerger's postural test. There was no significant 
reduction in serum ^-tocopherol (8.5 +/- 1.5 vs. 10.9.+/-
2.2 ug/ml, before vs after treatment) and no changes in
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the routine serum chemistry screens or clotting studies 
were noted.
Discussion
This study has demonstrated that fish-oil 
supplementation, using a diet which simulated the fish 
content of an Eskimo diet, significantly reduced the 
elevated excretion of Tx-M in patients with severe
atherosclerosis and platelet activation in vivo. However,
endogenous biosynthesis of thromboxane was not completely
inhibited and remained at levels significantly above those
found in healthy individuals. This was consistent with the 
moderate effects observed on other indices of platelet
function in vivo and was similar to the degree of
inhibition achieved with a thromboxane synthase inhibitor 
in the same model. Moreover, there was a concomitant
return in thromboxane biosynthesis to pretreatment values
as the eicosapentaenoic acid content of erythrocyte
phospholipids declined when patients were changed to a
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lower, more palatable dose of fish-oil. The alterations in 
endogenous thromboxane formation have therefore been shown 
to relate directly to the red cell membrane incorporation 
of eicosapentaenoate which in turn is determined by the 
dose and duration of fish-oil administration.
There was also a reduction in prostacyclin biosynthesis 
during chronic administration of fish-oil to these
patients. This is in contrast to healthy individuals in
whom endogenous production of prostacyclin is maintained
(315)(457). The corresponding trienoic compound, 
PGI^f was formed to a similar extent in the patients 
with atherosclerosis to the levels seen in normal subjects 
(457). These observations, and the concomitant fall in 
B-thromboglobulin and prolongation of the bleeding time, 
are consistent with a reduction of platelet activation in 
vivo in these patients in response to fish-oil. The 
reduction in prostacyclin biosynthesis was accompanied by 
a much greater depression of endogenous thromboxane 
formation. Thus, inhibition of platelet activation leading 
to reduced thromboxane generation appears to suppress the 
stimulus to enhanced prostacyclin biosynthesis in these
patients. This provides further evidence that the 
increased production of prostacyclin seen in this and
other human syndromes of platelet activation in vivo (see 
chapter 4 and reference 422), reflects an enhanced
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frequency or intensity of platelet-vessel wall 
interactions (180).
There is little information available relating the dose
of fish-oil to its effects on platelets. While previous
studies in healthy volunteers have reported only minor or 
insignificant inhibition of platelet function, most of
these have employed too low a dietary content of 
eicosapentaenoic acid and have therefore attained a ratio
of eicosapentaenoate to arachidonate in membrane lipids of
0.3 or less (315-318)(321)(322)(447). In this study, as in
the membrane lipids of Eskimos (279), this ratio was much 
higher (greater than 1.0). The results of the present
study also showed that a reduced dose of fish-oil, lg
daily, was insufficient to maintain the
platelet-inhibitory effects achieved with the higher dose,
even when treatment was continued for six months. 
Similarly, in a study of survivors from myocardial
infarction, Saynor et al found that the bleeding time was
significantly prolonged by 3.6g, but not 1.8g, of
eicosapentaenote daily for a year (448). More recently
others have also reported dose-related effects on platelet
aggregation in volunteers who ingested cod-liver oil
(449).
These results suggest that higher doses of fish-oil, at
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least equal to those employed in the present 
investigation, will be required to significantly influence
platelet function in patients with platelet activation in 
vivo and enhanced endogenous biosynthesis of thromboxane.
The considerable depression of thromboxane formation which
accompanied the changes in other indices of platelet
activation using this regimen, strongly suggests that the
beneficial effects of fish-oil are primarily the result of
alterations in endogenous eicosanoid biosynthesis. 
Nevertheless, other properties of fish-oil, such as its
effects on membrane fluidity (326), whole blood viscosity 
(462), plasma lipids (325) and neutrophil function (463),
may confer additional advantages on this therapeutic
approach. In this regard, the results of two recent 
studies, in which administration of fish-oil was found to
inhibit the development of atherosclerosis in Rhesus
monkeys fed an atherogenic diet (464) and in a 
hyperlipidaemic swine model (465), are particularly 
interesting.
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CONCLUSION
The studies described in this chapter have investigated 
the effects of two distinct approaches to the inhibition
of thromboxane formation in a human model of platelet
activation in vivo in which thromboxane biosynthesis was
markedly enhanced. The model chosen, patients with
advanced atherosclerotic disease, was selected both
because it was one in which there was clear evidence of
thromboxane-dependent platelet activation and also because
it represents an extremely common clinical problem in
which therapeutic intervention has generally yielded
disappointing results.
The principal conclusion which can be drawn from these
studies is that although both of the regimens employed
were successful in considerably reducing endogenous 
thromboxane formation, platelet activation in vivo
persisted. In addition, while the numbers studied were 
small and the methods used to assess efficacy were
limited, the presence of continuing platelet activation
was accompanied by a failure to demonstrate significant 
clinical benefit. Increasing evidence from biochemical,
pathological and pharmacological studies implicates
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platelets in the pathogenesis of vascular occlusive
disease and there is growing interest in particular in the
role of platelet-derived growth factors released during 
platelet activation. The studies described in this chapter 
indicate that in order to suppress platelet activation in
vivo, therapeutic regimens must be directed towards
achieving virtually complete inhibition of thromboxane
biosynthesis throughout the dosing interval. Large-scale
studies will, however, be necessary to establish the
clinical value of this approach.
I acknowledge the help of Ms Johniene Doran with some 
of the platelet function tests carried out in these 
studies.
Chapter 6
FINAL DISCUSSION AND CONCLUSION
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The potent biological properties of thromboxane
A 2 an^ its putative role in vascular occlusion
provide the rationale for therapeutic regimens designed to 
reduce thromboxane synthesis in man. This can be readily 
achieved in vitro and in vivo by aspirin. However, concern 
about the functional significance of concomitant
inhibition by aspirin of the platelet-inhibitory 
eicosanoid, prostacyclin, has stimulated interest in the 
development of selective approaches to reducing 
thromboxane production. The studies described in this work 
have investigated the human pharmacology of the different 
methods of achieving this objective.
The biochemical and functional effects of a new
thromboxane synthase inhibitor,
3-(lH-imidazol-l-yl-methyl)- 2-methyl-lH-indole-l-
propanoic acid (UK 38,485), were evaluated in healthy 
volunteers. The thromboxane synthase inhibitor efficiently 
blocked platelet thromboxane synthesis ex vivo confirming 
the potency of this group of drugs in reducing platelet 
capacity for thromboxane generation. In addition, in the 
higher dose, the synthase inhibitor significantly
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increased endogenous prostacyclin synthesis, consistent 
with diversion of platelet-derived prostaglandin
endoperoxides accumulated in the presence of thromboxane 
synthase inhibition to be utilized by a source of
prostacyclin synthase. Despite these findings, the effects
of the thromboxane synthase inhibitor on platelet function
were relatively minor and transient.
The reasons for this apparent dilemma were explored by
comparing the effects of the synthase inhibitor with those 
of a "low" (120mg) dose of aspirin. The peak reduction in 
serum thromboxane in response to aspirin was
almost identical to that achieved with the synthase
inhibitor. However, the significantly greater
platelet-inhibitory activity of this low dose of aspirin, 
together with in vitro studies of platelet behaviour in 
response to thromboxane synthase inhibitors, suggest that
accumulated prostaglandin endoperoxides substitute for the 
proaggregatory effects of thromboxane when arachidonate
metabolism via thromboxane synthase is blocked. Since even
in this low dose aspirin also significantly inhibited
prostacyclin formation, and the corresponding decline in
thromboxane formation was far from optimal (around 30%), 
these results indicate that a truly selective, effective
single dose of aspirin was not achieved.
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Two new and potentially useful approaches, which were
selective with respect to their effects on eicosenoid 
formation, were identified in these studies. The
combination of low-dose aspirin with a thromboxane
synthase inhibitor appeared to offset the principal 
disadvantages of either drug administered alone. Thus the
fall in prostacyclin biosynthesis seen after low-dose
aspirin was no longer evident and there was substantial
and prolonged inhibition of platelet function. The second
approach employed repeated administration of extremely low
doses of aspirin (lmg every 30 minutes) to achieve
selective presystemic acetylation of platelet
cyclooxygenase. It was postulated that, in such a dose,
hepatic extraction of aspirin would be essentially
complete and vascular cyclooxygenase would therefore not
be exposed to significant concentrations of aspirin. 
Consistent with this hypothesis, aspirin remained
undetectable in peripheral plasma throughout the study, 
prostacyclin biosynthesis was unaltered and the rapid
recovery of serum thromboxane suggested that
megakaryocyte cyclooxygenase was also unaffected.
The possibility that the minor effects of UK 38,485 on 
platelet function might also result from incomplete 
inhibition of actual thromboxane synthesis in vivo was 
investigated by measuring the excretion of Tx-M
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(2,3-dinor-thrombpxane B 2 J' a maj°r urinary 
metabolite of thromboxane. Experiments with a range of 
doses of aspirin alone and in combination with UK 38,485, 
showed that the relationship between actual thromboxane 
biosynthesis (Tx-M) and the capacity for thromboxane 
generation ex vivo (serum thromboxane B^) was not 
linear. Following a single dose of UK 38,485 Tx-M fell by 
less than 30% despite a corresponding reduction in serum 
thromboxane Qf over 95%. Thus, inhibition of
thromboxane formation in vivo may be far from optimal 
despite apparently maximal depression of serum thromboxane
This observation has important implications for 
platelet-inhibitory therapy in patients with platelet 
activation in whom it is likely that pharmacological 
inhibition of serum thromboxane would have to be virtually 
complete before thromboxane-dependent platelet aggregation 
is influenced in vivo.
In order to evaluate the likely impact of selective
inhibition of thromboxane synthesis in a clinical setting,
an appropriate human model of thromboxane-dependent 
platelet activation in vivo was sought. Evidence of
platelet activation and markedly enhanced biosynthesis of
thromboxane was found in patients with severe 
atherosclerosis and, to a lesser degree, in patients with
systemic sclerosis and Raynaud's phenomenon. Moreover, an
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additional stimulus to platelet activation (the
precipitation of Raynaud's phenomenon on exposure to cold)
in the patients with systemic sclerosis, resulted in a
further increment in thromboxane formation. In each case
the increase in thromboxane biosynthesis was accompanied
by a significant though smaller increment in endogenous
prostacyclin production, consistent with an increased
frequency or intensity of platelet-vascular interactions. 
Other indices of platelet activation in vivo (elevated
plasma B-thromboglobulin, the presence of circulating
platelet aggregates and a shortening of the bleeding time)
were also present. These studies confirmed the value of
Tx-M as a sensitive, non-invasive index of platelet
activation in vivo, both in the setting of chronic disease
and in response to acute changes.
The effects of selective inhibition of thromboxane
formation were then investigated in a group of patients
with severe atherosclerosis, chosen to fulfil preset
criteria for the presence of platelet activation in vivo
and with markedly enhanced endogenous biosynthesis of
thromboxane. Two different approaches were evaluated: 
specific blockade of thromboxane synthase by
imidazo-(l,5-2)-pyridine-5-hexanoic acid (CGS 13080), and
an indirect approach in which dietary supplementation with
fish-oil was used to inhibit platelet activation and
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reduce thromboxane formation. The decision to use a 
thromboxane synthase inhibitor, despite the apparently
inferior platelet-inhibitory properties of these
compounds, was based on the recognition that these are the 
only drugs known to increase endogenous prostacyclin
production. Dietary supplementation with fish-oil was
similarly hoped to enhance the formation of endogenous
vasodilator and platelet-inhibitory eicosanoids. Previous 
studies in healthy individuals had shown that synthesis of
prostaglandin I which has similar biological
acivity to prostacyclin, was increased by fish-oil.
Administration of the thromboxane synthase inhibitor,
in a dose representative of those used in clinical trials,
caused reversible inhibition of platelet thromboxane
formation in these patients and also significantly
increased endogenous prostacyclin production more than
two-fold. Nevertheless, cumulative complete inhibition of 
thromboxane biosynthesis was not achieved and platelet 
activation persisted during chronic drug administration.
This was found to be due in part to the pharmacokinetics
of these drugs. Significant recovery of platelet
thromboxane formation was shown to occur within the 6-hour
dosing interval, reflecting the short pharmacological
half-lives which are common to all the thromboxane
synthase inhibitors under investigation in man. However,
the superior anti-platelet activity of aspirin in the same
patients, and the failure of the thromboxane synthase
inhibitor to influence platelet function at the time of
maximal drug action, suggested that the substitution by
accumulated endoperoxides for the proaggregatory effects 
of thromboxane A^ also contributed to continuing
platelet activation in these patients. It therefore seems
likely that realization of the therapeutic potential of
thromboxane synthase inhibitors will depend both on
prolongation of drug action and on their combination with
antagonists of the endoperoxide/thromboxane A
2
receptor.
Dietary supplementation with lOg daily of 
eicosapentaenoate for one month also significantly reduced 
thromboxane biosynthesis in patients with severe 
atherosclerosis and platelet activation in vivo. The
decline in thromboxane A^ production coincided with 
the formation of inactive thromboxane A_^  and 
increased eicosapentaenoate incorporation into erythrocyte 
phospholipids. Prostaglandin I biosynthesis was 
also significantly increased. Inhibition of thromboxane 
generation was not complete, however, and platelet
activation in vivo although significantly reduced was 
still apparent. A lower dose of eicosapentaenoate (lg 
daily) was insufficient to maintain the changes in
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thromboxane synthesis. Although chronic administration of 
the high dose will be required to modify eicosenoid 
formation and platelet function, other biological
properties of fish-oil, particularly its potential ability
to prevent the development of atherosclerosis, make this 
approach worthy of further investigation.
In conclusion, these studies have shown that in several
syndromes of platelet activation in vivo, thromboxane 
biosynthesis is markedly increased. Such syndromes provide 
an appropriate model to investigate the effects of
regimens to inhibit thromboxane formation in man. It is 
apparent that in order to suppress platelet activation in 
patients with these conditions, therapeutic regimens must
achieve virtually complete inhibition of thromboxane 
biosynthesis throughout the dosing interval. The
observation that prostacyclin synthesis is also enhanced
in this setting supports the development of selective
approaches to inhibition of thromboxane generation which
spare, or even increase, prostacyclin production. These
studies suggest that efforts should be directed towards
the synthesis of new, long-acting thromboxane synthase 
inhibitors to be used in combination with thromboxane
receptor antagonists. In addition, the potential benefits 
of extremely low dose 1slow-release' preparations of
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aspirin and of long-term administration of pharmacological
doses of eicosapentenoate need to be investigated in 
controlled clinical trials in vasoocclusive disease.
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APPENDIX I
Prostaglandin Metabolites 
:normal values
Serum Thromboxane B .
2 *
Normal values 
Effect of age 
Effect of sex 
Effect of platelet count
Urinary Tx-M and Thromboxane B^; 
Normal values 
Effect of sex 
Intraindividual variation 
Effect of age
Urinary PGI-M:
Normal values 
Intraindividual variation
Effect of age
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TABLE AI.1 SERUM THROMBOXANE B2 : NORMAL VALUES (ng/ml)
Subjects 1 2
San
3
nple Num 
4
ber
5 6 MEAN
WW 437 384 449 462 425 388 424
TL 314 166 137 119 209 236 197
BS 330 445 455 600 493 509 509
MM 382 470 463 474 389 419 433
WB 779 457 456 424 646 534 549
MA 275 272 339 253 348 230 286
DM 393 400 405/ 385 347 455 398
NK 225 246 208 233 222 199 222
RR 468 361 385 497 402 375 415
RP 358 299 348 359 389 347 350
PL 341 263 314 298 314 356 314
MV 324 293 260 270 341 299 298
Normal values of serum thromboxane in 12 healthy male subjects 
on 6 separate samples.
FIGURE AI.1 RELATIONSHIP BETWEEN SERUM THROMBOXANE GENERATION EX VIVO AND AGE
IN 30 HEALTHY SUBJECTS.
700
600
500
400
300
200
100
100
Age (years)
FIGURE AI.2 RELATIONSHIP BETWEEN SERUM THROMBOXANE AND SEX.
700
600
500
“ 400
300
200
100
WomenMen
Ser
um
 
Th
ro
mb
ox
an
e 
B2 
(n
g/
mi
)
FIGURE AI.3 RELATIONSHIP BETWEEN SERUM THROMBOXANE B GENERATION EX VIVO AND
PLATELET COUNT IN 30 HEALTHY SUBJECTS.
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FIGURE AI.4 URINARY EXCRETION OF Tx-M AND THROMBOXANE B : NORMAL VALUES IN 
HEALTHY SUBJECTS.
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FIGURE AI.6 URINARY EXCRETION OF Tx-M INTRAINDIVIDUAL VARIATION.
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FIGURE AI.8 URINARY EXCRETION OF PGI-M: NORMAL VALUES IN HEALTHY SUBJECTS.
FIGURE AI.9 URINARY EXCRETION OF PGI-M: INTRAINDIVIDUAL VARIATION.
FIGURE AI.10 EFFECT OF AGE ON PGI-M EXCRETION.
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APPENDIX II
Platelet Function 
:normal values
291
Bleeding Time
Platelet Aggregation:
Arachidonic acid
Collagen
Adrenaline
Whole blood platelet aggregation
Platelet Granule Proteins 
Circulating Platelet Aggregates
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FIGURE All. 1 TEMPLATE BLEEDING TINE IN 12 HEALTHY MALE SUBJECTS.
(5 separate estimations on each subject)
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TABLE AII.1 PLATELET AGGREGATION IN PLATELET-RICH PLASMA (PRP)
IN RESPONSE TO ARACHIDONIC ACID (1.33mM) :
NORMAL VALUES OF LT50* (mins).
Sample Number
Subjects 1 2 3 4 5 6 MEAN
WW 0.4 0.52 0.56 0.76 0.54 0.64 0.57
TL 1.12 1.04 1.06 0.7 ' 0.72 0.74 0.9
65 0.62 0.56 0.7 0.48 0.6 0.74 0.61
MM 0.52 0.66 0.76 0.64 0.76 0.73 0.68
WB 0.7 0.84 0.78 0.64 0.5 0.74 0.7
MA 0.64 0.7 0.66 0.6 0.64 0.80 0.67
DM 0.58 0.6 0.54 0.44 0.44 0.6 0.53
NK 0.6 0.52 0.5 0.48 0.82 0.48 0.52
RR 0.56 0.7 0.6 0.62 0.6 0.56 0.61
Rp 0.56 0.64 0.6 0.6 0.54 0.62 0.59
PL 0.56 0.6 0.48 0.64 0.78 0.76 0.64
MV 0.68 0.72 0.64 0.74 0.7 0.7 0.7
Normal values for in 12 healthy male subjects on 6 separate samples
* : Lag time to achieving 50% of maximal aggregation.
NA : no aggregation.
TABLE All.2 PLATELET AGGREGATION IN PRP IN RESPONSE TO ARACHIDONIC
ACID (0.66mM) : NORMAL VALUES OF LT^Q* (mins).
Sample Number
Subjects 1 2 3 4 5 6 MEAN
WW 0.52 0.58 0.6 0.76 0.6 0.76 0.64
TL 1.36 2.16 1.48 0.76 1.0 1.06 1.3
BS 3.7 4.16 3.04 2.56 3.96 4.72 3.7
MM 0.6 0.7 0.68 0.66 0.84 0.96 0.74
WB 1.8 1.1 0.74 0.64 0.66 1.06 1.0
MA 1.44 1.2 1.45 1.24 1.68 1.68 1.45
DM 1.0 0.8 1.04 0.8 0.72 0.8 0.86
NK 0.86 0.72 0.72 0.72 0.72 0.6 0.72
RR 0.88 0.7 0.62 0.76 0.64 0.76 0.73
RP 0.64 0.58 0.54 0.6 0.58 0.68 0.6
PL 1.0 0.7 0.54 0.96 1.14 1.2 0.92
MV 0.58 0.6 0.58 0.64 1.38 0.8 0.76
Normal values for LT^g in 12 healthy male subjects on 6 separate samples 
* : lag time to achieving 50% of maximal aggregation.
TABLE All.3 PLATELET AGGREGATION IN PRP IN RESPONSE TO COLLAGEN
(19jig/ml) : NORMAL VALUES FOR LT5Q* (mins)
Subjects 1 2
Sample
3
Number
4 5 6 MEAN
WW 1.54 1.6 1.72 2.5 1.42 2.46 1.87
TL 1.74 2.2 2.16 2.16 2.28 1.76 2.05
BS 1.6 1.36 1.36 1.4 1.54 2.28 1.59
MM 1.82 1.92 1.8 1.68 2.52 2.72 2.08
WB 1.94 2.46 1.72 1.86 1.6 2.48 2.01
MA 2.28 2.04 2.0 2.24 2.0 2.52 2.18
DM 2.48 2.24 2.24 2.3 1.86 2.36 2.25
NK 2.0 2.04 2.24 2.16 1.8 2.0 2.18
RR 1.62 1.92 2.24 2.06 2.52 2.2 2.09
RP 2.24 1.98 1.96 2.04 2.36 2.3 2.15
PL 2.2 1.88 1.85 1.62 2.02 1.6 1.86
MV 2.28 2.34 2.52 2.32 2.3 2.12 2.31
Normal values for LT^g in 12 healthy male subjects on 6 separate samples.
TABLE All.4 PLATELET AGGREGATION IN PRP IN RESPONSE TO COLLAGEN
(1.9pg/ml) : NORMAL VALUES FOR LT^Q* (mins)
Subjects 1 2
Sample
3
Number
4 5 6
i
MEAN
WW 3.7 2.92 3.56 5.58 5.48 4.24 4.25
TL 3.18 5.68 5.18 5.44 5.4 4.2 5.18
BS 3.68 4.16 3.04 2.56 3.96 4.72 3.69
MM 3.16 5.44 4.68 5.52 5.12 4.78 4.78
WB 4.72 -P
r
00 4.44 4.68 3.44 4.54 4.44
MA 3.54 5.2 5.56 4.96 4.68 5.48 5.24
DM NA NA NA NA NA NA NA
NK 5.72 3.94 4.12 5.28 5.32 5.28 4.94
RR 4.64 5.02 5.34 5.28 3.92 5.30 4.92
RP 3.84 4.64 5.28 5.04 4.56 4.66 4.67
PL 3.88 3.9 3.28 3.16 4.44 2.96 3.74
MV 4.74 5.28 5.4 4.44 4.72 3.8 4.73
Normal values for LT^q in 12 healthy male subjects on 6 separate samples. 
* LT<-g : lag time to achieving 50?o of maximal aggregation.
NA : no aggregation.
TABLE All.5 PLATELET AGGREGATION IN PRP IN RESPONSE TO ADRENALINE
(10pM) : NORMAL VALUES OF TMAX^* (cm).
Sample Number
Subjects 1 2 3 4 5 6 MEAN
WW 16.8 20.8 17.5 22.1 17.7 15.7 18.4
TL 19.3 17.0 16.5 15.0 14.4 17.2 16.6
BS 17.8 19.0 22.7 19.4 20.7 18.1 19.6
MM 19.1 15.3 17.5 18.2 17.6 17.5 17.5
WB 15.3 16.3 19.2 17.6 20.8 19.1 18.1
MA 16.0 15.8 16.9 17.1 16.3 16.6 16.5
DM 15.5 14.7 16.5 15.5 16.0 14.8 15.5
NK 13.6 16.7 17.1 17.7 18.1 16.8 16.7
RR 15.8 17.8 16.6 16.3 17.8 16.8 16.9
RP 16.6 15.5 16.5 19.3 14.5 14.4 16.1
PL 16.4 17.6 16.0 16.0 17.8 17.3 16.9
MV 18.2 17.9 14.4 19.0 22.3 19.7 18.6
Normal values for Tmax^ in 12 healthy male subjects on 6 separate samples.
* Tmax^ : maximum height of aggregation trace 6 minutes after addition
of agonist.
TABLE All.6 PLATELET AGGREGATION IN PRP IN RESPONSE TO ADRENALINE
(5pM) : NORMAL VALUES OF TMAXfi* (cm).
Subjects 1 2
Sample
3
Number
4 5 6 MEAN
WW 15.8 17.5 16.3 20.5 19.8 20.0 18.3
TL 19.0 17.9 16.8 15.4 16.4 16.5 17.0
BS 19.3 19.3 19.3 20.4 18.7 19.0 19.3
MM 18.1 14.5 18.3 16.4 15.7 16.6 16.6
WB 17.3 16.7 15.5 13.3 16.8 20.8 16.7
MA 16.5 15.6 18.2 16.2 14.3 17.2 16.3
DM 15.6 14.4 14.7 16.6 20.2 19.7 16.9
NK 12.9 16.1 15.5 16.3 16.5 19.3 16.1
RR 15.7 16.5 16.7 15.8 17.1 17.2 16.5
RP 16.2 17.8 15.0 16.6 16.3 15.4 16.2
PL 16.8 16.7 18.0 15.9 17.1 16.3 16.8
MV 15.2 15.4 17.0 18.2 16.9 16.5 16.5
Normal values for Tmax^ in 12 healthy male subjects on 6 separate samples.
* Tmax^ : maximum height of aggregation trace 6 minutes after addition
of agonist.
TABLE All.7 PLATELET AGGREGATION IN PRP IN RESPONSE TO ADRENALINE
(1pM) : NORMAL VALUES OF TMAXfi* (cm).
Subjects
1 2
Sample
3
Number
4 5 6 MEAN
WW 16.1 14.5 14.1 18.0 17.0 16.0 16.0
TI­ 6.0 14.4 15.4 5.0 10.6 9.1 10.1
BS 17.8 16.6 15.1 18.6 20.1 18.7 17.8
MM 16.4 13.8 17.3 16.8 17.5 15.9 16.3
WB 2.1 4.1 6.1 4.6 6.4 9.4 5.6
MA 16.3 14.7 16.6 16.1 16.8 14.8 15.9
DM 1.5 1.0 1.1 0.8 1.1 1.3 1.13
NK 16.6 15.3 17.4 16.9 17.5 16.2 16.6
RR 15.2 18.1 16.4 16.0 18.0 17.2 . 16.8
Rp 15.4 14.3 16.1 14.5 15.5 13.8 14.9
PL 15.6 17.9 15.5 15.3 18.7 16.6 16.6
MV 18.3 17.3 18.1 18.1 21.7 15.7 18.2
Normal values for Tmax^ in 12 healthy male subjects on 6 separate samples.
* Tmax^ : maximum height of aggregation trace 6 minutes after addition
of agonist.
TABLE All.8 PLATELET AGGREGATION IN WHOLE BLOOD IN RESPONSE TO
ARACHIDONIC ACID (0.66mM) : NORMAL VALUES FOR CHANGE IN 
IMPEDANCE (A OHMS)
Sample Number
&
Subjects 1 2 3 4 5 6 MEAN
WW 18.8 18.6 15.4 15.2 15.4 12.1 15.9
TL 17.4 19.2 19.5 13.5 12.4 9.5 15.3
BS 15.8 14.9 15.2 13.2 12.7 13.8 14.3
WB 12.9 12.8 7.6 5.6 9.5 4.2 8.8
PL 13.1 13.7 11.0 16.6 15.3 21.1 15.1
MV 11.4 23.3 19.5 16.0 - 14.4 12.9 16.3
Normal values for change in impedance from baseline levels in 6 
healthy male subjects on 6 separate samples.
TABLE All.9 PLATELET AGGREGATION IN WHOLE BLOOD IN RESPONSE TO 
COLLAGEN (9.5pg/ml) : NORMAL VALUES FOR CHANGE IN 
IMPEDANCE (AOHMS).
Subjects
1 2
Sample
3
Number
4 5 6 MEAN
WW 19.7 14.7 13.4 13.8 17.8 19.4 16.5
TL 16.3 11.0 15.2 12.3 10.9 12.0 13.0
BS 12.4 12.4 11.9 10.8 10.9 13.1 11.9
WB 6.1 4.1 8.5 5.0 9.8 8.7 7.0
PL 12.3 14.2 11.7 10.2 11.3 21.9 13.6
MV 19.0 19.6 8.0 10.2 12.6 15.3 14.1
Normal values for change in impedance from baseline levels in 
6 healthy male subjects on 6 separate samples.
FIGURE All.2 PLASMA CONCENTRATIONS OF B-THROMBOGLOBULIN AND PLATELET FACTOR 4:
NORMAL VALUES IN HEALTHY SUBJECTS
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Reagents
1.Reagents and materials for purification and 
derivatization of urinary eicosanoids:
Bonded phase phenylboronic acid columns 
(Analytichem International, Harbour City, CA.)
C-18 Sep-Paks (Waters Associates, Milford, M A . )
Silicilic Acid plates (Whatman Chemical
Separation Inc., Clifton, NJ. )
Pentafluorylbenzyl bromide (Pierce Chemical
Company, Rockford, IL.)
Diisopropylethylamine (Aldrich Chemical Company,
Milwaukee, WI. )
Trifluoroacetamide (Supelco Inc., Bellefonte,
PA)
Methoxyamine hydrochloride (Sigma Chemical 
Company, St. Louis, M O.)
Internal standards for Tx-M, thromboxane
an^ PGI-M were kindly provided by Drs F. 
Fitzpatrick and J. Pike (Upjohn Company, Kalamazoo, 
MI)
All other chemicals (methanol, ethyl acetate 
etc) were obtained from Burdick and Jackson, 
Muskegon, MI.
294
2.Reagents and materials for platelet function 
studies:
Arachidonic acid (Sigma Chemical Company) 
Collagen (Biodata Corporation, Horsham, PA.)
Adrenaline (Sigma Chemical Company)
Simplate Bleeding Time Device (General
Diagnostics, Morris Plains, NJ.)
3.Reagents for radioimmunoassay of
B-thromboglobulin, platelet factor 4 and thromboxane
B .
2 *
Amersham B-thromboglobulin Kit (Amersham, 
Arlington Heights, IL.)
Platelet Factor 4 Radioimmunoassay Diagnostic 
Kit (Abbott Laboratories, North Chicago, IL.)
PGEi (sigma Chemical Company)
Indomethacin (Sigma Chemical Company)
Rabbit anti-thromboxane B^ antibody 
(kindly provided by Dr RJ Workman, Vanderbilt
University)
125
I -thromboxane B^ (New England 
Nuclear, Boston, MA)
4.Drugs:
UK 38,485, aspirin 120mg and matching placebo
295
capsules (kindly provided by Dr P. Urquilla, Pfizer
Inc., Groton, CT.)
CGS 13080 and matching placebo capsules (kindly
provided by Dr N. Feliciano, Ciba-Geigy
Corporation, Summit, NJ.)
Aspirin lmg, 5mg, 20mg and 325mg capsules
(prepared in Vanderbilt University Pharmacy)
Max-EPA (kindly provided by Dr D. Davies,
Scherer Corporation, Troy, MI.)
Internal standards for aspirin and salicylate
assays (kindly provided by Dr A.K. Pedersen, 
Vanderbilt University)
Equipment
Gas chromatography/mass spectrometry:
Nermag 10-10C mass spectrometer (Nermag 
Corporation, Houston, TX.) linked to a Varian Vista 
6000 gas chromatograph (Varian Corporation, Palo 
Alto, CA. )
Hewlett Packard 5980 (Hewlett Packard, Palo 
Alto, CA.)
Platelet Aggregometry:
Payton Dual-Channel Aggregometer (Payton
296
Associates, Buffalo, NY.)
Chrono-log Whole Blood Aggregometer (Chrono-log 
Corporation, Havertown, PA)
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Ethical Considerations
All the studies included in this thesis were
approved by the local ethical committee, the Committee
for the Protection of Human Subjects, of Vanderbilt 
University Medical Center, Nashville, Tennessee. When
patients were attending the Veterans Administration
Hospital, adjacent to Vanderbilt University, the.
studies were also approved by the ethical committee of 
that hospital. The aims and procedures of the study
were explained to all the subjects individually by 
myself and by an experienced research nurse, Ms
Cynthia Healy. All the participants signed a consent
form prior to inclusion in the studies.
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